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ABSTRACT
This study has examined activation of human
polymorphonuclear leucocytes (neutrophils) by complement
components and the role of such activation in the production
of inflammation. Using release of the secondary granule
component cobalamin binding protein as a marker of cell
activation, complement activated serum was shown to contain a
single low molecular weight peak of degranulating activity for
cytochalasin B treated neutrophils dependent on the presence
of C5.
Thus neutrophil degranulation could be used as a
functional assay for the detection of C,. fragments and anti-Cj.
fragment activity.
Cobalamin binding protein was also slowly lost from
cells in the presence of serum, a phenomenon which is not
complement dependent but which may be of importance in control
of granulopoiesis.
Autologous complement-activated serum, when injected
intradermally rapidly produced an inflammatory response of
flare, wheal and accumulations of intravascular neutrophils.
The wheal and flare response was C^ dependent and also
partially neutrophil dependent, since severely neutropenic
subjects showed significantly impaired skin responses, despite
normal serum levels of C,. fragments, and irrespective of
platelet count.
Possible mechanisms of neutrophil involvement in this
microvascular response to C^ fragments were examined.
Complement-activated neutrophils did not release the
z
inflammatory arachidonic acid products prostaglandin or
leukotriene B , nor were the skin responses to complement
reduced by aspirin, hydrocortisone or ibuprofen. Oxygen
radicals did not appear to be important as chronic
granulomatous disease carriers (and one affected male) had
normal reactions. Chronic granulocytic leukaemia patients,
however, had impaired responses, for reasons as yet unclear.
Skin responses to complement in normal subjects were
reduced by local anti-histamine drugs of anti-H^ type. This
could, however, have been due to neutrophil blockade rather
than histamine antagonism, for antagonists significantly
reduced neutrophil degranulation in vitro, as did histamine.
Studies with and antagonists suggested the presence of
receptors on neutrophils with H-^ antagonists having local
anaesthetic type effects on the cell membrane.
Neutrophil degranulation was also blocked by extracts of
the plant Tanacetum parthenium (feverfew), a herbal remedy for
migraine and arthritis. Studies with different degranulating
stimuli suggested that feverfew might be acting on the pathway
to protein kinase C activation. Phagocytosis of opsonised
yeasts was also blocked by feverfew.
Neutrophil activation by complement fragments thus
appears to lead, by unknown mechanisms, to increased vascular
permeability and vasodilatation. Such activation which may be
particularly important in the pathogenesis of the adult
respiratory distress syndrome and rheumatoid arthritis,
appears to be amenable to pharmacological modulation by
antagonists and feverfew extracts. The therapeutic
significance of these observations remains to be tested.
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Although the human polymorphonuclear leucocyte (PMN) has
been considered primarily as a phagocytic cell, increased
attention has recently focussed on its role as a secretory
cell with involvement of its extracellular products in the
processes of inflammation and immunity. PMN secretory events
can occur independently of phagocytosis in response to soluble
stimuli such as activated complement components and bacterial
peptides. Products released include hydrolytic enzymes,
inflammatory derivatives of arachidonic acid and membrane
phospholipids, toxic oxygen radicals and binding proteins for
iron and cobalamins such as vitamin B^-
Secretory activities of PMN's are being increasingly
implicated in the microvascular changes and tissue damage seen
in a number of diseases associated with either complement
activation and/or sepsis, such as the adult respiratory
distress syndrome (ARDS) and rheumatoid arthritis.
PMN activation also occurs during elective surgery, with
loss of secondary granules within hours"'", and a transient
defect in cell killing associated with loss of primary granule
2
myeloperoxidase . Investigation of the possible source of a
stimulus to degranulation focussed on the complement system,
although secondary granule secretion can also occur in serum
3
without complement activation . In view of the possible role
of complement-mediated neutrophil secretion in the production
of inflammation, this study has attempted to answer the
following questions
1. Which complement components are the main secretory stimuli
12
for PMN's?
2. What are the other factors controlling PMN secretion?
3. Does PMN activation by complement lead to tissue
inflammation, and if so, what are the mechanisms?
4. Can these tissue damaging processes be inhibited?
The experimental work falls into three sections. The
first section examines secondary granule secretion from PMN's
in vitro, both in the presence of activated complement and by
other stimuli (Chapters 2 and 3). In the second section, an
in vivo model of inflammation is developed, namely intradermal
injection of activated complement and measurement of the
resulting flare and wheal reaction. Identification of active
complement components and the role of PMN activation in the
response are then investigated (Chapter 4), followed by
examination of the possible mechanisms of PMN involvement and
ways of inhibiting the in vivo response (Chapter 5). Finally,
in further in vitro studies, potential inhibitors of PMN
secretion are examined (Chapters 6 and 7) . The significance
of the findings are discussed (Chapter 8).
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
SECTION 1. THE POLYMORPHONUCLEAR LEUCOCYTE : STRUCTURE,
FUNCTIONS AND ACTIVATION PROCESSES.
A. Introduction
White blood cells or leucocytes are broadly divided on
the basis of nuclear appearance into two types, mononuclear
forms (monocytes and lymphocytes) and polymorphonuclear forms.
The latter are further subdivided according to the staining
characteristics of their cytoplasmic granules into
eosinophils, basophils and neutrophils. Neutrophil
polymorphs, otherwise known as neutrophil granulocytes, or
polymorphonuclear leucocytes (PMN's, although strictly this
term should include eosinophils and basophils also), are the
most numerous white cell in the peripheral blood, numbers
9 4
ranging from 1.8 - 7.3 x 10 /I , and are 8-10 times more
numerous than either eosinophils or basophils. The main
function of the PMN is recognition, ingestion and killing of
micro-organisms, and removal and repair of dead or damaged
tissue. It thus has a primarily restorative function, though
as will be discussed later in this chapter, PMN recruitment
and activation may under certain circumstances lead to
unwanted tissue injury.
14
B. PMN production and kinetics.
The lifespan of the PMN takes place sequentially in
three body compartments, the marrow, the circulation and the
tissues.
(i) Marrow
Generation of vast numbers of PMN's occurs in the bone
marrow from stem cells which undergo a number of cell
divisions to produce more differentiated forms (Table 1).
Table 1 (from Boggs 1975)^
Scheme of PMN maturation and storage



































The earliest stem cells in the maturation process are probably
pluripotent i.e. they can produce progeny of any blood cell
line . Stem cells committed to myeloid or granulocyte
differentiation then give rise to myeloblasts, and further
cell divisions and maturation steps proceed through the
promyelocyte and myelocyte stages till the non dividing
15
metamyelocyte form is reached. There is thereafter no further
increase in numbers, but changes in the nucleus continue,
giving rise firstly to the band form, and finally to the
mature segmented PMN.
It can be seen from Table 1 that the total time spent by
5
a PMN in the marrow is about 17-25 days of which 2-5 days is
storage time once maturation is completed. This storage pool
is enormous, consisting of between 7 and 13 times as many
5
PMN1s as in the peripheral blood and is of great importance
in providing an immediate response to infection. The storage
pool can be mobilised by endogenous or exogenous
7 8
glucocorticoids or by the complement component C^e .
Segmented PMN's are released preferentially to band forms,
although the latter may appear if demand is excessive. The
presence of more immature forms such as myelocytes in the
blood may be 'physiological' as in recovery from hypoplasia,
but may also indicate an abnormal process in the marrow such
as fibrosis or tumour invasion.
(ii) Circulation
Once in the peripheral blood, PMN's move between two
5
pools of approximately equal size , the circulating pool and
the marginated pool which are cells adherent to blood vessel
endothelium and therefore not included in peripheral blood PMN
counts. Movement between these two pools is rapid, as shown
9
by studies using labelled cells , and the marginated pool can
be rapidly mobilised by exercise, glucocorticoids or
catecholamines'*"^. Movement of cells from marrow to blood and
from blood to tissues is presumed to take place via the











Fig 1. Movement of neutrophils between different body
pools .
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widely, with particular sites being lung, and to a lesser
9
degree, liver and spleen . The time spent by PMN's in the
peripheral circulation, whether in marginated or circulating
pools, appears to be only a few hours, with a half life of
labelled cells in man being only 6-7 hours'^. Since loss of
labelled cells from the blood is exponential, it can be
calculated that the average PMN spends about 10 hours in the
bloodstream, and that the mass of blood PMN's turns over about
5
two and a half times daily . The exponential loss of labelled
cells also suggests that loss to tissues is random, with no
preferential loss of older cells, although there is also some
12
evidence that PMN's may become senescent . Labelling studies
also confirm that while PMN's move from marrow to blood and
blood to tissues, there is little or no migration in the
opposite direction^.
(iii) Tissues
The general response of PMN's to tissue damage or
infection begins with adhesion to endothelium followed by
migration between endothelial cells (diapedesis) through into
13
the tissue . PMN's enter tissues even in health and spend
1-2 days there, where they undergo damage and death, being in
turn phagocytosed by macrophages. PMN's in tissues do not
constitute a mobile reserve of cells, so local tissue demands
for increased numbers of PMN's can be met only by increased
14
migration from the circulation . Clearly, reduced PMN
numbers in the peripheral blood will result in fewer available
cells to enter damaged or infected tissue. If, however,
neutrophilia is induced, no increase in migration is seen,
numbers entering an infected site being proportional solely to
1 8
15
the intensity of the stimulus
C. The mature PMN : structure and functions
(i) Structure
The mature PMN (Fig 2) has a diameter of 12-14and a
characteristic multilobed nucleus. The cytoplasm contains
glycogen particles, important as an energy source,
microfilaments and microtubules essential to the cell's
mobility, and also important in phagocytosis and secretion, a
few mitochondria and a small Golgi apparatus. The most
striking feature of the cytoplasm, however, is the granules,
which are of two main types with different constituents (Table
2) .
Table 2
















Alkaline phosphatase appears to exist in a completely separate
population of granules.
The primary granules (also known as azurophilic, since they
take up 'sky-blue' dyes, although their final stained colour
is*reddish purple) appear at the promyelocyte stage of cell
18
development from the concave side of the Golgi apparatus
Their numbers are thereafter diluted by cell division. They
19








contain mainly degradative enzymes and their function is to
kill and break down material contained within the phagocytic
19vacuole or phagosome, with which they fuse (see (vii)
below). The secondary or specific granules appear at the
myelocyte stage of development and outnumber the primary
18
granules by 2:1 . Although they contain the antibacterial
protein lysozyme, the functions of their main constituents
lactoferrin and cobalamin binding protein are not fully known.
Since behaviour of the secondary granules constitutes a large
part of this study, they are discussed more fully in part D of
this section.
(ii) Responses to phagocytosable and soluble stimuli.
The mature PMN when stimulated is capable of a variety
of responses, including chemotaxis, aggregation,
degranulation, phagocytosis and killing, a respiratory burst,
and production of biologically active mediators such as
prostaglandins and leukotrienes. Which of these responses it
displays in a given situation depends on whether the stimulus
is particulate and therefore phagocytosable, bound to a
surface too large to ingest, or soluble. Examples of soluble
stimuli include the complement components and C^. des Arg,
discussed more fully in section 2 of this chapter, for which
20
PMN's have receptors on their surface . Peptides from
bacteria, which are generally formylated, also attach to
surface receptors. An example is the tripeptide produced by
21
Escherichia coli, formyl-methionyl-leucyl-phenylalamme
(FMLP). Both C^. and FMLP are used as PMN stimuli in this
study. They can promote chemotaxis, granule release and a
respiratory burst in the absence of any phagocytosable
21
21 22
stimulus ' . PMN responses also differ according to whether




Occupation of surface receptors for stimuli such as C
Ids
and FMLP results in a rapid reduction in membrane negative
24
surface charge , and a rise in free cytoplasmic calcium, due
25
at least partly to calcium loss from the cell membrane
Recent evidence suggests that biochemical events linking
membrane receptor occupation with responses such as chemotaxis
and degranulation may also involve breakdown of membrane
phosphatidyl inositol 4,5-bisphosphate to form two
intracellular messengers, 1, 2-diacyl glycerol and inositol 1,
2 6
4, 5-triphosphate . The former activates the membrane enzyme
protein kinase C, which via a series of phosphorylation steps,
leads to polymerisation of the actin and myosin-containing
microfilaments responsible for chemotaxis, phagocytosis and
granule release. Inositol 1, 4, 5-triphosphate, on the other
hand, mobilises calcium from an intracellular store, possibly
27
in the endoplasmic reticulum . Thus the rise in
intracytoplasmic calcium may be preceded by these lipid
















This complex process by which PMN's move on a surface
along a chemical gradient, firstly involves detection by the
cell via surface receptor occupation, of a directional
difference in chemotactic factor concentration across its
28
dimensions . The cell changes from round to wedge shaped,
spreads out and finally moves in an amoeboid fashion. These
processes appear to involve both actin and myosin-containing
microfilaments, for locomotion, and also the microtubule
29
system, for stability and orientation . Migration of cells
exposed to attractants is accompanied by other
receptor-mediated events, including a respiratory burst and
degranulation. Secondary granule release involves fusion of
the granule membrane with the plasma membrane with which it is
identical and interchangable. This may be important in
renewing surface chemotactic factor receptors, which, with
their bound ligands, are constantly lost from the cell surface
23
29
by internalisation . Degranulation thus provides the free
receptors necessary for PMN migration.
The nature of the substratum on which the cell moves is
also an important determinant of direction of migration.
Cells will tend to follow grooves or dips in the surface, even
if their orientation conflicts with the chemotactic
,. 30
gradient
(v) Adhesion and recognition.
One process in the final maturation of the PMN is the
development of surface receptors for two important
immunological aids to phagocytosis namely C^, derived from
the third component of complement, and the Fc end of the
31
immunoglobulins IgG^ and IgG^ • Bacteria and viruses become
coated with IgG antibody which then fixes complement to the
bacterial surface. This process, known as opsonisation,
greatly facilitates phagocytosis, for IgG opsonisation
increases both affinity of the coated particle for the PMN
receptor site as well as increasing the maximal rate of
. 32
phagocytosis . does not increase receptor affinity but
does maximise the phagocytic rate.
(vi) Phagocytosis.
Phagocytosis takes place by the PMN forming two
cytoplasmic outflowings (filopodia) round the particle. These
then fuse, and the particle, along with some fluid and the
relevant portion of plasma membrane becomes internalised
31
forming the phagocytic vacuole or phagosome . The phagocytic
process, like chemotaxis, probably involves both
microfilaments and microtubules, and divalent cations are
33




(vii) Intracellular killing and degradation.
Microbicidal mechanisms are of two types,
oxygen-dependent and oxygen-independent.
a. Oxygen-dependent. Phagocytosis is accompanied by an
increase in oxygen consumption, which is converted by a cell
membrane NAD(P)H oxidase (described more fully in the next
section) to hydrogen peroxide (H2O2) and other reactive oxygen
metabolites. Since the oxidase is incorporated, as part of
the membrane, into the phagocytic vacuole, a high
33
concentration of can be generated within the vacuole
Although H2O2 is bactericidal alone, this activity is greatly
enhanced by the presence of the enzyme myeloperoxidase, which
becomes incorporated into the phagosome when it fuses with
primary granules. An oxidisable cofactor such as halide ions
33
is also required . Low levels of myeloperoxidase may underly
35
the defect in killing found in pregnancy and following
2
surgery . Oxidative microbial damage may also occur
independently of myeloperoxidase, by the reactive unstable
products of oxygen reduction, namely the superoxide anion
(O2 ), singlet oxygen (0) and hydroxyl radical (0H-) as well
33
as hydrogen peroxide itself (see (vm) below) .
b. Oxygen-independent. At least four systems are
recognised:-
1. The low pH in the phagocytic vacuole, which may be due to
3 6
accumulation of both lactic acid from glycolysis and
37
carbonic anhydrase-mediated carbonic acid production




3. Cationic proteins, which are also found in the primary
39
granules, and which can bind to and damage bacteria
4. Lactoferrin, a secondary granule component. In its
unsaturated form, lactoferrin can chelate the iron required
33
for growth of certain bacteria . As discussed later in this
section, its main site of action may be outside the cell.
(viii) The PMN oxidase and its deficiency.
As stated above, an increase in oxygen consumption or
respiratory burst accompanies phagocytosis in human PMN's. As
33
it is not inhibited by cyanide and because PMN's contain
few mitochondria, this appears to take place almost
40
exclusively via the membrane NAD(P)H oxidase . As well as
being activated during phagocytosis, the oxidase can be
stimulated by soluble factors such as the complement component
14
^5a' Particularly in the presence of serum , and the
42
bacterial peptide FMLP . Under these circumstances,
measurable amounts of superoxide anion (0^-) appear outside
the cell. Hydrogen peroxide can also be detected, generated
probably from the dismutation of superoxide, thus:-
2H+ + 02~ + 02~ > 02 + H202.
It is highly likely that other reactive oxygen species are
also generated, and from their destructive effects on
bacteria, it could be predicted that the extracellular
appearance of such reactive moieties could cause unwanted
damage to normal tissue. This is believed to be the case in
certain disease states (see sections 3 and 4 of this chapter).
Deficiency of the PMN oxidase is seen in the inherited
condition chronic granulomatous disease, in which impaired
function of the microbicidal myeloperoxidase-halide-hydrogen
peroxide system leads to chronic sepsis from early in life
with both Gram positive and Gram negative bacteria, which are
40
ingested but not killed . There is no respiratory burst
during phagocytosis, which can be detected by failure of
33
reduction of nitroblue tetrazolium , or by direct measurement
of superoxide or hydrogen peroxide.
D. PMN secondary granules and their extra-cellular
functions.
(i) Contents (see Table 2)
The secondary or specific granules of PMN's contain
about half the cell's lysozyme, and practically all the
intracellular lactoferrin"^ and cobalamin binding protein
43
(CBP) , also referred to as vitamin B binding protein
although it binds other cobalamins as well as vitamin B.^ or
cyanocobalamin.
(ii) Responses to stimuli
Secondary granules respond quite differently from
primary granules during either phagocytosis or exposure to
soluble stimuli. Phagocytosis produces a degree of secondary
19
granule fusion with the phagosome , but most of the secondary
44 45
granule components CBP and lactoferrin appear
extra-cellularly. In contrast, very little primary granule
. 44
content appears extracellularly during phagocytosis . A
similar disparity is seen when considering extracellular
granule release in response to a variety of soluble stimuli.
For some stimuli e.g. the phorbol ester phorbol myristate
acetate, significant secondary granule release occurs with
46
absolutely no primary granule discharge at all . For other
stmuli such as C or FMLP, secondary granule release takes
27
place both more rapidly and to a much greater extent than does
47
primary granule release . This sequential release of granule
contents would support the hypothesis that the two granule
types are controlled by different mechanisms.
(iii) The use of cytochalasin B in degranulation studies
Cytochalasin B (CB) is a fungal metabolite which
prevents the polymerisation of cytoskeletal actin necessary
48
for phagocytosis . When presented to the cell along with a
phagocytic stimulus, CB thus blocks phagocytosis and the
primary granules discharge themselves not into the phagosome,
49
but into the extracellular environment . Addition of CB to
PMN's along with a soluble stimulus, however, greatly speeds
49
up and magnifies both primary and secondary granule release ,
with secondary granule release beginning in seconds and
reaching a plateau in 2 or 3 minutes, as opposed to the 45 or
60 minutes needed in the absence of CB. Despite these major
effects, CB causes little or no degranulation when added in
the absence of a stimulus.
CB has become widely used in experimental studies of
control of degranulation and investigation of the actions of
degranulation inhibitors. It may be argued that its use is
unphysiological and renders interpretation of results open to
question. On the other hand, it has been pointed out that the
study of PMN's in suspension is in itself highly
unphysiological, as responsive PMN's in vivo are almost
23
invariably adherent to a surface , be it vascular
endothelium, collagen or fibrin. The addition of CB to
in vitro studies, it has therefore been argued, actually
restores conditions to a more natural state by substituting
for an adherent surface, and allowing the cells to behave as
23
they would in vivo . CB has been used in this study as an
enhancer of stimulus-induced secondary granule release,
although many comparable experiments have been performed
without it. The role of surfaces in the PMN response to
in vivo inflammation is further discussed in section 4 of this
chapter.
(iv) The extracellular functions of PMN secondary granule
components.
a. Lysozyme. Its actions on bacteria outside the cell
are probably similar to those seen when it enters the
phagosome. In addition, it appears to inhibit PMN
50
chemotaxis , thus localising PMN's to inflammatory sites.
Lysozyme also appears to act as a negative feedback of PMN
activation, for there is some evidence that it suppresses
superoxide generation^0.
b. Cobalamin binding protein (CBP). This occurs with
lactoferrin in many body fluids, as well as in PMN secondary
granules, where it is in a completely unsaturated form. There
are several different cobalamin binding proteins
(transcobalamins) in the body, with different binding
affinities for the various cobalamins and corrinoids, of which
cobalamins are a subgroup. The CBP in neutrophils is of the R
binder type i.e. it particularly binds cobalamin analogues of
51
vitamin B^ (cyanocobalamin) rather than the vitamin itself
Its function is not known, although it may have a role in
removing cobalamin analogues produced by bacteria.
There may also be a binding protein for folate in PMN
secondary granules, (Sheppard K, unpublished observations) but
29
as yet this is poorly characterised.
c. Lactoferrin. This iron binding protein is present in
PMN's in a completely unsaturated form, so that it readily
binds any free iron present in the surroundings. Since iron
is a growth factor for certain bacteria, this chelating action
33
may be protective . Lactoferrin also promotes PMN adhesion
both to other PMN's and to endothelium, a property which may
52
amplify the inflammatory response . Lactoferrin may
additionally have a role in bacterial killing, for in the rare
inherited condition of specific granule deficiency, moderate
53
impairment of bactericidal activity is seen . While the
exact basis for this is not known, it may be indirectly due to
lack of lactoferrin-bound iron, which can promote the
production from superoxide of the highly toxic hydroxyl
54
radical . A further important role for lactoferrin appears
to be in the control of PMN production (granulopoiesis). The
growth of myeloid or granulocytic colonies in culture depends
on the presence of one or more colony stimulating factors
(CSF) produced via a series of complex interactions between
55
monocytes and lymphocytes . Cell-free supernatants from
activated PMN's can exert an inhibitory effect on CSF
56
production , and there is now evidence that lactoferrin may
57
play a major role in this control process
It can thus be seen that extracellular discharge of PMN
secondary granules plays an important role in the inflammatory
response, as do also biologically active lipid mediators
generated on cell stimulation. A fuller discussion of the
effects of these and of PMN products generally in inflammation
and tissue damage follows in section III of this chapter.
SECTION II. THE COMPLEMENT SYSTEM AND ITS EFFECTS ON
NEUTROPHILS
A. Functions and activation pathways
The human complement system consists of a series of nine
plasma proteins (Cl-9) which circulate in an inactive state,
and which, when activated, undergo a cascade of cleavage
reactions resulting in the generation of biologically active
peptides, and of complexes which can damage the membranes of
bacteria, viruses and foreign cells. In addition, attachment
of complement proteins, particularly C^, to foreign material
assists in its adhesion to and phagocytosis by PMN's and
macrophages. Thus the system exerts a primarily protective
function, although endogenous tissue damage may also result
from complement activation. There are two pathways by which
the system may become activated, each with its own control
proteins. The classical pathway is primarily activated by
antigen-antibody complexes, while the alternative pathway is
triggered largely by foreign material and cell surfaces'^
(Table 3). The later steps in each pathway are identical.
The classical and alternative pathways (Fig 3) differ in their
requirement for divalent cations, the former being calcium
dependent, while the latter requires magnesium.
31
Classical Pathway





























^ * C6, C7, C8, C9
C5b-9
Membrane lysis
Fig 3. The classical and alternative complement pathways.
Table 3
32





Antigen may be soluble
or a surface component
Antibodies must be






Yeast cell walls (zymosan)
Cell surfaces of certain
bacteria and fungi
Certain immune complexes




Modified from Goldstein 1980
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B. Anaphylotoxins
It is crucial to the understanding of the complement
system to appreciate that many active conversion products of
complement proteins will remain attached to the target cell
e.g. C^, an(3 will fix to that site later components in
the pathway. These solid phase components contrast with a
number of smaller proteins, e.g. an<^ C4a' ^nown
collectively as anaphylotoxins, which can diffuse through
tissue fluids and set up concentration gradients with effects
on motile cells such as PMN's and monocytes. In addition,
such proteins can interact with fixed cells such as mast cells
and tissue macrophages, triggering secretion and thereby
amplifying the tissue response to infection. The term
anaphylotoxin refers to the ability of and C to trigger
33
severe anaphylactic reactions in animals and man, with
collapse, hypotension, bronchospasm and death. This property
appears to be mainly due to mast cell activation, with release
of histamine and other mediators, leading to contraction of
59
bronchial and vascular smooth muscle . Indeed contraction of
guinea pig ileum is one traditional biological assay for these
mediators. A further property of C and C. is the
J3 ->cl
production of increased microvascular permeability in the
59
skin . All properties of C^a and C^a are displayed down to
nanomolar concentrations^0. Not surprisingly, these powerful
molecules have a half-life of only a few minutes in vivo,
being acted upon by a plasma enzyme carboxypeptidase B, which
removes their carboxy terminal amino acid arginine generating
C^a des Arg and C^a des Arg respectively . Although these
stable derivatives are 100-1000 times less active towards mast
6 2
cells than Cb or Cc , they remain active in their effectsJa ba
on PMN's and macrophages, and C^. des Arg remains a potent
60
producer of increased vascular permeability (see Table 4).
The anaphylotoxic properties of C^a are 2-4 orders of
64
magnitude less than those of CU or
34
Table 4
Biological activities of C,-, C^^ and their des Arg
derivatives
Co C0 Cc Cc3a 3a 5a 5a
des Arg des Arg
Contraction of smooth + - + -
muscle
Mast cell degranulation + - +
Increased vascular + ? + +
permeability
PMN chemotaxis - - + +*
and activation
6 3
* may require 'helper factor' or 'cochemotaxin' from plasma
C. Interactions between and fragments and PMN's.
This study is particularly concerned with the effects
of C^a and and their des Arg derivatives on PMN
activation and degranulation in vitro, and on the
micro-circulation and permeability control in vivo. One of
the technical difficulties in describing the actions of
and cleavage products is that native and are
structurally very similar, as are C and Cc , although3cl j3
human C,. has a small carbohydrate side chain^. The
methodological limitations to the separation of these
molecules were not overcome till 8 or 10 years ago, so that
in discussing the biological actions of C^a and C^a, the
literature prior to the mid 1970's referred to both of them
as chemotactic factors for PMN's. More recent work on the
35
effects of C_ and Cr on PMN's however has cast doubt on3a 5a
whether or its des Arg derivative have any effects on
PMN's at all. A careful study of chemotaxis showed that
neither C^a nor C^a des Arg could activate PMN's, and
proposed that earlier results suggesting that they could
were due to contamination of C^a preparations by small
66
amounts of potent C^. . This point will be further
examined in this study.
C,_a and C^a des Arg are both capable of activating
PMN's through the same receptor although the des Arg form
20
has reduced binding affinity , and its for PMN
22
effects is 10-20 times higher . (See Table 5)
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Table 5
Concentrations of human C,. and Cn des Arg5 a 5a ■2-


























N.D. = Not determined
60 .22
Combined data from Hugli 1979 and Webster et al 1980
The estimated concentration of either or Cc5a 5a
des Arg which could be generated in maximally activated
plasma is 3-8. 5xl0~^M^.
Since C,_ and C^ des Arg are always produced togetherj3 J3
and because their effects on PMN's are qualitatively similar,
they will henceforth be described collectively as C^
fragments, unless one or other is specifically stated.
Although C fragments are well known for their5
chemotactic properties towards PMN's, chemotaxis is but one
response of the cell to such stimuli. If the cells are in
suspension, aggregation follows within minutes, accompanied by
37
release of secondary granule components and generation of
22
superoxide via the membrane oxidase . More intense
6 7
stimulation can also lead to primary granule discharge
Involvement of such mechanisms in the production of tissue
damage in various disease states is discussed in the next
section.
D. Inactivation and clearance of des Arg
Two mechanisms of inactivation of Cr des Arg have been5a
described. The first is a plasma inactivator of many
6 8
different chemotactic factors first described in 1973 , known
as chemotactic factor inhibitor (CFI). Prolongation of the
plasma half-life of Cj. des Arg injected intravenously into
rabbits by protease inhibitors such as aprotinin may represent
69
blockage of CFI . CFI, which may have more than one
70
component , has been reported as being elevated in certain
conditions such as sarcoidosis, Hodgkin's disease and
.71 . .
cirrhosis . The significance of this observation to the
pathogenesis of these diseases remains unclear.
The second way by which C^. des Arg is cleared from the
circulation and tissues appears to be via PMN's themselves.
Once Cj. des Arg has bound to PMN surface receptors, the C^a
des Arg-receptor complex becomes internalised, and the Cj. des
72
Arg is no longer available . The plasma half-life of
73 6973
labelled C^. and C^a des Arg ' was prolonged in
neutropenic rabbits, almost entirely due to reduced splenic
uptake of the label. Accumulation in the lungs, however, was
independent of circulating PMN's and was probably due to C,.
and C,_ des Arg adhering directly to the vascular
73
endothelium . This may have bearing on the lung damage
38
believed to be produced by activated complement and PMN's in
the adult respiratory distress syndrome or shock lung,
described in section III of this chapter.
E. Detection of complement activation.
Although assay of non-activated (native) complement
components such as and by radial immunodiffusion is now
standard in immunological laboratories, such measurements give
little information about the state of complement activation or
turnover, since increased conversion and breakdown of and
may be offset by increased synthesis. Such information can
be gained only by assay of fluid phase activation products
such as or fragments. At present, this is readily
possible only for fragments. Methods available include 2
dimensional Immunoelectrophoresis (measuring mainly C^c and
74
C^) and rocket electrophoresis for • Such methods are
not however sensitive enough to detect the tenfold lower
concentrations of fragments produced even in maximally
activated plasma^0, and for this reason, biological assays
have till now been their main method of detection. The
traditional anaphylotoxin assay employing contraction of
guinea pig ileum has however two major drawbacks, as well as
being time-consuming and technically complicated. Firstly, it
does not differentiate between C_ and Cn , which both have3a 5a
anaphylotoxic properties, and secondly it does not detect the
stable and potent PMN activator des Arg. Assays utilising
the unique actions of fragments on PMN's have therefore
75
been devised. These incude PMN aggregation and
degranulation, which is investigated in this project.
Finally, radioimmunoassay for C /C^a des Arg is becoming
39
available as a research tool. The relative advantages and
disadvantages of these various assay systems are discussed
more fully in chapter 2.
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SECTION III. THE ROLE OF NEUTROPHIL ACTIVATION BY CHEMOTACTIC
COMPLEMENT FACTORS IN HUMAN DISEASE.
Clearly the most commonly occurring situation in which
generation of C^ fragments leads to PMN recruitment and
activation is in local tissue infection, where demarcated self
limiting tissue injury is seen, but which resolves without
major problem.
In other circumstances, however, interaction between Ccb
fragments and PMN's may have more serious consequences.
Situations in which C._ fragment generation and/or neutrophilb
activation are believed to be important in disease production
are listed in Table 6.
Table 6
Situations in which complement and/or PMN activation may be
important in disease production in man.
1. Adult respiratory distress syndrome.
2. Haemodialysis and cardiopulmonary bypass.
3. Following surgery or burns.
4. Rheumatoid arthritis and gout.
5. Myocardial infarction.
6. Sepsis.
A. Adult Respiratory Distress Syndrome (ARDS - synonyms
include shock lung and fat embolism syndrome).
7 6
This puzzling condition, carrying a 60-70% mortality ,
complicates a number of disorders including septicaemia,
particularly with Gram negative organisms, multiple trauma,
41
• • 77
pancreatitis and thermal injury . The earliest clinical
features are dyspnoea and hypoxia, and although the chest Xray
may be initially unremarkable, patchy shadowing quickly
develops across both lung fields. A protein-rich alveolar
exudate develops so that the lungs become stiff, and
artificial ventilation requires high inspiratory pressures.
There is no specific therapy, beyond support and treatment of
the antecedent condition, although some centres claim benefit
7 8
from very high dose steroids i.e. in gram quantities
Although the exact pathogenesis of the condition is not fully
known, evidence is accumulating from both animal and human
studies that complement and/or PMN activation plays a part in
the abnormal permeability of the pulmonary vasculature and the
resulting lung damage. For example, the increase in pulmonary
capillary permeability to labelled proteins was increased in
. .79
sheep following experimental pancreatitis and in guinea pigs
80
following challenge with intravenous pneumococci . In either
case, the permeability change was absent or reduced in
neutropenic animals. Administration of pre-prepared
80 81
fragments either intravenously ' or directly into the
8 2
lungs can also produce some of the changes of ARDS, with PMN
adhesion to pulmonary endothelium, migration into alveolar
spaces, and increased vascular permeability which is again
80
preventable by neutropenia . Observations in human ARDS have
highlighted the frequent development of transient neutropenia
8 3
immediately prior to the appearance of clinical signs ,
thought to be due to PMN trapping in the lungs. PMN's
entering the lungs may have already been 'primed', with
increased basal superoxide production in pulmonary artery
42
84
PMN's , and increased basal enzyme release with impaired
7 6
chemotaxis in peripheral blood PMN's . Neutrophil elastase
has also been found in bronchial lavage fluid from ARDS
4- • 4- 85patients
In a review of experimental complement-mediated ARDS,
Henson points out that production of the full picture of ARDS
8 6
may also require an additional insult such as hypoxia , and
also stresses that although fragments undoubtedly cause PMN
aggregation in vitro, they may trigger PMN adhesion to
endothelium rather than to each other, when present in the
circulation. Indeed the endothelium itself may be altered by
C,. fragments such that PMN/endothelial adhesion is enhanced.
Other contributory factors may include pulmonary macrophages
8 7
which can be acted upon by PMN granule glycoproteins , and
which may compound the situation by the release of enzymes
8 8
capable of generating further Cj. fragments from , and by
the synthesis of chemoattractant lipid products such as
platelet activating factor and leukotrienes.
One metabolic feature of the PMN which may be important
in the production of lung damage is the membrane oxidase which
generates the superoxide anion and hydrogen peroxide from
molecular oxygen. Lung damage produced in animals by the
complement activator cobra venom factor could be prevented by
either the hydroxyl radical scavenger dimethyl sulphoxide or
the ionic iron scavengers desferrioxamine and apolactoferrin
8 9
(but not iron saturated lactoferrin) . This has led to the
hypothesis that generation of the highly reactive hydroxyl
radical, a reaction catalysed by Fe^+, is an important step in
the production of increased vascular permeability, perhaps via
peroxidation of membrane lipids. The reactions are:-
~ - 3+ 2+
02 + Fe >02 + Fe
(superoxide
anion)
Fe^+ + H2°2 ^Fe^+ + OH- + 0H~ (Fenton reacti
(hydrogen (hydroxyl (hydroxyl
peroxide) radical) anion)
02 + H2®2 * ^2 + 0H (Haber Weiss Reaction)
One proposed mechanism of ARDS production is therefore
that fragments generated either in the circulation or in
the lungs, increase adhesion between PMN's and pulmonary
capillary endothelium either by altering either the PMN or
endothelial cell membrane, or both. Migration of PMN's
through into alveoli may then follow, with release of granule
contents and toxic oxygen products, leading to increased
vascular permeability and exudate production. Possible
mechanisms for this will be discussed further in the next
section. Some of the lungs' protective mechanisms such as
8 5
antitrypsin may also be destroyed by oxidation . Other
cell types, such as pulmonary macrophages and platelets, may
also play a part in the production of some of the features of
the condition, but complement and PMN activation appear to be
central.
Several points of interest emerge from this hypothesis.
Firstly, the role of Gram negative sepsis, and particularly
90
of endotoxin, appears to be a major one . Haemorrhagic
44
shock alone, for example, does not appear to cause ARDS in
man. As well as being a potent activator of the alternative
complement pathway, endotoxin may alter pulmonary endothelium
directly, rendering it 'sticky' and more liable to trap PMN's
by preventing release of temporarily marginated cells.
Secondly, the possible therapeutic benefit of high dose
steroids in ARDS may at least in part be explained on the
basis of an inhibitory effect on PMN's, for high
concentrations of hydrocortisone inhibit PMN degranulation in
91
vitro in response to either C^. or FMLP . Although the
millimolar concentrations required for inhibition of
degranulation in vitro are much higher than those achieved by
'normal' steroid dosage in vivo, intravenous administration
of the 30mg/kg of methyl prednisolone recommended for shock
by the current British National Formulary (1985) means that
these millimolar levels may be approached in plasma.
Thirdly, it is apparent that clinical diagnosis of
ARDS, based on radiological, blood gas, and ventilatory
criteria, can only be made once the condition is already well
advanced pathologically. While prevention of PMN involvement
may be possible with high dose steroids, little can be done
once lung damage supervenes. If free C,- fragments can be
detected in the circulation of ARDS patients, and if, as is
claimed, their detection is a better predictor of ARDS than
the currently available fragment detection by
92
immunoelectrophoresis , then a reliable, robust detection
system for fragments should prove a valuable tool in ARDS
detection and management. This aim is further elaborated in
chapter 2.
B. Extracorporeal circulation of blood : haemodialysis and
cardiopulmonary bypass.
The observation that when a cellophane membrane was
used for haemodialysis a transient neutropenia and
monocytopenia was seen during the first hour of dialysis, led
to the finding that dialysis cellophane can activate
93
complement . Infusion of plasma leaving the dialyser into
rabbits produced identical leucopenias, with PMN entrapment
93
in pulmonary capillaries . Although dialysis neutropenia is
now well documented it rarely gives rise to clinically
significant pulmonary damage. Similar activation of has
94 95
been seen in cardiopulmonary bypass ' , with the nylon
mesh liner of bubble oxygenators being a potent complement
95
activator, as well as the oxygenation process itself
Although elevated levels of free C^. in association with
bypass have not been reported, the neutrophilia pertaining
during bypass may be followed by a neutropenia immediately on
reestablishment of cardiopulmonary circulation, suggesting
95
pulmonary entrapment of C -coated granulocytes . WhetherId ci
this phenomenon is responsible for any of the pulmonary
complications of cardiopulmonary bypass is as yet unclear.
C. Post-operatively and following burns.
The complement and neutrophil changes in ARDS may
differ only in degree from the effects of much less severe
trauma, such as elective surgery. Elective gastric surgery,
for example, is frequently associated with rapid conversion
96
of and a fall in and levels . A study of patients
undergoing elective hysterectomy has also shown evidence of
intravascular release of PMN secondary granules, with
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intracellular levels of both lysozyme and NCBP falling to
about 60% of their pre-operative levels within four hours of
skin incision"'". The changes were not seen in patients
undergoing minor procedures only, and could not be accounted
for by anaesthesia, endogenous release of glucocorticoids or
release of young cells from the marrow. Plasma levels of
both NCBP and lysozyme both rose post operatively and were
significantly elevated by the fifth post operative day.
Similarly, loss of PMN lysozyme has been seen following
97
burns , as have raised plasma levels of another secondary
98
granule marker, lactoferrin . Interestingly, intravenous
administration of the chemotactic peptide FMLP into rabbits
has resulted in both transient neutropenia and raised plasma
99
lactoferrin , confirming that stimulus-mediated lactoferrin
release from PMN's can occur intravascularly. The clinical
significance of such changes following surgery and burns is
not clear, although in both circumstances there are also
2 97
defects in neutrophil function '
D. Rheumatoid Arthritis and Gout.
Although rheumatoid arthritis is characterised by the
development of lymphocyte-derived rheumatoid factors, a
prominent PMN infiltrate is seen in synovial fluid and in the
synovium itself, where some of the tissue damage may be
caused by PMN proteases"*"00 and oxygen products"'"0"''. Evidence
of classical complement pathway activation is also seen in
synovial fluid with isolation of breakdown products,
and the complex"'"00, and low levels of C-^, and .
Such complement activation is not a feature of traumatic or
degenerative joint conditions.
C"5a generation and neutrophil activation may also play
a part in gout. Monosodium urate crystals can not only
activate the alternative complement pathway"*"0! but may
trigger PMN's directly. Indeed, joint damage due to
intra-articular urate may depend on the presence of PMN's"*"00.
E. Myocardial Infarction.
There is evidence for plasma activation of the
classical complement pathway in the first 72 hours following
104
acute myocardial infarction in man . In experimental
infarction in dogs, prior complement depletion using cobra
venom factor significantly reduces both PMN infiltration and
105
extent of myocardial necrosis . The zone at the edge of an
area of established infarction usually receives an early
influx of PMN's and may itself then become infarcted.
Infusions of PMN-inhibiting anti-inflammatory drugs such as
106
the cycloxygenase inhibitor ibuprofen and the combined
cycloxygenase/lipoxygenase inhibitor BW755C"*"°^ both attenuate
this PMN infiltrate and reduce infarct size significantly,
with no effect on platelet infiltration. Moreover, induction
of neutropenia prior to experimental infarction also results
in smaller infarcts"*"0^.
F. Sepsis.
In discussion of ARDS, myocardial infarction and gout,
the basic hypothesis has been the same, i.e. that unwanted
PMN activation by fragments or other complement components
leads to the extracellular release from PMN's of tissue
damaging compounds, and that inhibition of such PMN
involvement might prevent some of the clinical
manifestations.
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Excessive exposure of PMN's to C,_ fragments or other
soluble stimuli may have another effect however, which is to
prevent the cell responding appropriately to an infective
agent. As mentioned previously, both surgery and burns are
conditions in which complement and PMN activation appear to
occur in the absence of infection. Both are also associated
with defects of PMN function, namely reduced intracellular
2
killing postoperatively , and impaired chemotaxis with loss
97
of granules following burns . It may therefore be that once
the cell has been initially activated by C^. and partially
degranulated, a state of unresponsiveness ensues.
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SECTION IV. IN VIVO MODELS OF NEUTROPHIL-MEDIATED TISSUE
DAMAGE
A. Introduction
Attempts to relate the in vitro responses of PMN's to
the in vivo signs of inflammation have been in progress for
over thirty years. The cardinal signs of inflammation,
namely rubor (redness), calor (heat), tumor (swelling), and
dolor (pain) are almost invariably accompanied by a marked
PMN infiltrate, but the ways in which these relate to one
another are not yet fully unravelled. The aspects of
PMN-related inflammation with which this study is concerned
are the vasodilatation responsible for both heat and redness,
and the increase in vascular permeability which must precede
the formation of tissue oedema and swelling. The work
attempts to explore the ways in which these changes result
from PMN-complement interactions. Most previous studies of
this nature have been done, for obvious reasons, in animals,
but since there is considerable interspecies variation in the
properties of certain complement components, extrapolation
from animal studies to man is not always valid. However, a
review of some animal models will demonstrate how the problem
has been approached.
B. Early descriptive studies of PMN-dependent tissue damage
In the late 1940's and 1950's, before immunoglobulin
and complement components could be purified, a number of
models were used to produce inflammatory tissue damage in the
skin of animals. Two such models were the Arthus and
Schwartzman phenomena, which were recognized as having many
50
108
features in common . The Arthus phenomenon is produced by
giving an animal repeated intradermal injections of an
antigen till it becomes sensitized i.e. produces an
appropriate antibody response. Further injections of antigen
at the same site then produce local necrosis, with a
histological picture showing clumps of PMN's in vessels and
109
migrating into the tissues . A slightly different
technique, the Reversed Passive Arthus reaction (RPA),
involves giving the antigen intravenously followed by
intra-dermal injection of antibody. A similar histological
picture results"'""'"0. The Schwartzman phenomenon is produced
by injecting bacterial endotoxin into the skin, followed 24
hours later by an intravenous injection of the same
endotoxin, and was first described by Schwartzman in 1928"'""''"''.
Two to six hours after the intra-dermal injection, a
haemorrhagic skin reaction develops locally, with evidence of
PMN accumulation and vascular injury histologically. Unlike
the Arthus reaction, agglutinating or precipitating antibody
112
is not involved . With present day knowledge, it is clear
that the Arthus reaction involves the development of
complement fixing antibodies. The exact mechanism of the
Schwartzman reaction is less clear, but probably, as with
both the Arthus and RPA reactions, includes complement
activation. Generation of Cc fragments would then result inb
PMN recruitment.
The technical limitations of the time did not prevent
investigators making astute observations and speculations as
to how the tissue damage of the Arthus and Schwartzman
phenomena might be being produced. These included the
51
following:-
1. In 1948, Becker produced suppression of the
Schwartzman reaction in the rabbit by benzol (the alternative
name for benzene), irradiation and nitrogen mustard, provided
112
they were given 2-3 days before the intravenous injection
He concluded, however, that:
"suppression by these agents is exerted through their
specific but common suppressive action on the
reticuloendothelial system, primarily the vascular
endothelium. These endothelial cells being rendered
anergic are not able to react to the active principles
in a way that otherwise would be self-destructive"
We do not now think that these agents would significantly
alter vascular endothelium, but were probably working via
marrow suppression.
2. In 1951, Stetson and Good, also using rabbits,
confirmed the suppressive effects of benzene and nitrogen
mustard on the Schwartzman reaction, and found that this
suppression correlated closely with the degree of
neutropenia"'""'"^. Lack of suppression was seen in animals
whose marrow was protected from the effects of the nitrogen
mustard.
3. Stetson also observed that the intravenous injection
. 114
of antigen was accompanied by a transient neutropenia
prior to the onset of skin necrosis, and that clumps of PMN's
and platelets were seen plugging capillaries in the lungs and
other organs. These observations bear close resemblance to
changes seen in experimental models of ARDS.
Following these studies, Stetson drew attention to the
similarities in development of Arthus and Schwartzman
lesions, viz:-
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(i) perivascular PMN accumulation in affected skin area
(ii) increased aerobic glycolysis in injected area
(probably due to the large numbers of PMN's)
(iii) production of leucocyte and platelet blockage of
capillaries locally and elsewhere
(iv) transient systemic neutropenia
108
(v) haemorrhage from affected vessels
4. Observations on the Reversed Passive Arthus reaction
115
in the rabbit were made by Humphrey in 1955 , who again
demonstrated suppression of the reaction by exposure of
marrow to nitrogen mustard. Partial restoration of responses
could be obtained by local injection of harvested exudate
PMN's from other animals. These PMN's would have been
already activated and partly granule depleted by the initial
harvesting procedure, so lack of complete restoration of
responses is not surprising. Humphrey also formally
demonstrated an increase in capillary permeability and showed
marked inhibition of responses by cortisone or ACTH and
partial reduction by sodium salicylate, though not by
. . . 115
antihistamines . He attributed these findings to an effect
on endothelium, but inhibition of PMN activation is an
. . 91
alternative possibility
5. In 1965, Kniker and Cochrane induced yet another
type of antigen-antibody mediated tissue reaction in rabbits,
namely serum sickness"'""'"^. In this model, antigen-antibody
complexes, formed in antigen excess and hence soluble, are
deposited in the vessel walls of many organs, including
kidneys, joints and heart. Lesions in coronary arteries show
endothelial proliferation and damage to the internal elastic
D3
lamina, with sub-endothelial fibrinoid and damage to the
media. In animals rendered neutropenic, although immune
complexes could still be demonstrated in vessels by
immunofluorescence, coronary artery damage was much reduced,
and damage to the internal elastic lamina was absent.
C. Quantitative studies using purified chemotactic factors.
Studies which have attempted to quantify the vascular
permeability changes and other skin changes produced by
purified complement components and other chemotactic stimuli,
have been notably performed by two groups of workers,
Issekutz and colleagues in Toronto, and Williams and
colleagues in London, both using rabbits. Issekutz and
co-workers demonstrated that intradermal injection of various
chemotactic factors, including human complement-activated
plasma, partially purified C,. des Arg, and the bacterial
peptide FMLP not only caused accumulation of ^"'"Cr-labelled
PMN's in the skin, but was associated with a rapid increase
in vascular permeability, as measured by leak of
1hr 117 118
I-labelled albumin from capillaries ' . Both PMN
accumulation and the permeability increase took place in the
first hour following injection, and PMN's continued to
accumulate for 3-4 hours. In some animals, neutropenia was
induced by intravenous nitrogen mustard. During the period
of neutropenia, intradermal injection of activated complement
was not associated with either an increase in vascular
118
permeability or red cell leakage
A further model which the Toronto group used was
intradermal injection of whole E coli which, as expected,
also caused PMN accumulation, as well as the permeability and
54
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red cell effects produced by chemotactic factors alone
Their action was independent of complement, but again,
neutropenic animals did not show the micro-vascular changes
of neutrophil replete animals. Their work therefore suggests
that activated PMN's in some way are able to impair the
ability of small vessel endothelial lining cells to prevent
fluid and protein loss from the circulation.
Williams and co-workers confirmed that complement
activation results in the generation of a permeability factor
120
with the physico-chemical characteristics of C[- and also
found that this permeability factor was inactive in the skin
121
of neutropenic animals . Their studies on the mechanism of
action of Cr also demonstrated that:-5a
1. its permeability effects in rabbit skin could not be
inhibited by concentrations of anti-histamines which totally
abolished histamine-induced skin oedema, suggesting that Cj.
.Del
does not act via skin mast cell activation"*"^'
2. the des Arg form of human C^, demonstrated to be
inactive by the standard guinea pig ileum assay for
anaphylotoxic activity, could still increase skin vascular
permeability, further proof of a mast cell-independent
. . 122
mechanism
Their observations and conclusions, however, differ in
one important regard from those of Issekutz et al. While
Issekutz et al found that both complement-activated plasma
and partially purified C des Arg each produced significant
D3.
permeability changes when injected alone, Williams et al
could not demonstrate a permeability effect of either or
C,_a des Arg unless a vasodilator such as prostaglandin
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(PGE^) was injected also . This has been termed the 'two
mediator hypothesis' of inflammation and proposes that for
significant tissue oedema to be produced by an inflammatory
stimulus, there must be generation of both an endogenous
vasodilator such as PGE^ and a permeability promoting factor
123
such as C^. des Arg . Thus a stimulus like whole zymosan
(dead yeast cell walls) can cause extravasation of plasma
through both complement activation and prostaglandin
synthesis. Anti-inflammatory agents which inhibit
prostaglandin synthesis (e.g. aspirin, indomethacin etc)
suppress the increase in local blood flow and hence block
local oedema formation. Exogenous C,. or C^a des Arg, in
contrast, produces little extravasation alone, but its action
can be greatly potentiated by the addition of PGE2.
Why there should be such disparity between the findings
of the two groups is not immediately obvious. Williams et al
appear to have used much purer preparations of C[- and C^a
des Arg so it may be that the partially purified material
used by Issekutz et al contained an additional vasodilator or
permeability promoting factor. Alternatively, the results
may simply reflect differences in concentrations of mediators
injected. Williams' group used human C^a des Arg at a
concentration of lo""*"0 - lO-"^ mol/site in an injection
volume of 0.1ml, equivalent to 10 ^ - 10 , which, at
least at the upper end of that range, is within the effective
6 6
concentrations of C,_ des Arg for PMN activation . Because5a
Issekutz et al used less than pure material, exact
concentrations of C^. des Arg cannot be calculated, and their
technique for measuring skin response is also different from
56
that of Williams et al, so quantitative comparisons cannot
readily be made. These disparities, although important when
considering detailed mechanisms of inflammation, do not alter
the two main findings agreed by both groups, which are (1)
the C,. derivative, des Arg, increases vascular
permeability in rabbit skin when injected locally (2) this
effect is absent in neutropenic animals. Some possible
explanations for this will now be considered briefly.
D. Possible mechanisms for the effects of PMN's on vascular
permeability
For PMN's to increase vascular permeability in the
skin, they would require to have one or more of the following
effects
1. release of a mediator or mediators which would act
directly on vascular endothelial cells to produce gaps
between them or to impair their integrity. Examples of
possible mediators with direct effects on the vessels are the
124
cyclooxygenase product prostaglandin , the lipoxygenase
125
product leukotnene and the phospholipid derivative
126
platelet activating factor . Endothelial integrity might
also be impaired by toxic oxygen species generated by the PMN
127
oxidase
2. release of mediators which would act on another cell
type to release a second mediator with effects on the
endothelium. An example of this is the mast cell stimulation
128
produced by the myeloperoxidase-^C^-halide system
3. production of gaps between endothelial cells by
direct PMN/endothelial interaction and PMN migration, as
121
suggested by Williams
The work in the in vivo section of this study (Chapters
4 and 5) will therefore attempt to answer the following
questions:
1. Does activated human complement increase blood flow
and vascular permeability in human skin, and if so, which
complement components are responsible?
2. Does this effect require an exogenous vasodilator?
3. Does this effect require circulating PMN's?
4. If so, how are they acting?
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CHAPTER 2
IDENTIFICATION OF PMN DEGRANULATING ACTIVITY IN ACTIVATED
COMPLEMENT AND USE OF A PMN DEGRANULATING SYSTEM TO DETECT
COMPLEMENT ACTIVATION.
The work in this chapter was performed in collaboration with
Dr J M Davies.
INTRODUCTION ^
In this chapter, the effects of activated complement on
PMN cobalamin binding protein (NCBP) release are studied, and
attempts made to identify, both functionally and
immunologically, the complement component(s) responsible. The
uses of a PMN degranulating system are then explored, with
particular reference to the detection of complement
activation.
The role of activated complement as an important source
of PMN degranulating activity in the circulation was suggested
by observations on patients following elective surgery, as
discussed in Chapter 1, Section III. Surgery causes a rapid
fall in intracellular levels of NCBP and lysozyme, within
circulating PMN's taken postoperatively, suggesting that
surgery generates a degranulating stimulus intravascularly"*".
This stimulus does not appear to arise from the coagulation,
3
kinin, or fibrinolytic pathways . PMN's incubated in vitro,
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however, with serum in which the alternative complement
pathway has been activated with the yeast cell wall product
3
zymosan, show rapid release of NCBP . Evidence that activated
complement is the PMN degranulating stimulus generated
postoperatively is suggested by studies showing that plasma
96
complement is activated by surgery , and also from in vitro
observations on PMN's taken from postoperative patients.
These PMN's show stimulus-specific desensitisation to
complement, which works as follows. If normal PMN's are
exposed to a degranulating stimulus, washed, and re-exposed to
the same stimulus, little further degranulation is seen. If,
however, the second stimulus is different to the first,
degranulation occurs normally. This phenomenon, known as
stimulus-specific desensitisation, is probably due to a
temporary loss of specific surface receptors for the initial
stimulus due to internalisation of receptor-ligand
29
complexes . Receptors for other stimuli are largely
unaffected. Post-operative PMN's, when challenged in vitro
with different stimuli, degranulate normally in response to
the bacterial peptide FMLP, but are refractory to
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complement-activated serum . This suggests that they have
been exposed to activated complement in vivo and that this
stimulus can arise within hours of the start of the
operation^.
The following steps in the identification of the
complement-derived degranulating activity will now be
described and discussed.
1. Optimal method for isolating PMN's and setting up a
degranulation system to detect NCBP release.
2. Optimal method for preparing activated complement.
3. Identification of degranulating activity by physical
and immunological means.
4. Uses of a PMN degranulation system.
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EXPERIMENTAL WORK
For details of suppliers of materials, see Appendix 1.
For details of buffers, see Appendix 2.
GENERAL METHODS
1. Preparation of Neutrophil Suspensions
Venous blood was mixed in plastic universal containers
with the anti-coagulant EDTA (ethylene diamine tetraacetic
acid-disodium salt). 0.34 mis of 1.34 x 10-1M EDTA was mixed
with 15 mis blood giving a final EDTA concentration of 3.04 x
-3
10 M. Two different separation procedures could then be
followed.
Method (i)
7.5 mis blood were carefully layered over 3 mis Monopoly
Resolving Medium, a Ficoll-Hypaque density gradient with a
specific gravity of 1.114, in a 10 ml glass tube. When spun
at 400g for 45 minutes at room temperature, separation of
plasma, mononuclear cells and PMN's in a single step was
130
seen (Fig 4).
The PMN layer was harvested and washed twice in cold
phosphate buffered saline, (PBS) by resuspending and spinning
at 100 g for 10 mins, and finally suspended in 4 mis PBS for
counting.
Notes 1. As contamination by red cells was usually very
slight, no specific measures were taken to lyse them. 2. To
prevent nonspecific release of neutrophil granules during the
preparation process, all washing and counting steps were
performed in PBS devoid of calcium and magnesium, which are
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Fig 4. Separation of blood into red cells, mononuclear
cells, neutrophils and plasma in a single step on a Ficoll-
Hypaque gradient.
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required for degranulation. Only when the degranulation
experiment was ready to begin was the required final volume of
phosphate buffered saline with albumin (PBS-A), containing
calcium and magnesium, added to the cells. Preliminary
studies determined the best concentration of albumin to use in
this solution (see below).
Method (ii)
Although method (i) of neutrophil preparation worked
satisfactorily for most donors, the blood of certain
individuals, usually females, did not fractionate
satisfactorily by this technique, because the red cells failed
to sediment through the Ficoll-Hypaque gradient. Examination
of these individuals' blood films and distribution of red cell
volumes usually indicated a mild degree of iron deficiency.
For such donors, neutrophils could be prepared by the
following technique:
EDTA-anticoagulated venous blood was layered on to
Lymphocyte Separation Medium, a Ficoll Hypaque mixture with a
specific gravity of 1.077, in the ratio of 3 volumes of blood
to 1 of LSM and centrifuged at 400 g for 20 minutes at room
temperatue. This causes separation of the mononuclear cell
layer while the red cells and PMN's sediment to the bottom.
The mononuclear cell layer was then discarded and the red
cell/PMN mixture remixed with the plasma. This suspension was
then mixed with 6% dextran in 5% dextrose, (MW = 70,000
Daltons), in a 1:1 ratio in a 30 ml syringe and allowed to
stand at an angle of 45° at room temperature for 60 minutes.
At the end of this time, most of the red cells had sedimented,
and the supernatant containing PMN's and some red cells was
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collected. The remaining red cells were lysed by exposure to
0.87% NH^Cl containing a small amount of NaHCO^ at 4°C for 5
minutes. The remaining PMN's were washed twice in PBS as
before then counted.
2. Preparation of activated ccmplanent in whole serum
Three main complement preparations were used as
degranulating stimuli (i) whole serum in which the alternative
complement pathway had been activated with the yeast cell wall
product zymosan, giving zymosan-activated serum (ZAS), (ii) a
similar preparation in which conversion of C0 and Cb toJcl
their des Arg forms had been prevented by the addition of
epsilon-amino caproic acid (EACA), giving EACA-ZAS, (iii) a
partially purified preparation of EACA-ZAS containing the
fraction which had passed through a 30,000 dalton molecular
exclusion filter (low molecular weight fraction - LMW fr, see
Exp 7 below).
Other complement-activated sera used in the
identification of the degranulating activity were heated, C,-
depleted or chromatographed (see below).
(i) Zymosan-activated serum (ZAS)
Venous blood from three or four donors was allowed to
clot in glass tubes for 60 minutes at room temperature, and
the serum separated by centrifugation at 1500g for 10 minutes.
The serum was pooled and mixed with boiled, washed zymosan
(final concentration 2mg/ml of serum) on a rotator at 37°C for
60 minutes. To remove the zymosan, the serum was centrifuged
at 1500g for 15 minutes and passed through a 0.8/u filter. 1.0
ml aliquots of the ZAS were stored under liquid nitrogen.
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(ii) Zymosan-activated serum containing EACA (EACA-ZAS)
To pooled serum, EACA was added and thoroughly
dissolved, and the serum complement activated with zymosan as
before. Preliminary studies compared various EACA
concentrations (see below), following which 0.5M was used in
all experiments.
3. The degranulation system
The general method of this type of experiment was the
same no matter what the stimulus, except that in some
experiments the cells were exposed to the fungal metabolite
cytochalasin B, which although unable to degranulate PMN's on
its own, both accelerates and amplifies degranulation in
response to most stimuli. The general outline is illustrated
in Fig 5. Where a drug inhibitor of degranulation was being
tested, it was usually added prior to the cytochalasin B.
Details of method
The PMN's were kept at room temperature, in an undiluted
form in PBS till the start of the experiment, when they were
diluted to the required volume with PBS-A. Each experimental
condition was performed in duplicate, and the final reaction
volume in each tube was 1.0ml. To start the experiment, 2 x
£
10 PMN's in PBS-A were pipetted into LP3 polypropylene tubes
and prewarmed at 37°C for 5 minutes. If cytochalasin B was
used, 0.1 ml of a 50yug/ml solution was then added giving a
final concentration of 5yag/ml, and the cells incubated with
it for 5 minutes at 37°C. 0.1 ml of the stimulus was then
added and the incubation continued for a further 5 minutes,
after which degranulation was terminated by centrifugation at
4°C at 1500 g for 10 minutes. The supernatants were removed
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Cytochalasin B 5pg/ml in DMSO
5 minutes at 37°C
Stimulus - ZAS
low MW fraction
5 minutes at 37°C
o.
Centrifuge at 4 C
Supernatant assayed for
cobalamin binding protein
Results expressed as a percentage of the total intracellular
cobalamin binding protein obtainable by sonication of the cells.
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and stored at -20°C till the NCBP assay was performed. Where
cytochalasin B was not included, the incubation time with the
stimulus was lengthened appropriately (see Chapter 3).
Calculation of results
Each experiment contained a blank (PMN's in PBS-A with
cytochalasin B if appropriate), and a sonicate, obtained by
sonicating a measured aliquot of PMN suspension containing 2 x
10 cells, at setting 5 on a cell sonicator for 2 minutes.
These conditions have been previously shown to give maximal
3
release of granule contents . The amount of NCBP in the
sonicate was therefore presumed to be 100% of the
intracellular level. Results were therefore calculated as
follows
o , mean of duplicates - blank l00o% NCBP release = £- x %
sonicate 1
4. Assay of neutrophil cobalamin binding protein
131
(unbound vitamin B.^ binding capacity)
This assay is based on the binding of vitamin B^
512]labelled with the Remitter "^cobalt (~*^CoB, „) , to the NCBP.
57
Excess Co B-^2 is added, and any which has not bound to NCBP
132
is removed by adsorption on to protein-coated charcoal
57
The Co B-^2 which has bound to NCBP is not taken out by the
charcoal, and appears in the supernatant which is collected
for counting. Each batch of samples contains a standard (no







































Thus the number of counts in the supernatant is directly
proportional to the concentration of NCBP present.
Notes
1. Because the assay depends on the availability of vitamin
B^2 binding sites on the binding protein, only CBP which has
not already bound some B^2 can be counted. PMN cobalamin
binding protein has no B-^2 bound to it, and can thus be
measured in this way. Hence results are expressed as vitamin
B^2 binding capacity i.e. the amount of vitamin B^2 (ng/ml)
which could be bound by the CBP present.
2. It follows that all test samples and reagents used must be
free from extraneous vitamin B^2 or CBP, which sometimes
occurs as a contaminant in preparations of albumin and other
proteins. Where this is unavoidable, e.g. when whole
complement-activated serum is used as the degranulating
stimulus, the serum CBP is measured and subtracted, since at a
final serum concentration of 10%, the serum CBP may be as much
as 25% of the total"^.
3. If all the supernatant is removed from cells which have
69
secreted, and the cell pellet then sonicated, the total NCBP
in supernatant plus cell pellet is the same as in a sonicate
3
of unstimulated cells . Thus the cells do not appear to
rapidly resynthesise NCBP as it is secreted.
57
4. The charcoal used to remove the unbound Co B^ must be
coated with a protein to reduce the pore size and thereby
57exclude any Co B^-NCBP complexes. Initial experiments used
bovine serum albumin although later, bovine haemoglobin was
used. This had certain advatages:-
(i) there was less CBP contamination
(ii) its binding to the charcoal was more stable,
allowing more samples to be processed in one batch.
The overall results were not affected by whether albumin
or haemoglobin was the protein used.
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Details of NCBP assay (After Lau et al 1965)
To save reagents, smaller volumes were used, so to
achieve greater accuracy, positive displacement pipettes were
used throughout.
1. 50yul of each sample was pipetted into an LP^
polypropylene tube, 50yul distilled water being used for the
standard and blank tubes.
57
2. Using an Eppendorf multipipette, 100yul CoB]_2 was ac^ec^
to all the tubes, which were vortexed and incubated at room
57
temperature in the dark (because of photolability of the Co
B12^ ^°r mi-nutes*
3. Using the multipipette 200yal protein-coated charcoal was
added to all tubes except the standard, which received 200yul
distilled water.
4. All tubes were vortexed and immediately centrifuged at 1500
70
g at 4°C for 7 minutes.
5. 200yul of supernatant was removed from each tube and placed
in a separate tube for counting. The tubes were counted for 4
minutes each in a gamma counter.
Volumes r—|5s distilled water plasma 57c°-b12 Charcoal
standard (A) 250 0 100 0
blank (B) 50 0 100 200
test (C) 0 50 100 200




binding capacity (ng/1) = x conc. Co-B x plasma
A dilution
57
provided that Co-B.^ of specific activity 15yuCi/ug of B^ is used,
at a concentration of 2000 ng/1. (see below).
Preparation of reagents
57 57
1. Co-B^2 ( Co-cyanocobalamin)
57
A 1 ml vial of high specific activity Co-B^ was diluted to a
concentration of 2000 ng/1 in 0.9% benzanol in distilled water,
and stored at 4°C.
2. Protein coated charcoal (made fresh daily) .
0.5g activated charcoal was added to 20 ml of either bovine
haemoglobin (2.5g/l in distilled water) or bovine serum albumin
(6g/l in distilled water). After mixing on a magnetic stirrer
for at least five minutes, the charcoal was ready for use, and
could be stored at 4°C for the rest of the working day.
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Experiment 1 Comparison of PMN's prepared by the single step
and two step preparation methods.
As preparation of PMN's by the single step method was
considered a departure from standard techniques, PMN's prepared
by the 2 methods were compared for yield, purity, viability,
NCBP levels, and response to stimuli.
A. PMN counting and calculation of yield.
Method PMN suspensions were counted by diluting 20yul of
suspension in 10 mis isotonic saline (Isoton II). Red cells
were lysed by the addition of 4 drops of Zaponin. Counts were
performed on a Coulter DN counter.
Yield was calculated from the final PMN count and the
donor's peripheral blood PMN count obtained by performing a
differential count of 100 leucocytes on a standard blood film,
actual count x 100oThen yield = expected count
For example, from 1 donor, 44 x 10 PMN's were obtained from 30
9
mis blood, in which the initial count was 4.24 x 10 /I.
. . , 44 x lot x 100 0
' * ^leld =4.24 x 109 — %
33.33
44 x 106n x 100 0




Results For most experiments, yields of between 30 and 40%




Method A slide of the PMN suspension was made by passing 0.1
ml of a 0.2 x 10^/ml dilution of cells through a cytospin. The
slide was dried and stained with Diff-Quik, a variation of the
Leishman stain. Two hundred cells were counted, and a
differential count calculated.
Results PMN suspensions were usually at least 95% pure, the
main contaminant being eosinophils, with the occasional
lymphocyte and monocyte, and there were no significant
differences between PMN's prepared by the two methods.
C. PMN Viability
Method Viability was assessed using the fact that viable PMN's
can exclude the dye Trypan Blue, while dead cells take it up
passively. Three drops of a 0.3 x 10 /ml cell suspension were
mixed with 1 drop of a 5% solution of Trypan Blue in isotonic
saline on a microscope slide. After 5 minutes, the proportion
of stained cells was counted.
Results
Greater than 99% of PMN's were viable as assessed by this
method, no matter by which method they were prepared.
D. NCBP levels and release
Previous studies had compared behaviour of PMN's prepared
by the new single step method using monopoly resolving medium
to those separated by the traditional 2 step method of
mononuclear cell removal followed by dextran sedimentation of
red cells. In these studies, no differences in PMN random
134
mobility or chemotaxis were found , but no comparison of
degranulation had previously been made.
Method PMN's prepared by each of the two methods were
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challenged with ZAS as described above in the general methods.
Results Figure 6 shows that both stimulated and unstimulated
cells separated by the two methods behaved identically. Levels
of NCBP in sonicated cells were within 10% of each other,
suggesting that the new method does not cause excessive granule
loss during preparation.
Experiment 2 Effect of the albumin concentration in PBS-A on
NCBP release in response to ZAS.
Method As exposure of PMN's to albumin alone can cause
aggregation and hence possibly granule release, control tubes
had to include albumin to correct for that present in
serum-based stimuli. A comparison of NCBP release in response
to ZAS was therefore made in PBS containing albumin
concentrations of zero, 0.1% and 1.0%, using the general
method.
Results Measurement of NCBP in sonicated PMN's was unaffected
by albumin concentration, but NCBP release from both
unstimulated and stimulated cells was influenced by it (Fig 7).
Release from unstimulated cells increased as the albumin
concentration rose, so that at an albumin concentration of
1.0%, release was nearly 30% of the sonicate. There was no
difference in NCBP release in response to ZAS between cells
containing 0.1% albumin and those containing 1% albumin.












Sonicate Cells + PBS ZAS i/lOO
Fig 6. Release of NCBP, measured as unbound vitamin ^
binding capacity (UBBC), from sonicated PMN's, PMN's in
PBS only, and PMN's stimulated with ZAS (1%). Comparison
is made of responses of cells prepared either on monopoly






| 1 No albumin
0.1% albumin
■I 1.0 % albumin
Sonicates Cells + PBS Cells + ZAS 1/100
Fig 7. Effect of different albumin concentrations on
release of NCBP (measured as UBBC) by sonication, in
resting cells, in PBS and in cells stimulated with ZAS
1/100.
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Experiment 3 Effect of the concentration of epsilon amino
caproic acid (EACA) on the generation of degranulating
activity in EACA-ZAS.
Method Although inhibition of conversion of C,_ to Cr- des Arg
bcl
by the plasma enzyme carboxypeptidase B requires high
concentrations of EACA, it has been suggested that excessively
135
high concentrations can actually block Cc formation . A5a
preliminary comparison was therefore made of the degranulating
activity in dilutions of EACA-ZAS prepared in the presence of
different EACA concentrations, namely 0.1M, 0.5M and 1.0M,
using the general method.
Results There was no significant difference between
degranulating activity generated in the presence of 0.5M and
1.0M EACA (Fig 8). The reduced amount of degranulating
activity generated in the presence of 0.1M EACA suggests that
this concentration of EACA is insufficient to prevent
conversion of C,. to its less potent des Arg form. Therefore
an EACA concentration of 0.5M was used in all subsequent
preparations of EACA-ZAS.
Note on release from unstimulated cells.
Cytochalasin B treated cells, when suspended in PBS-A,
will secrete a small amount (<5%) of their NCBP during the
incubation period, probably due to activation during the
3
separation process . In early experiments, this release was
noted to be excessively high, up to 25-30% of sonicate values.
This was eventually discovered to be due to the stimulation of
the cells by micro-crystals of calcium and magnesium phosphate,
formed when calcium and magnesium chloride were added to the
cell suspensions in PBS just prior to the start of the
Final Cone. EACA-ZAS
Fi9 8. Effect of different concentrations of EACA during
complement activation on the generation of NCBP-releasing
activity in EACA-ZAS. —
Fig 9. NCBP release from cytochalasin B treated PMN's bv
dilutions of ZAS and EACA-ZAS. (mean ± SEM, n = ToT^
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experiment. The method was altered so that PBS-A was prepared
as described in Appendix 2, so that the calcium and magnesium
salts were thoroughly dissolved before addition to the cells.
When this method was adopted, secretion of NCBP by unstimulated
cells fell to less than 5% of sonicate values.
Experiment 4 Release of NCBP from PMN's by zymosan-activated
serum with and without EACA.
Method Dilutions of ZAS and EACA-ZAS (containing 0.5M EACA)
were added to cytochalasin B treated PMN's as above.
Results Both ZAS and EACA-ZAS produced dose dependent NCBP
release (Fig 9). Serum activated in the presence of EACA was
approximately 5 times more potent a stimulus than
non-EACA-treated serum. The dose-response curve obtained for
EACA-ZAS begins to flatten off at the top end, while that for
ZAS does not. It is likely that if the serum could be
concentrated further, both curves would flatten off. However,
the highest concentration (10 "S was obtained by adding neat
serum to the cell suspension. No release above that obtained
with PBS-A alone was seen with 0.5M EACA alone or with
unactivated serum.
Experiment 5 The effects of heat-treated sera, and EDTA and
ECTA plasmas on NCBP release.
Method In order to inactivate complement components, pooled
serum was heated at 56°C for 30 minutes prior to, or following,
zymosan activation. To assess the relative importance of the
classical and alternative complement pathways, plasma was
obtained from venous blood containing either ethylene-diamine
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tetraacetic acid (EDTA), which chelates calcium and magnesium
ions, or ethylene-bis-(oxy-ethylene-nitrile) tetraacetic acid
(EGTA), which chelates calcium ions only (final concentration
of each = lOmM). EDTA, by chelating both calcium and magnesium
ions, inhibits both classical and alternative complement
pathways, while EGTA, chelating only calcium ions, inhibits
only the classical pathway. To allow degranulation to occur in
response to these sera, excess calcium and magnesium had to be
added so that the chelating effects could be overcome.
Therefore, calcium and magnesium chloride were added to a final
concentration of 12 mM, estimating that between 1 and 2 mM of
these would remain in the ionised form.
Results Heating serum to 56°C for 30 minutes prior to zymosan
activation prevented the generation of degranulating activity,
but sera heated after zymosan activation showed little loss of
activity (Fig 10).
The inhibitory effect of EDTA, but not EGTA, suggested
, ++
that an intact alternative complement pathway, requiring Mg
but not Ca++, is necessary for generation of degranulating
activity (Fig 10).
Experiment 6 Column chromatography of EACA-ZAS.
Method EACA-ZAS was passed downwards on a Sephadex G200
column, 28 x 300 mm, using 0.4M PBS containing 0.01M EDTA at
room temperature. Fractions were collected, and 0.5 ml
aliquots of each fraction were tested for their ability to
stimulate NCBP release.
Results A single broad peak of degranulating activity was














PBS 1/50 ZAS !/50ZA- !/50ZA- 1/50 Heat !/50 ZAS
EGTA EDTA inactivated + heat
plasma plasma serum + inactivation
ZA
Fig 10. NCBP release from cytochalasin B treated PMN's by









Fig 11. NCBP release from cytochalasin B treated PMN's by
fractions of EACA-ZAS from a Sephadex G 200 column.
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than that of the marker protein haemoglobin (MW 64,500 Daltons,
Fig 11) .
Exeriment 7 Use of a micropartition membrane to further
identify and partially purify the degranulation activity in
EACA-ZAS.
Method The sample to be fractionated was layered in 1ml
aliquots over a 30,000 Dalton exclusion ultrafiltration
membrane (Fig 12) and centrifuged for 30 minutes at 2000g at
room temperature. This membrane excludes >99.9% albumin, and
it can therefore be assumed that the ultrafiltrate is of low
molecular weight, although not all small molecules in the
original solution are able to pass through, due to 'clogging
up' of the membrane pores by large molecules.
Results When the chromatography peak of degranulating activity
in EACA-ZAS was applied to the micropartition membrane
degranulating activity was found only in the low molecular
weight fraction (ultrafiltrate) (Fig 13).
When whole EACA-ZAS was applied to the 30,000 Dalton
exclusion filter, degranulating activity again appeared in the
ultrafiltrate. When aliquots of a batch of ultrafiltrate were
applied to cytochalasin B treated PMN's, dose-dependent NCBP
release was obtained (Fig 14). As with whole ZAS and EACA-ZAS,
the dose-response curve does not flatten off at higher
concntrations, although this may have been demonstrated had it
been possible to concentrate the stimulus further.
When ZAS prepared in the absence of EACA was
ultrafiltered, very little degranulating activity appeared in
the ultrafiltrate, in contrast to that obtained with EACA-ZAS.
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Fig 12. The micropartition membrane system (membrane
cut off point 30,000 Daltons) used to prepare the low











Fig 13. NCBP release from cytochalasin B treated PMN's by
the peak of degranulating activity from sephadex chromat¬













Log1Q stimulus volume (jil)
Fig 14. Release of NCBP from cytochalasin B treated PMN's
by the low molecular weight fraction of EACA-ZAS.
(Mean ± SEM, n = 10).
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Possible reasons for this are disussed below.
Experiment 8 Preparation and assessment of an affinity gel
to remove C,. and products of from sera.
To assess the role of C,- derived products in NCBP release
serum was depleted of prior to or following zymosan
activation using an anti-C,- antibody bound to a carbohydrate
gel. When serum, or any other mixture of proteins, is exposed
to such a gel, the appropriate antigen, in this case C,., will
bind to the antibody while other antigens remain unbound,
allowing specific removal of a single protein in a mixture. In
some instances, the bound protein can be eluted from the gel by
a change in pH or ionic strength, although in the case of C,.
136
this is not possible without damage to the molecule . In any
case, the bound protein must be washed from the gel before
further use. For linking any ligand with NH~ groups, including
antibodies, to a gel, cyanogen-bromide-activated sepharose 4B
137













Carbohydrate gel Antibody Gel linked to antib
with cyanogen
bromide
Methods (from handbook of Pharmacia Fine Chemicals Ltd,
Upsalla).
The antibody bound was a polyclonal sheep anti-human C^
antiserum (see Appendix 1 for details of all antibodies).
(i) Preparation of the gel
Since 1 gram of gel binds 10 mg of protein, the exact
protein concentration in the antiserum was calculated from its
optical density at 280 nanometers (0D„orJ , knowing that an IgG
z oO
solution of 1 mg/ml has an OD2go 1-4.
0D„o of a 1 in 30 dilution of sheep anti-human C._ =
Z oU D
Therefore 5 ml antiserum and 5 g freeze dried gel were used.
The gel was first washed with 1 litre 1 mM HC1 (pH 2.5) on a
sintered glass funnel (64) to allow reswelling and to remove
the dextran and lactose which are added to the gel as
stabilisers. The gel was then washed with coupling buffer (pH
8.3) (see Appendix 2 for details of buffers). The antiserum
0.526.





was dissolved in coupling buffer to a final protein
concentration of approximately 2 mg/ml. This was then mixed
with the gel in a cell culture flask on a rotator overnight at
4°C to allow binding, then washed with coupling buffer. To
block any remaining active groups on the gel which might
nonspecifically bind proteins in samples, the gel was mixed
with 1.0 M diethanolamine (pH = 8.0) for two hours at room
temperature, then washed again alternately with 1 litre
aliquots of 0.1 M acetate buffer containing 1.0 M NaCl (pH =
4.0), and 0.1 M borate buffer containing 1.0 M NaCl (pH = 8.0)
to a total of 4 litres of each. The gel was finally washed
with 1 litre PBS and two drops sodium azide added as a
preservative. The gel was packed into a 10 ml column, covered
with a permeable disc, filled to the top with PBS and stored
at 4°C.
(ii) Use of the anti-C^. gel to remove and conversion
products from sera
A. Removal of by incubation of serum with the anti-C^ gel.
A portion of gel-antibody was added to 3 mis of neat
unactivated serum in a 10 ml glass tube, and mixed on a
rotator at room temperature for 30 minutes. The serum was
collected by passage through a serum harvester (Fig 15). In an
attempt to wash the bound C<- off the gel, the gel was washed
twice for 20 minutes with glycine HC1 to produce 'eluates'
which were collected in the same way as the serum. The gel
was then washed 4 times in PBS, in which it was stored. This
method was also applied to EACA-ZAS and ZAS, and to the low
molecular weight fraction of EACA-ZAS. Serum and eluates were











10 ml glass tube
Fig 15. Preparation of C^.-depleted serum by incubation
with anti-Cc gel.
CHO gel - CNBr + NH^ - anti
CHO gel - C - N - anti CL
II II
NBr H
Glycine HCI - Serum containing Cr
followed by PBS
Gel binds Cc
1 f depleted serum
Gel washed with glycine HCI to allow further binding
Fig 16. Preparation and use of Anti-C^ affinity column,
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B. Ranoval by passage over a column of gel.
Three mis neat pooled unactivated serum were layered
over the filter disc and allowed to flow into the gel by
gravity alone (Fig 16). When all the serum had entered the
gel, it was washed through with PBS and 3 ml fractions
collected at the bottom. The protein concentration in each
fraction was calculated from its 0Docw and fractions wereZoU
collected until the 0Doo was less than 0.050. Most of theZ oO
protein appeared in 2 or 3 consecutive fractions, usually
numbers 3-5, when dilutions had to be made to measure the
^D280" T''ie co-'-umn was then washed with glycine HC1 (pH
2.8)and further 3 ml fractions collected.
Results These are the results of a typical preparation.












When the gel was washed with glycine HC1, there appeared
to be a small amount of protein in one fraction (No 4),
suggesting that the C,_ had been washed off:-
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The gel was then washed thoroughly with PBS, and the eluate
neutralised with NaOH 1.0 M to pH 7.4.
The above process was followed for unactivated serum, and
for both EACA-ZAS and ZAS containing the C,. conversion products
Cj. and C^a des Arg respectively. The low molecular weight
fraction of EACA-ZAS was also treated identically. All
preparations were examined for and (see Experiment 9).
Experiment 9 Immunological examination of normal serum, ZAS,
and sera and eluates from the anti-C,- gel.
In order to examine the effects of exposure to the
anti-C,- gel on complement activated sera, the immunological
properties of normal serum and ZAS first had to be defined.
Both immunoelectrophoresis (IEP) and Ouchterlony
immunodiffusion were used to attempt to identify C^, and




Antigen and antibody are placed in wells cut in agar.
From there they diffuse towards each other, and precipitation
lines are formed if the appropriate antigen is present. Since
lines between antibody and a single antigen always form at the
same distance into the gel, lines of identity will form round
the central antibody-containing well if the same antigen is
present in several wells (Fig 17). Additional antigens to
which the antiserum also reacts will form 'spurs' beyond the
lines of identity.
Details of Method
4 mis agar (1%) was poured into a 3 inch round plastic
Petri dish, and when cool, holes were cut in the agar. 20 1
placed in the centre well, and 20yul of the following sera were
placed in the other 6 wells.
1. neat untreated human serum
2 & 3. the high protein fractions 3 & 4 (pooled) from
column-treated serum (not zymosan activated)
4. the eluated protein fraction (fraction 4 post glycine-HCl)
5 & 6. fractions 6 & 7 post glycine HC1 (Low OD280 contr°ls) •
Further plates were prepared using either sheep
anti-human C,. or rabbit anti-human C~. (Blood Transfusion
D -i
service, Bristol) (both 1 in 5 dilutions) in the centre well
and the following preparations in the outer wells:
1. neat untreated human serum
2 & 5. high protein fractions (pooled) after passage of pooled
unactivated serum
3. serum incubated with the anti-C,. gel as above
4. glycine HC1 eluate from column
6. glycine HC1 wash from incubation method.
The plates were placed in a moist cupboard at room
temperature for 18 hours to allow diffusion to occur.













antigens as well as those
identical in wells 3 and 4
Fig 17. Ouchterlony immunodiffusion,
IEP plate
shaded area replaced with
antibody-containing gel




Visible precipitation of Ag-Ab
complexes. Antigens not
represented by antibody remain
invisible.
Fig 18. Two-directional immunoelectrophoresis (IEP).
(B) Two-dimensional immunoelectropheresis (IEP)
Principle
This separates a mixture of protein antigens on the basis
of electrophoretic mobility on a gel. The plate is then turned
through 90°, and a second electrophoresis performed into a gel
containing antibody. Peaks of precipitation form where
antibody and antigen meet, and the various antigens
precipitating with the antibody can be identified by their
position on the plate (Fig 18).
Details of Method
1% agarose in barbitone buffer (pH 8.6) was poured on to
a 5 cm square glass plate to a depth of 1.5 mm and allowed to
cool. A 1.5 mm diameter well was cut in the bottom left corner
and 4jal serum added. The serum proteins were separated by
electrophoresis at 8 volts/cm in a 4°C cold room for 60
minutes.
The gel not containing proteins was scraped off the plate
3
and 3.0 cm of 1% agarose containing either 90jal rabbit
anti-human (Blood Transfusion Service, Bristol) or 40ja 1
sheep anti-human layered on. The separated proteins were
then electrophoresed into the antibody-containing gel at 5
volts/cm for 3 hours at 4°C. Visible precipitates could then
be seen. To make a permanent record unprecipitated protein was
removed by covering the plates with wet filter paper and
leaving overnight. The plates were then dried with filter
paper and stained with 0.5% Coomassie Blue in a solvent mixture
of ethanol, distilled water, glacial acetic acid (45:45:10).
Excess stain was washed out with solvent, and the plates
thoroughly dried.
Results
A. Normal serum, ZAS, and EACA-ZAS.
(i) c3
When the IEP appearances of either ZAS or EACA-ZAS were
compared with those of normal unactivated plasma, an obvious
peak persisted, representing either unconverted or large
conversion products with similar mobility and antigenic
structure to (Fig 19). There were also additional peaks
representing small conversion products with faster
mobility. The polyclonal anti-C^ antisera obviously contained
some activity towards these fragments, likely to be and
C3d*
(ii) c5
On IEP, an obvious peak was detected in normal serum,
with or without EACA, and in ZAS, with or without EACA (Fig
19). Unlike the findings with anti-C^, however, neither ZAS
nor EACA-ZAS contained extra peaks of small C^ conversion
products, suggesting that they did not form visible
precipitates with the anti-C,. antibody. IEP of the low MW
fraction of EACA-ZAS produced no detectable peaks at all.
Immunodiffusion studies using anti-C^ diluted 1 in 5
revealed a single line of identity linking normal serum with
and without EACA, and ZAS with and without EACA. There were no
additional lines which might have represented C^ conversion
products.
As with IEP, immunodiffusion studies of the low MW
fraction of EACA-ZAS produced no visible lines at all.
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Fig 19. Immunoelectrophoresis of normal serum
(2 left squares) and ZAS (2 right squares) into gel
containing anti-C-, (top 2 squares) or anti-C,- (bottom
2 squares). J J
When anti-C-, is used, activation of serum by zymosan
produces 2 obvious additional peaks, a small 'hump'
to the right of the main C-, peak, and a faint peak
to the right of and further out than the main peak.
When anti-Cc- is used, however, activation of serum by
zymosan produces no similar additional peaks.
y4
B. Sera which had been treated with the anti-C^ gel.
(i) c3
To ensure that the key complement component was not
also being removed by the anti-C^ gel, normal serum, serum
after treatment with gel, and eluates from the gel were all
examined with anti-C^ by IEP and immunodiffusion.
Similar findings were obtained with both methods. Normal
serum and gel-treated serum both gave clear precipitation lines
with anti-C^, suggesting that little, if any, is removed by
the anti-C^ gel. Eluates from the gel gave no precipitation
lines with anti-C^.
(ii) C5
Both IEP and immunodiffusion gave similar results. While
normal human serum gave strong precipitation lines in both
detection methods, no precipitation lines were seen with serum
which had been exposed to the anti-C^ gel, either by incubation
or on the column. This suggests that either method completely
removes from normal human serum, or that any residual C,- is
present in concentrations below the limits of detection of
these methods.
When eluates from the gel were examined, no precipitation
lines were seen either by IEP or immunodiffusion. The most
likely explanation for this is that the elution process using
glycine HC1 destroys the antigenic structure of the molecule,
as previously found
As C,- conversion products in neither ZAS, EACA-ZAS nor
low MW fraction could be detected by IEP or by immunodiffusion,
their possible removal by gel-bound anti-C^ antibody could not
be detected by these techniques. Sera so treated were
95
therefore merely tested for degranulating activity.
Experiment 10 Release of NCBP from PMN's by ZAS prepared
from sera depleted of, or deficient in, Ch.
D
This experiment was designed to assess the importance of
Cj. products compared with products, in triggering NCBP
release.
Method Sera depleted of C,. by exposure to the anti-C,. gel,
whether by incubation or on a column, were then activated with
zymosan in the presence of 0.5M EACA and added to cytochalasin
B treated PMN's as before. Since sera depleted by either the
incubation or column methods gave similar results in the
degranulation system, the data from the two methods have been
pooled.
Congenitally C,_ deficient serum was also used in this
experiment (kindly supplied by Dr R A Thompson). This was
investigated at East Birmingham Hospital and found to be
deficient in C^, while having normal levels of other complement
components. Insufficient material was available to confirm
these findings.
Results NCBP release in response to sera which had been C<-
depleted prior to zymosan activation was very markedly reduced
compared to normal (Fig 20), and indeed at concentrations
which would normally give more than 80% NCBP release, less than
5% release was obtained. These differences were highly
significant statistically (Student's t test for paired
samples). A similar reduction in NCBP release was seen when
the low molecular weight fraction of serum which was C







I I Normal serum
VH/A C5 depleted serum
** p = <0.001
2ZZ2L
EACA-ZAS EACA-ZAS UVIW fr. lllO
1/30 1/100
Fig 20. NCBP release by serum depleted of then zymosan
activated, and by the low molecular weight fraction of
that serum.












Fig 21. NCBP release from cytochalasin B treated PMN's
exposed to Cr depleted serum (1%) which was then zymosan
activated. Restoration of degranulatinq activity of C,-
depleted serum by addition of fractions of EACA-ZAS.
* Addition of low MW fr produced significantly more NCBP
release than C,- depleted serum alone (p = 0.05, n = 4).




Attempts were made to restore the degranulating activity
of C,- depleted serum by addition of the low molecular weight
fraction (ultrafiltrate) or high molecular weight fraction
(retained by the 30,000 Dalton exclusion filter) prepared from
normal EACA-ZAS (Fig 21). There was a slight, but not
significant restoration of activity by high MW fr, but a much
greater and significant rise in degranulating activity was
achieved by the addition of low MW fr, as expected from the
results of experiment 7 above.
Activation of the congenitally deficient serum with
zymosan, in the presence of EACA, yielded practically no
degranulating activity, NCBP release being little greater than
that seen with PBS-A alone (Fig 22). There was insufficient
serum to prepare a low molecular weight fraction.
Experiment 11 NCBP release from PMN's by sera which had been
zymosan activated, then exposed to the anti-C^ gel.
The purpose of this experiment was to see whether the gel
could remove C,.-dependent degranulating activity, as well as
unconverted Cc.
D
Methods Both EACA-ZAS and its low MW fraction were treated
with the anti-C^ gel, either by incubation or on a column, then
added to cytochalasin B treated PMN's as before.
Results Results by either method were identical and so the
data were pooled. As shown in Figure 23, treatment of either
EACA-ZAS or its low MW fraction produced no loss of
degranulating activity when compared with untreated













Fig 22. NCBP release from cytochalasin B treated PMN's by
dilutions of EACA ZAS prepared from either normal serum or
congenitally C^. deficient serum.
(mean ± SEM, n indicated above each pair).
□ Normal
V777A Anti -C5 column treated
Fig 23. NCBP release by EACA-ZAS (or its low molecular
weight fraction) produced by zymosan activation followe'd by
passage over the anti-C^. column (Mean ± SEM, n indicated
above each pair.
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effective at removing C , it appeared not to bind C^-dependent
degranulating activity.
Experiment 12 Use of antibodies in the degranulation system.
From the above data on deficient or depleted sera, it
appeared that the major degranulating stimulus in ZAS or EACA
was of low molecular weight and was derived from C^. It seemed
likely that this stimulus was C,- fragments, either or
des Arg. To further test this possibility, and to specifically
examine the role of conversion products in NCBP release,
antisera to various serum components were mixed with either ZAS
or low MW fraction before addition to the cells. As specific
antisera to C3 /C^g ^es an<^ ^a^Sa ^es were not
readily available, antisera to whole and were used.
Method Initially 100yul EACA-ZAS and 100yul antibody were
incubated together for 30 minutes at 37°C prior to addition to
cytochalasin B treated cells. In later experiments, antisera
were similarly incubated with the low molecular weight fraction
of EACA-ZAS.
The following polyclonal antibodies were used (see Appendix 1
for details):
With ZAS : goat anti-human IgG
: 2 different rabbit anti-human antisera
: goat anti-human C,.b
With LMW fr: 4 different anti-human antisera
(2 rabbit, 1 goat, 1 sheep)
: 2 different anti-human Cc antiserab
(1 goat, 1 sheep)
Results When whole ZAS was the stimulus, anti-human IgG and 2
100
different anti-C^ preparations did not cause any inhibition of
degranulation (Fig 24). The addition of an anti-C.. antiserum,5
however, caused marked inhibition of degranulation. This
effect was even more striking when low MW fraction was the
stimulus, for 2 different anti-C,_ antisera then caused complete
inhibition of release (Fig 25). Again antisera to
non-complement components cause no inhibition. Although 3
anti-human antisera were likewise non-inhibitory, partial
(35%) release was seen with a fourth, an anti-C^ preparation
(C^(2) on Fig 25). This antiserum has been shown by Dr R J
Powell to also react immunochemically with human C^, unlike
those anti-C^ preparations which did not inhibit NCBP release.
When the anti-C,- antisera were diluted before addition to5
the degranulating system, their inhibitory effects could be
overcome (Fig 26). Antisera differed in the concentration at
which they ceased to be inhibitory, suggesting that they varied


















Fig 24. Effect of antisera to human IgG, C_, and C,- on NCBP
release from human cytochalasin B treated PMN's by EACA-ZAS












PBS 1/20 LMWF LMWF LMWF LMWF LMWF
+ Anti-H + Anti-H + Anti-H + Anti-H
C3(l) C3(2) C3 (3) C3M)
T
LMWF LMWF
+ Anti-H + Anti-H
C5 (1) C5t2)
Fig 25. Effect of four antisera to human C-, and two
different antisera to C on release of NCBP from
cytochalasin B treated PMN's by the low molecular weight






















Fig 26. The effect of dilutions of anti-C,,, anti-C-,. and
anti-Cr antisera on NCBP release from cytochalasin B
treated PMN's by low molecular weight fraction of EACA-ZAS.




The work in this chapter reports dose-dependent release
of the PMN secondary granule component NCBP, in reponse to a
stimulus derived from the alternative complement pathway, as
shown by the effects of heating and divalent cation chelators
on the generation of degranulating activity.
The findings using column chromatography and the
ultrafiltration membrane suggest that low molecular weight
conversion products of either or C,. are responsible. The
absence of NCBP release with activated Cr-deficient orb
Cj--depleted sera (using an affinity gel which appears to remove
only C^) is consistent with the hypothesis that the main
degranulating stimulus in either ZAS or EACA-ZAS is derived
from Cj.. C^ remains readily detectable in sera after exposure
to the anti-Cj. gel, and will thus form C^a and C^a des Arg on
zymosan activation. The fact that C^-depleted serum is totally
inactive suggests that C^ conversion products are not
degranulating stimuli for PMN's, just as they have been shown
6 6
not to be chemotactic . The data obtained using the gel are
supported by the findings with congenitally Cj. deficient serum.
It is not possible to study the effect of removal of C^ on the
generation of degranulating activity, since this would block
the complement pathway totally, and prevent activation and
conversion of Cc and other later components. Although there is
no absolute proof in these studies that the active moiety is
actually C,. and/or C,-a des Arg, the body of evidence in the
literature from studies using pure compounds, suggests strongly
that Cc and C,- des Arg are the main degranulating stimuli inba ba
104
this system. Since degranulating activity is generated whether
the carboxypeptidase B inhibitor EACA is present or not, it
would appear that both C^ and des Arg are effective, as
would be expected from other studies on their chemotactic and
22 60
degranulating properties ' . EACA-ZAS, however, is only
5-10 times more potent than ZAS, whereas the ED,, 's for pure
C,. and Cj-a des Arg with regard to PMN activation would predict
that ZAS formed in the presence of EACA would be 100-1000 times
22
more potent . The apparent enhancement of effect of ZAS
without EACA may lie in the fact that the activity of CK des
Arg generated in whole serum may be enhanced by a high
6 3
molecular weight 'helper factor' protein
Some apparent anomalies in the results require
consideration. Firstly, the activity of the low MW fraction of
EACA-ZAS appears much less than that of unfractionated
material, causing a maximum of 40-50% release of total NCBP, as
apposed to the 80% or so maximal release triggered by whole
EACA-ZAS. This loss of activity by fractionation was seen in
several different batches of EACA and is probably explained
simply on the basis of 'clogging up' of the ultrafilter with
large proteins so that a proportion of serum, with solutes and
low molecular weight peptides cannot pass through.
Concentration of the ultrafiltrate by dialysis or
lyophilisation would probably have yielded a more potent
material. Secondly, it proved impossible to generate an active
low MW fraction from ZAS formed in the absence of EACA. The
material collected in the ultrafiltrate caused virtually no
NCBP release. Although the reason for this is not absolutely
clear, it may again be due to binding of C,- des Arg to a high
1 0 5
molecular weight helper protein. Such binding would prevent
C des Arg from appearing in the ultrafiltrate, which would
thus fail to trigger NCBP release.
Results of experiments using various antisera to detect,
remove or inhibit either native or its conversion products
have also produced some anomalies. For example, anti-C,-b
antisera form visible precipitates with C._ in unactivated and
b
activated sera using IEP or immunodiffusion techniques, and,
when coupled to a gel, effectively remove C<- from whole
unactivated sera. C conversion products, however, are not
detected by anti-C,- by either IEP or immunodiffusion.b
Similarly, degranulating activity, which cannot be generated in
congenitally C,. deficient or C,- depleted seum, and which
therefore is likely to be derived from C,-, is not removed by
the anti-C,- gel. This may be explained by the fact that the
anti-C,- antisera used were polyclonal antisera raised in
animals, so that they would contain antibodies against many
different antigenic determinants on the C,. molecule. Little
antibody may therefore have been formed specifically against
the C^a part of the molecule, which is only a small part of the
end of the chain of Cc. Thus adequate binding of C wouldb bs
not necessarily be achieved. In addition, when the antiserum
is exposed to whole ZAS or EACA-ZAS, it might preferentially
bind to any unconverted C_, reducing the concentration ofb
antibody available to bind C_ fragments. This factor cannotb
however totally explain the inability of anti-C^ to complex C,-
fragments, since low MW fraction, containing no C,., can be
neither detected nor removed by anti-C,-.
Given the inability of anti-C to either detect or remove
106
C5 fragments it is surprising that anti-C^, when incubated in
the fluid phase with either ZAS or low MW fraction can block
their ability to trigger NCBP release. This blockage is
partial in the case of ZAS, again perhaps because of
preferential binding to unconverted Cr, but is total in the
o
case of low MW fraction. This ability of various anti-C,_
antisera in the fluid phase to block the cellular effects of Ce
D
fragments is unlikely to be due to a direct effect of antibody
on the cells, since control antisera had no such inhibitory
effects on NCBP release. One possible explanation is that
fluid phase incubation of antigens and antibody together allows
more effective complexing to take place than during IEP or
using the anti-C,_ gel. This would have to take place rapidly,
to prevent the initiation of cellular events which normally
follows occupation of receptors. Because C and Cc des ArgD5i j3
differ by only one arginine residue, it seems unlikely that
anti-C,. antisera would bind to one and not the other,
b
The apparent specificity of C,. fragments in triggering
NCBP release, and the difficulty in detecting these fragments
immunologically, suggests that this degranulating system might
be of value as a functional assay for complement activation in
general, and C^ conversion in particular. The most widely used
assay to detect complement activation in present use is
measurement of C^ split products, particularly C^ by IEP.
This 2-stage procedure is time consuming and labour-intensive,
and results are rarely available the same day. A double-decker
rocket IEP technique has been described, however, which may
74
shorten the procedure . Because of the unique actions of C,.
fragments on PMN's, however, and because such actions may
o o Q 1
mediate tissue damage in disease states such as ARDS ' , an
assay for C,_ conversion may be a better predictor of outcome in
these situations. This has been described in one study of
92
ARDS .
Previous functional assays for conversion products
such as contraction of ileal smooth muscle depend on the
anaphylotoxic properties of the C^. molecule. They are
therefore of very limited value in a clinical context, since
Cj-^ des Arg, the stable form of C^a in plasma, has only 0.1%
the spasmogenic activity of , and is virtually undetectable
139
by these means . Functional assays using PMN's have the
advantage that both and C^a des Arg can be detected, since
both trigger chemotaxis, aggregation, and degranulation.
Chemotactic systems do not readily lend themselves to use as an
assay for C,- conversion, since not many samples could be
handled at once. In addition, depending on the system, C,. des
6 3
Arg may need the presence of the serum 'helper factor' . PMN
aggregation has been used as a functional assay for de¬
fragments, and appears to be a more sensitive index of
complement activation than either breakdown products
92
detected immunochemically or fragments detected by
75
chemotaxis . They do, however, require a platelet
aggregometer, channeliser, and expertise in their use.
Degranulation assays, on the other hand, are easy to
learn, are robust and reproducible, and require no special
equipment. When neutrophils are stimulated by C and CR desbcl
Arg to degranulate, primary granule markers such as B
6 7
glucuronidase and myeloperoxidase can also be released , and
could theoretically be used as the detection system. At the
108
same time, however, the superoxide anion is generated via the
22
neutrophil oxidase . Under such circumstances, p
glucuronidase is liable to intracellular oxidative damage,
, . . 140
resulting in up to 20% loss of detectable activity . The
same problem arises with myeloperoxidase, where phagocytosis of
opsonised zymosan by human neutrophils produces a 40-50%
reduction in intracellular myeloperoxidase levels, while only
141
5-10% is detectable extracellularly . In addition any
functional assay system for myeloperoxidase will measure both
neutrophil and eosinophil peroxidase. As eosinophil peroxidase
142
is several times more potent than neutrophil peroxidase ,
minimal amounts resulting from eosinophil contamination of
143
neutrophil suspensions markedly influences results
An alternative neutrophil enzyme to assay as a reflection
of degranulation is lysozyme, which, although present in both
primary and secondary granules, is released in similar
144
proportions to NCBP . The principal advantage of NCBP over
lysozyme in this system is that fewer cells are required (2 x
6 7
10 compared with 1 x 10 ), a factor which becomes important
when large numbers of samples are to be tested. In addition,
lysozyme, like myeloperoxidase and p glucuronidase, is liable
140
to intracellular oxidation and is more time consuming to
assay than NCBP. The latter, however, is more expensive and
requires the use of a radio-isotope label as well as a system
free of extraneous cobalamin and cobalamin binding protein.
Because of the presence of unsaturated cobalamin binding
protein activity in human plasma, whole blood cannot be used as
a "substrate" for test samples, as there would be competition
between neutrophil CBP and the plasma binder for uptake of the
109
radiolabelled cyanocobalamin used in the assay. Availability
of a one-stage neutrophil preparation medium °, however,
greatly shortens the duration of the assay, allowing its
potential development in clinical situations.
Non-functional assays of conversion products are
145 146
becoming available, using radioimmunoassay techniques '
These assays incorporate antisera specifically raised against
C^. or des Arg, and estimate their concentrations by
competition with a known amount of radiolabelled Cj. for the
antibody. However, it is recognized that even with an
antiserum raised against , binding to whole may occur,
giving falsely high results. The success of the assay depends
therefore on initial removal of whole C from the sample by
precipitation with acid or other agents. The success of this
awaits full evaluation, although the assays appear to be able
145
to detect concentrations of C(- 10-20 ng/ml , equivalent to
-*6
1-2 x 10 M. This is greater than the estimated concentration
of C,-a achievable in maximally activated plasma in vitro,
although in vivo levels could be higher in states of rapid
turnover. Comparison of NCBP release and radioimmunoassay as
detection methods for conversion has not yet been made. One
potential problem with immunological assays is the albeit rare
situation of an immunochemically reactive but functionally
defective molecule. This has been described in a case of
147
congenital C,. deficiency
Whatever method is used for the detection of
conversion, extreme care is needed in the method of blood
collection and plasma separation. Artefactual complement
activation can readily occur, for example if blood is allowed
110
3
to coagulate , or by contact with siliconised plasma
148
separators . An anticoagulant is therefore required,
preferably in the syringe. However, this presents problems for
the degranulation system described above. Firstly, heparin can
itself occasionally activate PMN's, causing NCBP release from
PMN's in the sample before the plasma can be separated"^. The
plasma will therefore contain spuriously high levels of NCBP
which will be detected in the final assay system. This
emphasises the importance of measuring the NCBP in all plasma
samples tested, and subtracting the result from the total
measured after PMN release. Other PMN factors contaminating
plasma samples may further interfere with the assay by
triggering complement activation in vitro, giving falsely high
results. An alternative anticoagulant to use for blood
collection would be EDTA, since this inhibits both coagulation
and complement activation in vitro. However, this would
interfere with degranulation by removing Ca++ and Mg++ from
solution. Overcoming this by increasing the Ca++ and Mg++
concentrations then carries the risk of initiating coagulation.
A suggested method of blood collection for C<- conversion assay
is therefore shown in Figure 27. This involves rapid removal
of cells from plasma at 4°C before the addition of a small
amount of heparin.
The two clinical situations in which measurement of Cc
3
conversion might be of most value are in ARDS and in joint
inflammation. As discussed in Chapter 1, PMN activation by C
fragments is believed to play an important part in the lung
damage seen in the former condition. Plasma from ARDS patients

















stored at - 20°C.
(not needles as they
become brittle).
heparin (preservative free)
final concentration 2 units/ml
Can then be stored at -20°C till assay
Fig 27. Suggested method of blood collection
for assay of plasma C,- fragments using PMN
degranulation assay.
be C,_a des Arg . This may be a more accurate predictor of
ARDS than conversion and the facility of a rapid
semi-quantitative assay for C des Arg should now allowJcl
further prospective studies to be done, not only to monitor the
progress of established ARDS, but as an early predictor for
high risk patients on intensive care units. Activated
complement components may be present in plasma before clinical
features develop, and it is at this time, before lung damage is
established, that therapeutic intervention should have its
greatest chance of success. Examination of bronchial lavage
fluid for C,- fragments could also be performed.
Since activated components of the classical complement
pathway have been found in synovial fluid in rheumatoid
. . 102
arthritis (see Chapter 1), examination of synovial fluid for
Cj. fragments could aid in the diagnosis of the inflammed joint.
In established rheumatoid disease, such examination would
provide an opportunity to study local disease activity as it
proceeds.
An assay of C^-related degranulating activity also has
certain in vitro uses, and may be of value in quantitating the
titre of anti-C^a activity present in antisera. In experiments
which examined the inhibition by antisera of NCBP release in
response to activated complement, release was inhibited by two
different anti-Cj. antisera but not by three different anti-C^
antisera. The exception was the inhibition producted by a
single anti-C0n antiserum, but this antiserum also reacted3d
immunochemically with human C,.. To determine a titre of
D
anti-C^a activity, serial dilutions of test antisera could be
incorporated into the degranulation assay.
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A further application of this assay system is in the in
vitro testing of anti-inflammatory agents. Indomethacin and
other non-steroidal anti-inflammatory agents have been shown
• • 42 91
to inhibit both superoxide production and NCBP release from
neutrophils triggered with soluble stimuli. In neither case
was acetyl salicylic acid affective. Corticosteroids appear to
91 149
inhibit both secondary and primary granule discharge. The
inhibitory effect of a given anti-inflammatory drug, however,
does not correlate with its ability to block the
91 .....
cyclo-oxygenase pathway so that degranulation inhibition may
provide a new model for assessing such agents. It may be
particularly valuable in the development of agents active in
the prevention of complement and neutrophil mediated damage as
seen in ARDS and rheumatoid arthritis. Inhibition of NCBP
release by pharmacological agents is considered further in
chapters 6 and 7.
CHAPTER 3
CONDITIONS INFLUENCING COBALAMIN BINDING PROTEIN REI.FASE
FROM STIMULATED AND UNSTIMULATED NEUTROPHILS
INTRODUCTION
The work in the previous chapter was concerned with NCBP
release from cytochalasin B (CB) treated PMN'S in response to
C^ derived fragments of activated complement. In this
chapter, the following aspects of NCBP release will be
considered
1. release by activated complement in non CB treated
cells.
2. the kinetics of release in both CB and non CB treated
cells (in collaboration with Dr Tony Brown).
3. release in non complement-activated serum, and the
effect of cell concentration on this.
4. the role of the lipoxygenase pathway of arachidonic
acid metabolism in NCBP release (in collaboration with Dr Paul
Maurice).
As mentioned in Chapter 1, CB greatly amplifies and
speeds up PMN secondary granule release in response to various
stimuli, but degranulation can occur in its absence.
Comparison of the kinetics of NCBP release in the presence and
absence of CB might indicate whether CB merely allows normal
115
secretory processes to take place more rapidly, or whether a
different degranulation mechanism is induced.
When CB treated cells are exposed to serum in which
complement system has not been activated, NCBP secretion is
3
not significantly greater than in PBS-A alone . This would
suggest that no specific stimulus to NCBP release is present
in unactivated serum. In the absence of CB, however, NCBP is
3
slowly lost from PMN's suspended in such serum . Moreover,
PMN's from post-operative patients, which are refractory to in
vitro NCBP release in response to activated complement also
release much less NCBP than normal when suspended in
3
unactivated serum . Since NCBP release by such post operative
PMN's is normal when FMLP is the stimulus, it is possible that
unactivated serum also contains a specific degranulating
stimulus to which post operative PMN's are desensitised. The
nature of any such stimulus is not clear, but the complement
system is one possible source. The role of C<- activation in
NCBP release by unactivated serum will therefore be examined,
as will the effect of cell concentration.
Stimulation of PMN's by certain degranulation factors,
such as the calcium ionophore A23187 a-^so triggers metabolism
125
of membrane arachidonic acid (AA) . One possible fate of AA
is transformation via the enzyme 5'lipoxygenase, via a series
of unstable intermediates, to the biologically active 5,12
125
dihydroxy-eicosatetraenoic acid, or leukotriene B^ (LTB^)
(Fig 28). LTB^ can also trigger PMN reactions, including
chemokinesis, and aggregation"*""^. It is therefore possible
that LTB^ acts as an intracellular messenger, and that its
synthesis is a prerequisite for NCBP release in response to


























stimuli such as fragments or FMLP. The literature on this
is however conflicting, with some authors concluding that
although LTB^ synthesis and degranulation frequently occur
together, they are independent events151. Others, however,
believe that blockade of LTB^ synthesis will prevent
152
degranulation . This point is therefore examined in this
chapter, firstly by examining degranulation and lipoxygenase
activity in parallel in response to FMLP and A23187' an<1
secondly by examining the effects of a known lipoxygenase
inhibitor, BW755C, on NCBP release by these stimuli.
Lipoxygenase products can be detected by providing a
radiolabelled source of arachidonic acid, and separating the
products by thin layer chromatography. The peaks of activity
can then be counted and each product quantified.
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EXPERIMENTAL WORK
Experiment 1 Stimulus-mediated NCBP release in cytochalasin
B and non-cytochalasin B treated cells.
Method The general method for the degranulation assay was
followed. PMN's were incubated at 2 x 10 /ml in PBS-A with
either unactivated pooled human serum, ZAS or depleted
serum prepared as described in chapter 2, and incubated at
37°C for 45 minutes. The reaction was stopped by
centrifugation at 4°C and NCBP assayed in the cell-free
supernatants.
An additional stimulus used was formyl-methionyl-
leucyl-phenylalanine (FMLP) dissolved in dimethyl sulphoxide
(DMSO). The final concentration of DMSO (<0.05%) was
insufficient to interfere with either PMN responses or NCBP
assay.
Result Pretreatment of PMN's with CB (5pg/ml) prior to
exposure to either EACA-ZAS or LMW fr more than doubled the
percentage of intracellular NCBP release (Fig 29), despite the
fact that the incubation time with the stimulus was 5 minutes
in the case of CB treated cells, and 45 minutes where CB was
not used. Similar differences were seen when the stimulus was
FMLP (Fig 30). The presence of CB did not increase release
from cells suspended in PBS-A only.
Fig 29. Release of NCBP by EACA-ZAS and its low MW
fraction with (+) and without (-) cytochalasin B,




Non-Cytochalasin B treated cells








Fig 30. Release of NCBP by different concentrations of
FMLP in the presence and absence of cytochalasin B.
(mean ± SEM, n = 4).
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Experiment 2 Kinetics of NCBP release in response to FMLP
with and without cytochalasin B (in collaboration with
Dr Tony Brown) .
A. With Cytochalasin B
r:
Method A 20ml suspension of PMN's (2 x 10 /ml) in PBS-A was
divided into 4 5ml aliquots and incubated for 5 minutes at
37°C with CB. FMLP (final concentration 10~^M) or PBS-A was
then added. Two of the 4 tubes were stirred - thus:-
(i) - PBS not stirred
(ii) - FMLP stirred
(iii) - FMLP not stirred
(iv) - PBS stirred
At each time point from 15-300 seconds, 0.4ml cell
suspension was transferred to an Eppendorf tube and
centrifuged for 10 seconds through dibutyl phthalate oil (to
prevent diffusion of NCBP from cells into supernatant as they
are spun)in a microcentrifuge. Replicates at 2 time points
were centrifuged without oil to ensure that no NCBP was
retained by the oil. The supernatants were removed for NCBP
assay, and an aliquot of cells was sonicated to release all
the NCBP as before.
B. Without cytochalasin B
Method PMN's (2 x 10^/ml) were incubated in PBS-A with FMLP
_5
10 M, and the reaction stopped at time points from 10 seconds
to 60 minutes by centrifugation as in (A) above.
Results There was no influence of stirring or of the presence
of dibutyl phthalate oil on release or recovery of NCBP. In
CB-treated cells, NCBP release proceeded extremely rapidly on









Time after addition of FMLP
Fig 31. Kinetics of release of NCBP by FMLP 10 with
and without cytochalasin B.
Without Cytochalasin B (60 minute incubation)
■ ■ C5 depleted









Fig 32. Release of CBP from PMN's in PBS-A, unactivated
AB serum (5%) and unactivated Cr depleted serum (5%) in the
presence and absence of cytochalasin B,
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release in 10-15 seconds, 95% maximal release in 60 seconds
and a plateau of maximal release by 90 seconds. In contrast,
non-CB treated cells took 5 minutes to reach 50% maximal
release, and greater than 40 minutes to reach 95% maximal
release. Considering that only 40% of the total intracellular
-5
NCBP was released during a 45 minute incubation with 10 M
FMLP, it is likely that maximal release had not been reached
within this time period, and that a slow increase in release
would have persisted had the incubation been continued.
Experiment 3 Release of NCBP by non-cytochalasin B treated
cells suspended in pooled unactivated AB serum and C^
depleted unactivated serum.
Method A pool of unactivated serum was prepared from 2 normal
subjects of blood group AB. This was chosen to minimise
possible PMN activation due to red cell agglutination by
anti-A or anti-B present in added serum. Non CB treated cells
at various concentrations were incubated in this serum (final
concentration 10%) for 45 minutes.
Some of the pool of AB serum was depleted of C^ either
by passage over the anti-C<- column or by incubation with
anti-C,. gel as described in chapter 2. Non CB treated cells
were incubated in this C^-depleted, non-activated serum for 45
minutes as above.
Results Cells incubated in PBS-A lost intracellular NCBP very
slowly, with less than 5% secretion in 60 minutes (Fig 32).
When AB serum was present, release was significantly greater,
reaching 12% by 60 minutes. This release did not appear to
depend on the presence of C,_ derived products, for release in
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depleted serum was at least as great as, but not
significantly greater than, that seen in AB serum. For a
constant stimulus concentration, NCBP release in both ABS and
Cj_-depleted serum was inversely proportional to the
S 7
concentration of the cells over the range 4 x 10 - 2 x 10 /ml
(Fig 33). The effect of cell concentration was identical to
that seen when either FMLP or EACA-ZAS was the stimulus (Fig
33) .
Experiment 4 Measurement of lipoxygenase products during
NCBP release in response to FMLP and the calcium ionophore
A23187 ^"*'n co^-la^orat;'-on with Dr Paul Maurice) .
Method Venous blood was anticoagulated with EDTA (final
concentration 5mM), and spun at 160g for 10 minutes to produce
platelet-rich plasma, which was removed. Platelets have
3
previously been shown not to affect NCBP release from PMN's ,
but, since they also have a lipoxygenase, they interfere with
assay of lipoxygenase products from PMN's. PMN's were then
isolated by dextran sedimentation, removal of mononuclear
cells by LSM, and hypotonic lysis of red cells as described in
chapter 2. Aliquots of PMN's were suspended at 2 x 10 /ml in
7
PBS—A (for degranulation studies) or at 1 x 10 /ml for
leukotriene assay. Cytochalasin B, final concentration 5pg/ml
was added, and the cells incubated for 5 minutes. The stimuli
-5 14 . .
(A23187 2pM or FMLP 10 M) and C arachidonic acid in toluene
(60mCi/mmol, final concentration l.^juM) were then added, and
the incubation continued for a further 5 minutes. Control
cells had unlabelled AA 1.6uM added. The reactions were. bp
stopped either by centrifugation at 4°C (for degranulation) or
Fig 33. The effect of cell concentration on NCBP release
in non cytochalasin B treated cells. ~
(mean ± SEM, n = 4),
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by acidification to pH 3 (for lipoxygenase products assay).
NCBP was assayed in cell-free supernatants as before.
Lipoxygenase products were detected by thin layer
chromatography (TLC) (kindly performed by Dr Paul Maurice) as
follows:-
1. The lipid products in the cell-free supernatants were
extracted twice in ethyl acetate and the residue resuspended
in a small volume of ethyl acetate.
2. The samples were applied to multi-lane TLC plates
(Whatman LK6D).
3. The plates were developed in toluene : dioxane :
acetic acid (65:34:1) at This gives good separation
of cyclooxygenase and lipoxygenase products.
4. The plates were scanned to locate peaks of
radioactivity. These areas were scraped and counted in a
liquid scintillation counter.
The results of each peak were expressed as a percentage
of total radioactivity added. Arachidonic acid not converted
into cyclooxygenase or lipoxygenase products is incorporated
into neutral lipids.
Results When FMLP was the stimulus, very little arachidonic
acid was metabolised to either the cyclooxygenase product PGE2
or the lipoxygenase products 5 hydroxyeicosatetraenoic acid (5
HETE) or 5,12 diHETE (LTB4)(Fig 34), despite nearly 80% NCBP
release. In contrast, stimulation with A , causing only
z jlo /
45% NCBP release, was accompanied by much greater lipoxygenase
activity, with 20% of the labelled arachidonic acid appearing





NCBP release and synthesis of PGE. 12 diHETE
in cytochalasin B treated PMN's by FMLP and






FMLP 10"5M 23187 2 pM Arachidonic acid 0.25 mM
10"4 10"5 io-6 10"? None 10"4 10"5 10"6 None 10"4 10"5 10"6 10"7 None
Final Cone. BW755C (M)
Fig 35. NCBP release from cytochalasin B-treated PMN's by
FMLP, ^ -J g nt and arachidonic acid: effect of the lipoxy¬
genase inhibitor BW755C. (n = 2)
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Experiment 5 Effect of BW755C on NCBP release in response
to different stimuli
Method The lipoxygenase inhibitor BW755C was dissolved in
DMSO, and incubated at various concentrations with 2 x 10
PMN's/ml for 5 minutes. Because of the possibility of BW755C
binding to albumin, none was added to the PBS, and non serum
derived stimuli were used. Cytochalasin B (final
concentration ^ug/ml) was then added and the incubation
continued for a further 5 minutes. Three different
degranulating stimuli were then used:-
-5
(l) FMLP (final concentration 10 M)
(ii) the calcium ionophore A_010„ in DMSO (final2 jlo /
concentration 2jiM) .
(iii) arachidonic acid in hexane (final concentration 0.25mM.)
After 5 minutes with the stimulus, the reaction was
terminated by centrifugation at 4°C and NCBP assayed in the
supernatants as before.
Results BW755C did not interfere with NCBP assay nor did it
cause any NCBP release when added to the cells alone. At
-4
final concentrations up to 10 M, BW755C did not cause any
inhibition of NCBP release by any of the stimuli examined (Fig
35). This contrasts markedly with its effect on lipoxygenase
product synthesis at lower concentrations (Table 7, courtesy
of Dr Paul Maurice). While arachidonic acid alone at
micromolar concentrations caused no stimulation of
prostaglandin E^ or LTB^ synthesis (Table 7, column 1),
addition of A caused 35-40% of the radiolabel to appearzjlo /
in PGE^, LTB^ or the LTB^ precursor 5 HETE (column 2). The
presence of BW755C with A , however, completely blockedZjlo /
Table 7
The effect of BW755C. on arachidonic acid
metabolism by PMN's with and without ^ -j g-7
(% incorporation of recovered radioactivity into products :
each value is a mean of 2).










Polar lipid 7.3 14.4
PGE2 - 4.2
T x B2 3.0
5, 12 diHETE - 18.4
(LTB4)
5 HETE - 14.4











AA = arachidonic acid
production of any of these metabolites, so that practically




As is well documented , preincubation of PMN's with CB
both greatly amplifies and accelerates NCBP release in
response to whole EACA-ZAS, its low molecular weight fraction,
or FMLP, all of which trigger non-cytotoxic dose-dependent
degranulation via surface receptors. The kinetic pattern,
however, appears similar whether CB is present or not. There
is initially rapid secretion of NCBP, slowing down with time,
perhaps due to loss of surface receptors by internalisation of
receptor-ligand complexes. The similarity in kinetics of
release with and without CB would suggest that CB enhances
normal stimulus-induced secretory processes, rather than
triggering or permitting NCBP loss from the cells by other
means.
The apparent anomaly in the results is that while
release by unactivated AB serum is no greater than in PBS-A
for CB-treated cells, release is much greater in AB serum than
in PBS-A when no CB is present. Similarly, when no CB is
present, cells secrete just as much NCBP in ABS as they do in
ZAS, whereas in CB treated cells ZAS stimulates considerably
more secretion. Release of NCBP in the presence of AB serum
thus seems to differ fundamentally from release triggered by
specific complement fragments. The degranulating activity in
AB serum is stable at room temperature for 16 hours, and is
only partially abrogated by heating to 56°C for 30 minutes,
3
suggesting that it is not derived from complement . Release
from non-CB treated cells is also seen in C^-depleted serum,
and in plasma prepared by the 'rapid spin' technique designed
3
to minimise complement activation , suggesting that
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serum-dependent release is not mediated via C fragments.
Chromatography of AB serum on Sephadex G200 reveals 1 peak of
degranulating activity of high molecular weight for non-CB
3treated cells yet none for CB-treated cells . A similar high
MW peak appears to be present in ZAS, as well as the low MW
peak representing C5 fragments. The high MW peak, however,
has no activity for CB treated cells. Release in ABS by
non-CB treated cells varies with the concentration of both
3
serum and cells, as shown above, in the same way as
degranulation in response to known receptor-mediated stimuli
such as EACA-ZAS and FMLP. The stimulus-specific loss of
responsiveness of post operative PMN's to ABS and EACA-ZAS
might also argue for a specific receptor-mediated mechanism.
However, in normal cells in ABS concentrations as high as 60%,
release is never greater than 25% of the total NCBP. Release
3
also proceeds slowly in whole blood . It would thus appear
that 2 serum-derived degranulating stimuli can be identified.
The first is of high molecular weight, and is present in both
ZAS and ABS. It degranulates non CB treated cells slowly and
its activity is not enhanced by CB. The second stimulus is of
low molecular weight and arises from serum complement,
probably from C,-. It also degranulates non CB treated cells
slowly but its activity is greatly enhanced by the addition of
CB.
It has been suggested than PMN secondary granules may
contain a labile subpopulation which are slowly lost from the
3
cell under appropriate conditions, as when serum is present .
The presence or absence of CB would thus be irrelevant to such
granule loss. The lack of secretion in CB treated cells could
132
be simply due to the much shorter incubation time used when CB
is present, i.e. 5 minutes instead of 45 or 60 minutes. This
slow 'background' release of secondary granules could
57
influence various systems - granulopoiesis, via lactoferrin ,
50
reactivity of other PMN's via lysozyme , and possibly
bacterial function via binding of cobalamins by NCBP. Thus
NCBP release in normal serum may be a physiologically normal
and desirable phenomenon, although its exact mechanism remains
unclear.
NCBP release by CB-treated cells in response to FMLP is
accompanied by very little synthesis of lipoxygenase products
as assayed by thin layer chromatography. This is consistent
with previous observations using radioimmunoassay for LTB^, in
which the primary granule marker p glucuronidase was released
from CB-treated cells by FMLP without detectable LTB^
151
synthesis . Receptor-mediated stimuli such as FMLP
therefore appear much less able to stimulate leukotriene
production than does A23187* T^e TLC met'rio<^ use<3 our study
to detect lipoxygenase products also detected other stable
products of the lipoxygenase pathway, and none was produced in
significant quantities. The calcium ionophore A23187'
however, triggered both NCBP release and synthesis of
cyclooxygenase and lipoxygenase products in significant
quantities. The different behaviour of these stimuli may
relate to the direct effects of the ionophore on cytoplasmic
calcium levels, while FMLP acts via occupation of surface
receptors, followed by calcium mobilisation and breakdown of
membrane phosphotidyl lipids. In any case, it appears that
NCBP release can occur without significant lipoxygenase
133
activity. The behaviour of cells exposed to BW755C confirms
this, with concentrations of drug shown to totally block
lipoxygenase having no effect on NCBP release. This finding
151
is similar to that of Palmer and Salmon . In inflammatory
sites, secondary granule release and leukotriene synthesis
would both modify the inflammatory reaction. LTB^ would
recruit and activate further PMN's, while release of lysozyme
could localise PMN's to inflammatory sites. Within individual
cells, however, secondary granule release and leukotriene
synthesis appear to be separate events.
134
CHAPTER 4
THE ROLE OF C5 AND NEUTROPHILS IN THE WHEAL AND FLARE
RESPONSE TO INTRA-DERMAL ZYMOSAN ACTIVATED SERUM (ZAS).
INTRODUCTION
Activation of PMN's by C^ conversion products in vitro
clearly triggers a rapid secretory response by the cells, as
shown above, as well as chemotaxis and aggregation. C,_
products have also been implicated in vivo in the increased
vascular permeability and inflammatory tissue damage seen in
conditions such as the adult respiratory distress syndrome and
rheumatoid arthritis, as discussed in Chapter 1. The question
to be investigated in this chapter is whether PMN recruitment
by Cj- fragments can be implicated in the immediate vascular
response to activated complement in the skin.
Injection of activated complement into the skin produces
an immediate wheal and flare response, but the exact mechanism
remains unclear. The anaphylotoxins C and C^ cause releasej9
of histamine and leukotrienes from mast cells, but the des Arg
form of Cj., with little activity towards mast cells, remains
active in the skin, suggesting that a mast cell independent
mechanism may be operating. The observations of Issekutz"'"'^
121
and Williams on the role of PMN's in the skin response to
complement in the rabbit suggest that PMN products may mediate
the permeability response. Their studies also throw into
question the role of C^ fragments in the skin reaction, since
66
they have little chemotactic activity towards PMN's . The
135
role of C,_ fragments and neutrophils in the skin response to
complement in human subjects will thus be examined here.
While studies with normal and neutropenic animals suggest
that circulating PMN's are necessary for the vasodilatation
and microvascular permeability response to intradermal
117 121
C5a ' (reviewed in Chapter 1), no similar studies have
yet been performed in neutropenic human subjects. There are
obvious ethical and practical limitations to such work. The
main one is the necessity to inject each subject's skin only
with complement products from his or her own serum, rather
than with a well characterised and standardised batch of
5a
prepared from a serum pool. Another difficulty is in
obtaining patients with severe enough neutropenia, yet who are
well enough to be studied and totally infection-free. This
has of necessity limited the number of neutropenic patients
who could have been studied.
The other point which is examined here is whether
Williams' "two-mediator hypothesis" of inflammation applies to
this skin model in man. The hypothesis states that
demonstrable inflammatory reactions require both a vasodilator
123
and a permeability producing mediator (discussed in Chapter
1). Thus CR alone, despite increasing permeability, would-Del
not produce a wheal, as no vasodilator component would be
121
present. This was borne out in studies in the rabbit ,
where wheals were not produced by C unless PGE„ has been
j3 ^
present also. To see whether this two mediator hypothesis
applies in man, the skin response to ZAS and to PGE^ has been
examined for synergy between the two mediators. Synergy
between two mediators exists if the response to a mixture of
136
the two is greater than the sum of the responses when the two
mediators are injected separately.
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EXPERIMENTAL WORK
Experiment 1 Preliminary studies on technique
A. Assessment of accuracy of measurement of 50 ytil injection
volume.
Method By weighing weigh boats on an analytical balance
before and after the addition of 50yul distilled water from a
1 ml syringe, the accuracy and reproducibility of this method
of measuring 50yul could be assessed.
Results The results are shown in Table 8. The mean weight of
10 50yUl aliquots was 50 mg weight and all values lay within
10% of that figure, which was considered acceptable for this
study.
B. Reproducibility of measurement of wheal volume.
Method To assess the reproducibility of wheal response in
different subjects, and within each subject at different
times, repeat injections of dilutions of ZAS were made over
several weeks, and the wheal volume measured as described
below. Any variability in the results would therefore reflect
true variability of response, as well as inconsistencies in
measurement.
Results The results are shown in Table 9. The
reproducibility of wheal volumes at 12 minutes by both
concentrations of ZAS was acceptable considering the number of
variables involved (see discussion). There was, however
considerable inter-subject variation in response. By 30
minutes, both intra- and inter- subject variation was much
greater than at 12 minutes. Therefore, although many
experiments have measurements taken at both 12 and 30 minutes,
the 12 minute measurements are probably more meaningful.
Table 8
The weights of 10 50gl aliquots of distilled
water
No Weight (mg) No Weight (rng)
1 46.5 6 51 .0
2 50.8 7 44. 3
3 54.0 8 52.3
4 52.6 9 47.8
5 47.7 10 52. 8





Comparison of wheal volumes produced by buffered
and non buffered saline (n = 6)
Wheal volume (mm3)








Wheal volumes at 12 and 30 minutes after injections
of ZAS : assessment of reproducibility. Results 1 and 2
were obtained from injection of the same material
days or weeks apart.
Injection Injection
Subject
ZAS h : 12 mins ZAS h : 30 mins
Result 1 2 Result 1 2
1 105.67 100.37 96.09 93.01
2 107.35 86. 05 121.66 114.66
3 126.08 128.07 204.92 158.76
4 90.49 99.70 38.59 58.62
5 83.23 101.46 1 15.68 161.63
6 132.38 131.67 8 6.60 124.99
7 79.77 69.39 86.47 43.02
8 70. 12 99.39 50.32 77.99
9 76. 57 59.17 62.34 39.27
Injection Injection
Subject
ZAS h : 12 rains ZAS h : 30 mins
Result 1 2 Result 1 2
1 63.40 84.30 17.85 1 1 .82
2 68 . 70 86.65 106.89 42. 18
3 52.08 55.73 74.93 74.68
4 62. 59 44.31 59. 15 41.25
5 43.30 33.58 16.37 10.44
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C. Comparison of wheals produced by sterile, unbuffered 0.9%
NaCl and phosphate buffered saline (pH = 7.4).
Sterile, pyrogen tested saline has no buffering capacity,
but phosphate buffered saline made from laboratory chemicals,
while it can be autoclaved, is not necessarily pyrogen free.
A comparison was therefore made of wheals produced by each of
them (Table 10), which shows no signiicant differences.
Sterile pyrogen-tested saline was therefore used for all
subsequent dilutions and injections.
Experiment 2 Wheals and flares produced by ZAS preparations
in normal subjects.
Normal subjects were informed medical and laboratory
staff of both sexes aged 21-49.
Methods
A. Preparation of activated complement.
Serum from each subject was incubated with boiled washed
zymosan 2 mg/ml at 37°C for 60 minutes. Complement activation
was terminated by centrifugation at 2000 g for 5 minutes
followed by passage through a 0.2yu filter. A partially
purified low molecular weight fraction was prepared from
zymosan-activated serum (ZAS) which was layered over a 30,000
Dalton micro-partition membrane and centrifuged at 2000 g for
30 minutes at room temperature. The fraction of ZAS which had
passed through the membrane was used for injection. All
manoeuvres were performed under sterile conditions in a
laminar flow cabinet. Sera were stored under liquid nitrogen
and were sterilised by filtration immediately prior to
injection.
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B. Injection of solutions.
Control solutions injected were saline, the supernatant
from zymosan incubated alone, and serum not exposed to
zymosan. Solutions were coded by someone not involved in the
measurement and were injected randomly at numbered sites on
the flexor surfaces of both forearms, which had been cleaned
with alcohol. 50yul of each solution was injected from a 1 ml
syringe through a 27 gauge needle into the skin so that a
raised 'bleb' was formed on the skin surface (Fig 36). Where
the solution entered subcutaneously, no such bleb was formed,
and the injection was repeated at a fresh site.
C. Measurement of response.
Flare areas 10 minutes after injection, were calculated
by measuring 2 diameters, 1 in the long axis of the arm (D-^)
and 1 at right angles to it (D2), and calculating the area
from the formula
Area (mm^) = x (D-^+D^) ^
4 2
where and D2 are in mm.
Wheal volumes were calculated from wheal area, measured
as for flare area, and wheal thickness. 1Pseudopodia' were
not included in the measurement of wheal diameters. Wheal
thickness was calculated by measuring a double thickness of
skin (excluding sub-cutaneous tissue) at each site before and
after injection, using spring-loaded skin calipers (Fig 37).
154
This technique has previously been described and
155
validated . The calculation of thickness and volume is
shown in Fig 38. Because the skin calipers measure 2
thicknesses of skin, the final thickness of the wheal is half
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Fig 36. Intradermal injection of ZAS to produce a raised
'bleb' on the skin.
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Fig 37. Measurement of wheal thickness using spring-loaded
skin calipers.
Pre-iniection





= thickness x 2
Wheal volume 11 . 2 ±1 . ,
o = — x mean diameter x ^thickness,3 ■(mrrr) 2
Fig 38. Technique and formula for measurement of skin
wheals.
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the difference in skin caliper measurement pre and post
injection. To simplify the volume calculation, the formula
for the volume of a cylinder is used, where wheal area = base
and thickness = height. While the wheal is obviously not
cylindrical, its volume will be proportional to that of a
cylinder with the same base area and height. Each set of
injections included a saline control, the response to which
was subtracted from all other results when calculating
volumes, unless otherwise stated.
Results Injection of 50yul sterile saline always resulted in
3
a wheal volume at 12 minutes of less than 10 mm (Fig 39). No
significant increase on this was produced by either
unactivated serum or zymosan supernatant (Fig 39). Dilutions
of ZAS, however, produced a dose dependent wheal and flare
response by 12 minutes (Fig 40). The flare appeared within
minutes of injection, followed by the wheal, which was readily
measurable with well-defined edges by 12 minutes (Fig 41). At
lower serum concentrations, the wheals were reduced in size by
40 minutes, although with neat serum an increase in wheal size
occurred between 12 and 30 minutes (Fig 42). All wheals faded
over an hour or two, and no late reactions were noted, but
unlike histamine (see Chapter 5), injection of ZAS was not
associated with any pain or itching. Injection of the low
molecular weight fraction of ZAS also produced a wheal and
flare response (Fig 43), although less than that produced by
whole ZAS. Quantitative comparisons of potency with whole ZAS
are not meaningful, because not all low molecular weight
fraction is recoverable from the fractionation process. The
fact that the low molecular fraction of ZAS can generate a
Saline Zym.sup. Unact. serum
Time after injection (mins)
Fig 39. Wheal volumes in normal subjects 12 and 30 minutes
after injection of saline, zymosan supernatant and
unactivated serum. (mean ± SEM, n = 10).
Not corrected for saline alone.
Unactivaled ZAS ZAS ZAS ZAS Unactivated ZAS ZAS ZAS ZAS
serum Neat 50% 20% 10% serum Neat 50% 20% 10%
Fig 40. Wheal and flare responses to dilutions of ZAS at
12 minutes (mean ± SEM, n shown above each bar).
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Fig 41. Wheals of different sizes after injection of coded
solutions. Site 6 received ZAS and has a flare.
148
Fig 42. Time course of wheal response to ZAS
(mean ± SEM) (numbers are shown for each group).
60 600














Fig 43. Wheal and flare response in normal subjects to
the low molecular weight fraction (50%) of ZAS.
(mean ± SEM, n = 7).
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wheal and flare response, albeit an attenuated one, suggests
that the inflammatory mediators in ZAS are of low molecular
weight.
Experiment 3 Wheal and flare responses to heated or C^_
depleted sera.
Method
A. Inactivation of complement
Sera were heated at 56°C for 30 minutes prior to or
following zymosan activation.
B. Cr depletion
Sera from normal subjects were depleted of C,. using an
affinity chromatography gel, as described in Chapter 2. Sera
passed over the gel were negative for the hepatitis B surface
antigen. Sera prepared by this method were shown by
two-dimensional immuno-electrophoresis and Ouchterlony
immunodiffusion to be devoid of while retaining C^- They
were then zymosan activated as before. Statistical
comparisons were made between normal and either heated or C,-
depleted sera by paired t test, but because the responses were
not necessarily normally distributed, the non-parametric
Wilcoxon's signed rank test was also used.
Results Removing from sera prior to zymosan activation
resulted in a highly significant reduction in wheal volume at
both 12 and 30 minutes (Fig 44). The p values refer to those
obtained by paired t test; by Wilcoxon's signed rank test all
pairs were significantly different at the 1% level. No flares
were produced by depleted sera at any concentration.
Heating sera to 56° for 30 minutes prior to zymosan
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Fig 44. The effect of depletion or heating on
generation of wheal-proaucinq activity in the skin
(mean t SEM, n = 8 except for zymosan activated then
heated, where n = 2).
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activity (Fig 44), and likewise such sera produced no flares.
When sera were first zymosan activated then heated there was
an approximately 25% reduction in wheal size, but this was not
significant.
Experiment 4 Wheal and flare responses to ZAS, IJM fr and
histamine in subjects with severe neutropenia.
(Studied with kind permission of Drs J Fletcher and
Dr PAE Jones).
Methods Ten neutropenic subjects of both sexes with
9
peripheral blood neutrophil counts of less than 0.5 x 10 /I
were studied with their informed consent and hospital ethical
committee approval. Their ages ranged from 16-72 (mean age =
50) and their diagnoses included marrow dysplasia or
hypoplasia, hypersplenism, and neutropenia following
chemotherapy for Hodgkin's disease or acute leukaemia (Table
11). All subjects were apyrexial and free from infection when
studied and no subject was taking antibiotics or
anti-inflammatory agents. Subjects were injected with
autologous ZAS, and its low molecular weight fraction (LMW fr)
as described above.
To ensure that sera in the normal and neutropenic groups
contained comparable amounts of complement components, and
were measured turbidometrically, and total haemolytic
complement was measured by a standard haemolytic assay in sera
from normal and neutropenic subjects prior to zymosan
activation (kindly arranged by Dr R J Powell) . C.. conversion5
products were measured in sera from neutropenic subjects
following zymosan activation by the release of
cobalamin-binding protein from normal cytochalasin B treated
Table11










































































































neutrophils, as described in Chapter 2. This release appears
to depend on conversion products. To ensure that the
neutropenic patients were capable of producing reactive wheals
and flares, 3 neutropenic subjects also received 50 1 1.2 x
-4
10 M histamine intradermally.
Results In neutropenic subjects, the flare response to both
concentrations of ZAS was significantly reduced (Fig 45), and
the low MW fr produced no flares at all in the neutropenic
group. The p values were obtained by both unpaired t test and
Wilcoxon's signed rank test, which gave identical values.
Wheal responses to ZAS were also significantly less in
neutropenic subjects, both at 12 minutes (Fig 45) and at 30
minutes (Fig 46). The low MW fr also generated much less of a
wheal response in the neutropenic group at both time points
(Figs 45 and 46), although the difference at 30 minutes did
not reach statistical significance. These findings suggest
that PMN's are involved in producing both vasodilatation and
an increase in vascular permeability.
There was no significant difference between normal and
neutropenic subjects in the response to saline or unactivated
serum (Fig 47), and the wheal and flare response to histamine
in three neutropenic subjects was not impaired (Fig 48).
Because these subjects found the histamine injections both
painful and itchy, and because of the increased risk of skin
infection, it was not felt justified to test the rest of the
neutropenic group with histamine. Serum C^, and total
haemolytic complement (CH._^) were normal in neutropenic50
subjects (Table 12) except for one (subject 7) who had
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ZAS 50% ZAS 20% LMW Fr 50% ZAS50% ZAS 20% LMWFr50%
Fig 45. Wheal and flare resonses at 12 minutes to ZAS and
LMW fr. in normal and neutropenic subjects. (mean ± SEM,





ZAS 50% ZAS 20% LMW fr 50%
Fig 46. Wheal responses at 30 minutes to ZAS and low
molecular weight fraction in normal and neutropenic
subjects (numbers of subjects indicated above each bar)









(corrected lor saline alone)






Time after injection (mins)
NS
30
Fig 47. Wheal volumes 12 and 30 minutes after 50|j1 saline
or 50% unactivated serum in normal and neutropenic subiects.
(mean ± SEM, 10 in each group).
: | Normal Neutropenic
Fig 48. Wheal and flare responses 12 minutes after
intradermal injection of 10 histamine in normal and
neutropenic subjects. Results show mean t SEM in each
case, with n indicated above each bar.











































responses were not lower than other neutropenic subjects. Cr
conversion products as assessed by degranulation of normal
PMN's were similar in ZAS from normal and neutropenic subjects
(Fig 49), so that the reduced inflammatory responses in
neutropenic subjects could not be attributed to injection of
reduced levels of complement derived mediators.
There appeared to be no influence of platelet count on
the response, for when wheals and flares in those neutropenic
subjects who were also thrombocytopenic (platelet count < 50 x
9
10 /I were compared with those with platelet counts of > 100 x
9
10 /I no significant differences were seen (Fig 50).
Experiment 5 Effect of prostaglandin (K®^) and ZAS
together.
Method To see whether ZAS and PGE^ together produced synergy
of response, 50yul injections were made of ZAS (10 and 20%)
and prostaglandin (50yul of a 5.68 x 10~^ M solution,
giving 3 x 10~^0 mols/site, as previously described"'"^) . 50
/ul of mixtures of ZAS and PGE^, containing the same final
concentrations of each as when prepared separately, were also
injected. Synergy was considered to be present if the
response to ZAS + when injected together was
significantly greater than the sum of the responses to the two
substances injected separately.
Results When injected alone, PGE^ produced small wheals,
little bigger than saline alone, but with a noticable flare
response disproportionate to the size of the wheal (bars A,
Fig 51). There was no evidence of synergy with ZAS (Fig 51),
for wheals and flares produced by the ZAS/PGE^ mixture (bars
158
Fig 49. NCBP release from normal cytochalasin B
treated PMN's by ZAS from normal■and neutropenic
subjects. (mean t SEM, n indicated in each case).
I | platelets platelets
> 100,000 (7) < 50, 000 13)
Fig 50. Effect of platelet count on response to ZAS in
neutropenic subjects (n indicated in brackets above,































D) were not greater than the sum of the responses to ZAS and
PGE^ injected separately (bars C). Indeed, responses produced
by the mixture were always less than the sum of the separate
responses, particularly wheals produced by the higher ZAS
concentration, but this difference never reached statistical
significance.
Experiment 6 Biopsy of a wheal.
Method Punch biopsy of a wheal was made 10 minutes after
injection of 50yul 50% ZAS in 1 subject (kindly performed by
Dr Paul Maurice). The biopsy was taken into gluteraldehyde
(to prevent mast cell degranulation) , processed for light
microscopy, and stained with haematoxylin and eosin.
Result There was obvious oedema in the tissues. The most
striking feature was in the blood vessels as in Fig 52, which
shows a number of PMN's adherent to the wall of what is
probably a venule. There were no PMN's seen extravascularly.
16 1
Fig 52. Light micrograph of biopsy of a skin wheal
10 minutes after injection of 50|al 50% ZAS, stained
with haematoxylin and eosin.
This shows oedematous tissue with a venule containing




These studies have demonstrated the feasability of using
a simple skin model to assess the inflammatory activity of
mediators. The technique of measuring wheal thickness using
154 155
skin calipers has been evaluated by others ' . Their
data, and that presented here, shows that it is an acceptably
reproducible method, provided that not too many measurements
are made of each wheal during the response, for each act of
measurement may compress its size by up to 10%"*"^^. There is,
however, considerable variation between subjects in their skin
response to autologous ZAS. This is, surprisingly, no greater
than that seen with a standard stimulus such as histamine (see
Chapter 5), and therefore suggests that variations in basal
complement levels and generation of vasoactive complement
fragments are not as important as would be expected in
producing the variability of the final response, which
therefore appears to be much more dependent on factors
inherent in the skin and blood vessels.
The observation that activated complement can cause
local wheal and flare reactions in the skin is long
established. This study has attempted to define the mechanism
with respect to both the complement component(s) and cell
type(s) involved. The results of the experiments with heated
ZAS confirm a complement source for the inflammatory activity,
with loss of wheal producing activity by heating sera before
complement activation, as unactivated C_ and C,. are heat
o 5
labile. There is much less loss of activity when sera are
heated following complement activation, as complement split
products are much more heat stable^0. Separation of ZAS into
163
high and low molecular weight fractions suggests that a major
source of inflammatory activity lies in the molecular weight
range of less than 30,000 Daltons. This low MW fraction, at
the same concentration as the ZAS from which it was formed,
produced much less inflammatory activity than whole ZAS, but
as discussed in Chapter 2, not all small molecules can pass
through the filter due to 'clogging up' by large molecules.
For this reason, finding inflammatory activity in the 'high
MW' fraction would actually have yielded little information
about the molecular size of the inflammatory mediators.
depleted sera, despite the persistence of C^r
produced very little wheal and flare reaction in the skin.
C^, on maximal complement activation in the absence of EACA,
would yield C^a des Arg at a concentration of approximately
0.45-1.0 x 10 M, about 10 times the maximal concentration of
des Arg^. C^a des Arg therefore appears to have no role
in wheal and flare production in human skin, and the findings
point to low molecular weight C<- products being the main
inflammatory mediator. The main such product generated when
serum is activated without EACA is C des Arg, formed from
j3
Cj-^. It did not prove possible to test EACA-ZAS (which would
contain mainly C^a) in the skin, as the EACA itself was highly
inflammatory.
What cell type(s) could C- des Arg be activating? The
.Del
main contenders, from in vitro studies, are mast cells and
PMN's. Although unconverted C is a highly potent mast cell
activator, the des Arg form, at least at concentrations
achievable in serum, has little activity towards mast cells^0.
It is possible that mast cells could be activated by any
1 64
unconverted C_ or C. in ZAS, but in the absence of EACA3a 5a
removal of the arginine proceeds extremely rapidly. An
alternative mast cell stimulus could be one or more of the
PMN-derived mast cell triggering systems which have been
described"*"^' The possible role of mast cell histamine
in the response in examined further in Chapter 5, but the
notable lack of stinging and itching produced by intradermal
ZAS is in marked contrast to histamine, even when the subjects
do not know which injection is which, and suggests that any
histamine component in the response to ZAS is relatively
minor. Moreover, to invoke the mast cell as a major
contributor to the reaction, it would have to be postulated
that mast cells were in some way impaired in neutropenic
157
subjects. Mast cells have a slow rate of turnover , and are
therefore unlikely to be affected by alkylating agents or
other chemotherapeutic drugs. Mast cell function in
neutropenic subjects has not been formally tested, by, for
example, intradermal injection of the mast cell degranulator
48/80, but there was no difference in response to ZAS between
those who had had chemotherapy and those who had not.
The data can therefore best be explained by the
hypothesis that the final wheal and flare response in some way
involves circulating PMN's. Although reactions to ZAS were
not totally abolished in neutropenic subjects, as they were in
121
the mustine-treated neutropenic rabbits , the peripheral
blood counts in our subjects were often much greater than the
122
1% of normal obtainable experimentally , for even a count of
9
0.5 x 10 /I is no less than 10% of normal. Concentrations of
C des Arg achievable in ZAS are well within the range which
Del
165
activates PMN's, which is 10"8-10~*7 M60. The lack of wheal
response to Cj. depleted serum in the skin is strikingly-
similar to the failure of C5 depleted serum to attract PMN's
158into skin chambers in human subjects and to its inability
to degranulate PMN's in vitro. Thus wheal production and PMN
activation seem closely linked. Indeed the size of the
permeability response produced by chemotactic factors seems to
118
correlate closely with the rate of PMN accumulation
The response to activated complement in man also differs
from that in the rabbit in that ZAS is entirely effective in
producing wheals and flares without the simultaneous presence
of a vasodilator such as PGE2. PGE2 can be synergistic with
permeability agents such as platelet activating factor in
159
man , suggesting that basal blood flow in human skin is not
rate-limiting to be permeability reaction. However, not only
was there no synergy between ZAS and PGE2, but the response to
ZAS was actually reduced when PGE2 was present, for reasons as
yet unclear. It has been suggested that exogenous
vasodilators are not required in man for the permeability
response to ZAS to be seen, because a minor degree of mast
cell activation might be occurring with release of histamine
and leukotrienes A, C and D. This itself could dilate the
vascular bed sufficiently to allow wheal production without
the need for exogenous vasodilators (Williams TJ, personal
communication).
The exact mechanisms of PMN involvement in the
production of the vascular response to ZAS remain unclear, in
terms of both how C,_ fragments and PMN's come into contact
with each other, and how PMN's then contribute to the
166
permeability increase. Contact between C_ fragments and PMN's5
could be explained either by diffusion of between5a
160
endothelial cell junctions , or by transport of C,. through
.Del
the endothelial cell from the abluminal to the luminal
side"^"*". A further alternative mechanism is that the binding
of C,- fragments to be abluminal side of the endothelial cell
leads to alterations in the characteristics of its luminal
membrane, such that PMN's adhere to it.
There are many possible ways in which PMN activation
might produce microvascular changes. Activated PMN's undergo
degranulation and a respiratory burst, the possible role of
which will be examined in Chapter 5. They also convert
membrane lipids into products which have been implicated in
the inflammatory response. Prostaglandin Eas was observed
in this study, certainly causes a small wheal and notable
124
flare in the skin, confirming the observations of others
162
Thromboxane A^, on the other hand, causes vasoconstriction ,
and the lipoxygenase product leukotriene (LTB4), although a
163 164
moderately powerful chemoattractant ' and promotor of
164 165
neutrophil adhesion to endothelium ' , does not cause
immediate wheals and flares in human skin""^' but a
delayed, indurated reaction with neutrophil
infiltration"'"^' in animals, its effects in skin are
neutrophil dependent""^""' f and blockage of its synthesis
does not impair the skin response to C des Arg in the rabbit
so that although LTB^ may have a role in amplification of
the inflammatory respose by recruitment of further PMN's, its
synthesis by them is unlikely to play a major part in
immediate wheal and flare production in response to C^
1 67
fragments.
PAF-acether, on the other hand, which is produced by
171 172PMN's within minutes of exposure to C,. , or C^a des Arg
does cause an immediate wheal and flare response in rabbit
126skin which is independent of circulating neutrophils , and
. . 173
has similar effects in man , where it is 100-1000 times more
potent than histamine. Some subjects also show a late
reaction to PAF-acether, with erythema and hyperalgesia, which
we have not observed with ZAS, but it remains possible that
PAF-acether is one of the permeability-producing mediators
involved in the skin reaction to ZAS. An alternative source
171
of PAF-acether is vascular endothelium , although whether
PMN adhesion could stimulate its synthesis remains to be seen.
PMN's could also cause capillary leakage by direct
effects on the endothelial cell barrier. It has been proposed
that the actual movement of PMN's through capillary or venule
walls might open up tight junctions between the cells,
121
allowing the escape of plasma . This may not actually
require the physical presence of the PMN's between the
endothelial cells, but could result from impairment of
endothelial cell integrity by PMN products. Oxidation
products, for example, can cause K+ efflux and purine release
127
from endothelium . Adhesion to, or movement through, a
tissue barrier do seem to be important in activating PMN
release mechanisms. PMN's moving into sterile suction skin
blisters released secondary, but not primary granule contents
174
into the blister fluid , a phenomenon which may be important
in renewing surface receptors. The permeability response to
des Arg correlates closely in time with the period of PMN
168
118
adherence to and migration across the vessel wall , while
the presence of PMN's actually in the tissues seems to
contribute little to the vascular response to these mediators.
In this study, biopsy of a we11-developed wheal showed many
intravascular PMN's adherent to vessel walls, but none
extravascularly, supporting the suggestion that PMN's
activated during adhesion but prior to migration into the
tissues can produce an increase in permeability. PMN's in the
tissues might actually be refractory to further activation by
the same stimulus, for stimulus-specific desensitisation of
PMN's moving into inflammatory skin sites has been
described"*"^.
des Arg might attract PMN's by sticking, not only to
the PMN's but also to the vascular endothelium. The evidence
is however conflicting, with pre-treatment of the endothelium
116
with C,- being reported to either increase or have no
161
effect on PMN adhesion. Once adherent to endothelium,
PMN's could secrete factors such as oxidation products and




STUDIES INTO THE MECHANISMS OF PMN INVOLVEMENT IN THE SKIN
RESPONSE TO ACTIVATED COMPLEMENT
INTRODUCTION
As indicated in Chapter 4, there are many possible
mechanisms by which PMN's could cause an increase in vascular
permeability. The work in this chapter attempts to examine
the role of some of these mechanisms.
The oxidase enzyme of PMN's, situated in the cell
membrane, converts free oxygen to reactive tissue-damaging
oxygen radicals, such as the superoxide anion, the hydroxyl
radical and hydrogen peroxide. PMN's in certain inflammatory
sites, such as those entering the lung in ARDS, show increased
activity of this enzyme as demonstrated by
84
chemiluminescence . PMN oxidative products may also be
responsible for some of the damage to cartilage and synovium
in rheumatoid arthritis"'"0"'". In vitro studies using cultured
127177 89
endothelial cells ' and perfused rabbit lungs have
suggested that these oxidative products might be important in
increasing endothelial permeability to proteins.
The capacity of activated normal PMN's to increase
albumin transfer across cultured endothelial cells appears to
be absent in PMN's from individuals suffering from chronic
178
granulomatous disease (CGD) , in which oxidase function is
defective. To see whether the oxidase is equally important in
170
increasing endothelial permeability in vivo, we have examined
wheal and flare responses to ZAS in an individual wth CGD and
in four female carriers of the condition.
A further situation in which functional and biochemical
abnormalities of PMN's have been repeatedly described is
chronic granulocytic leukaemia (CGL). These include impaired
adhesion to glass"*-"^ and nylon"*"^, reduced emigration to
181 182
extravascular sites , and defective phagocytosis and
183 184
killing . Biochemically, low levels of lysozyme and
185
lactoferrin have been observed, as well as the well
characterised deficiency of alkaline phosphatase. In
addition, there may be defects in metabolism of oxygen
products, for reduced levels of hydrogen peroxide are formed
186
during phagocytosis , and in response to soluble stimuli
(Rule S, unpublished observations), though superoxide
generation appears to be normal. CGL PMN's appear to
degranulate normally during phagocytosis and in fact a greater
percentage of granule enzymes can be recovered from the medium
44
than when normal cells are used . Since normal PMN's degrade
140
up to 20% of their primary granule enzymes by oxidation ,
the increased enzyme recovery from CGL cells may reflect
44
reduced production of oxygen radicals . To see if these in
vitro defects are mirrored in an in vivo response, the skin
reactions to ZAS have been examined in CGL patients in the
chronic phase of the disease.
The role of mast cells in the skin response to
complement is investigated in two ways. Firstly a comparison
of the reaction is made in the presence and absence of local
and systemic anti-histamines of anti-H-^ type. Secondly, the
171
possibility that activated PMN's can trigger mast cell release
of histamine in vitro is examined, as previously suggested by
the observations of Stendahl"'"^ and Coble
Finally the possibility that stable inflammatory
products, such as prostaglandins and leukotrienes, contribute
to the reaction is tested by examining the skin reaction
following systemic corticosteroid, aspirin, or non-steroidal
anti-inflammatory (NSAI) drug administration. Steroids act by
preventing the release of arachidonic acid from membrane
phospholipids, thus blocking both cycloxygenase and
lipoxygenase pathways, while NSAI's in standard doses inhibit
the cycloxygenase pathway. The supernatant from actively
phagocytosing PMN's is also examined for wheal producing
activity in the skin to see whether stable inflammatory
mediators can be detected and identified.
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EXPERIMENTAL WORK
Experiment 1 Skin responses to ZAS and histamine in
subjects with chronic granulomatous disease (CGD).
(Studied with kind permission of Drs WG Reeves, JA Raeburn and
OB Eden)
Methods One male case of CGD (aged 9) and four female
carriers of the condition (including the mother of the case)
received intradermal injections of 50pl of autologous ZAS 50%,
20% and 10%, LMW fr from autologous ZAS, and histamine 1.2 x
-4
10 M. Wheal and flare responses were measured at 12 and 30
minutes as before. All subjects had been previously-
investigated and found to have either impaired reduction of
nitroblue tetrazolium, reduced chemiluminescence, or both.
Individuals were well when studied, and on no antibiotic
therapy.
Results No definite conclusions could be drawn. The case of
CGD was able to produce wheals and flares in response to both
ZAS and histamine. Wheals in response to both stimuli were
well below normal, (Fig 53), but there were no age matched
controls. Flare responses, on the other hand, were above
normal to both stimuli (Fig 53). The carriers also showed
normal flare responses to both stimuli, and normal wheal
production to histamine (Fig 53). Wheal responses to ZAS
appeared to be reduced, but whether this is a real finding is
unclear on such a small sample.
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12mins 30mins Flare 12 mins 30mins Flare
Fig.53* Wheal and flare responses to 50% ZAS and histamine
—E* case of CGD (a) and 4 female carriers (•)
Mean (± SEM) of carriers = 1 Mean (± SEM) of 1 (j normal
subiects = T. T
Experiment 2 Skin responses to ZAS and histamine in
subjects with chronic granulocytic leukaemia (CGL).
(Studied with kind permission of Drs J Fletcher, PAE Jones, DR
Ryrie, T E Bletcher and E A French)
Methods Nine subjects of both sexes, aged 34-68, previously
diagnosed as having CGL, were tested as above. All were in
the chronic phase of the disease - for details see Table 13.
All subjects received 50yul of dilutions of autologous ZAS and
LMW fr, as well as histamine 1.2 x 10~*^M as control. Serum
C^, and CH^Q was measured in unactivated serum from each
subject as described in Chapter 4, and C,. conversion products
were assayed in ZAS by release of NCBP from normal PMN's as
described in Chapter 2.
Results There was no difference between normal and CGL
subjects in wheal size after saline or unactivated serum (Fig
54). Similarly, the wheal size 12 minutes after histamine was
no different in the two groups (Fig 54), although resolution
was slower in the CGL group, which also showed a slightly
greater flare response to histamine. Neither of these
differences, however, reached statistical significance.
Wheal and flare responses to 50% and 20% autologous ZAS
were, however, significantly reduced in subjects with CGL (Fig
55). Responses to 10% ZAS were also reduced, but only the
flare response was significantly less (Fig 56). The biggest
difference was in the reaction to 50% LMW fr (Fig 56), with
minimal wheal formation and no flare response at all in CGL
subjects. These differences could not be accounted for by
reduced levels of baseline complement components in CGL group,
for all subjects had normal C^, C^ and CH^Q levels (Table 14),
Table13


























































































Fig 54. Wheal responses to saline and unactivated serum
(50%) and wheal and flare responses to histamine, in normal
subjects (n = 10) and subjects with CGL (n = 9),
(mean + SEM) NS - No significant difference between groups.
ZAS 50% ZAS 20%
Fig 55. Wheal and flare responses to 20% and 50% autologous
ZAS in normal subjects (n = 14) and subjects with CGL.
(mean ± SEM, n = 9) NS = No significant difference.
Table 14
Serum complement levels in patients with CGL
C3 C4 CH50
Normal range 0.79-1.60g/l 0.12-0.36g/l >180
Subject 1 ND ND >350
2 1.11 0.26 >350
3 1.43 0.28 >350
4 1.41 0.27 295
5 1.20 0.27 285
6 1-29 0.35 >350
7 1-09 0.17 >350
8 1.20 0.22 >350
9 ND ND 309
ZAS 10%
I §1




























12 m ins 30 mins Flare 12 mlns 30 inlns Flare
Fig 56. Wheal and flare responses to autologous ZAS (10%)
or low molecular weight fraction (LMW fr 50%) in normal
subjects or subjects with CGL. (Number of subjects is
beside each bar).
Mean ± SEM is shown in each case.
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and Cj_ conversion products in dilutions of ZAS were no
different to those from normal subjects (Fig 57).
Experiment 3 The effect of local and systemic
anti-histamine drugs (H^ antagonists) on the wheal and
flare response to intradermal ZAS.
Methods
(A) Local antihistamines
Ten normal subjects were injected at three separate
-4
sites with 50pl of either saline, clemastine 2 x 10 M, or
_5
clemastine 2 x 10 M (all solutions coded). Thirty minutes
187
later, as previously described , each site was reinjected
-4
with histamine (5^ul of 1.2 x 10 M) and the wheal and flare
response measured as before. Having ascertained that these
concentrations of clemastine produced inhibition of
histamine-induced reactions, 10 subjects were injected were
injected with saline or clemastine as before, followed at 30
minutes by 50^ul 50% autologous ZAS at the same sites.
Reactions were measured as above.
(B) Systemic antihistamines
The wheal and flare reactions to 50jal of dilutions of
-4
ZAS and to 5(^ul histamine 1.2 x 10 M were measured in six
subjects before and after clemastine lmg bd orally for three




When injected into the skin 30 minutes before histamine
the antagonist clemastine caused significant reductions of
179
40 □ Normal CGL
30
Fig 57. NCBP release from normal cytochalasin B
treated PMN's by ZAS (without EACA) from normal
subjects (n - 10) or subjects with CGL (n = 9)
Mean ± SEM shown for each group.
180
both wheal volume and flare area when compared to sites
injected with saline prior to histamine (Fig 58). Both
concentrations of clemastine were effective, but inhibition
was much greater at the higher concentration. When ZAS was
the stimulus, clemastine again caused a significant reduction
in both wheal and flare (Fig 59), but this time both drug
concentrations were equally potent with regard to their
wheal-inhibiting properties, with only a slight dose effect
seen in flare inhibition. Interestingly, however, clemastine
caused much greater inhibition of wheal production when the
stimulus was histamine than when it was ZAS, particularly at
the higher drug concentration (Fig 60). Histamine wheals were
reduced in volume by about 80%, but ZAS wheals by only about
40%. This difference did not hold true for flare responses
(Fig 60), with histamine and ZAS induced flares being
inhibited identically by clemastine at either conentration.
(B) Systemic antihistamines
As with local administration of the drug, oral
clemastine caused significant inhibition of the flare reaction
to two concentrations of histamine, and to dilutions of ZAS
(Fig 61), although this did not always reach statistical
significance. There was little difference between the stimuli
in the degree of inhibition achieved by the drug. Reduction
of wheal responses by oral clemastine was much less apparent
for both stimuli than when the drug was injected locally (Fig
62) and was highly significant only at the highest
concentration of either stimulus. The reduction in responses
also differed from local use of the drug in being similar in
degree for the two stimuli.
Q Saline j^j Clemastine 2 x 10 J M [M| Clemastine 2 x 10 ^ M
















Fig 58. Wheal and flare responses produced in normal
subjects by histamine 1.2 x 10~^M In the presence of
either saline or clemastine 2 x 10~^M or 2 x 10-5M.
(mean ± SEM, n = 10). " ~
Clemastine 2 x 10" JM| | Saline
*p <0.02, ** p < 0.01 when drug is compared to saline



















Fi9 59. Wheal and flare responses produced in normal
subjects (mean ± SEM, n = 10) by 50% ZAS in the presence
of either saline or clemastine 2 x 10~^M or 2 x 10~5m.
182
Fig 60. Percentage reductions in wheal and flare size by
clemastine (2 x IQ-^M and 2 x 1Q-4m) in response to either
histamine (1.2 x 10-"%) or 50% ZAS.~
(mean + SEM, n - 10) NS = No significant difference.
Fig 61. Flare areas produced by histamine and ZAS before
and after 3 days of oral clemastine 1mg bd (mean ± SEM,


















Fig 62. Wheal volumes produced by saline, histamine and
ZAS before and after 3 days of oral clemastine 1mq ba












H ZAS H ZAS LMWfr
1.2x10"% 20% 1.2x10"% 10% 50%
^;L<? Percentage reduction in wheal volume between 12
and^30 minutes in wheals of comparable initial volume
produced by different stimuli. Mean wheal volume at 12
minutes (mmh is above each column followed bv (n).
Mean + SEM shown in each case.
1 o 4
While measuring wheals during these studies on
antihistamines, a further difference between the responses to
histamine and ZAS because apparent, namely the rate at which
the wheals resolved. Histamine wheals reduced in volume by
25-40% between 12 and 30 minutes (Fig 63), while ZAS wheals of
comparable size reduced by only 10-13% over the same time
period.
Experiment 4 The effect of activated PMN's on histamine
release from mast cells.
(kindly helped by Dr B Gomperts, Dept of Experimental
Pathology, University College Hospital, London).
Methods Human PMN's were isolated using LSM and dextran, as
described in Chapter 2. Mast cells were obtained from the
peritoneal cavities of adult male Wistar rats by lavage with
++ ++
Hepes buffer (pH 7.2) containing Mg ImM, Ca 1.7mM,
D-glucose 5mM and 0.1% albumin. After washing and counting,
mast cells (5 x 10^/tube) were suspended in buffer and the PMN
degranulating stimuli added - FMLP, LMW fr or ZAS.
The PMN suspension was pre-exposed to cytochalasin B
(final concentration 1 for 20 seconds and aliquots of
the suspension then added to the tubes containing the stimulus
and mast cells such that the final PMN concentration was 2 x
incubated together for 5 minutes at room temperature. The
supernatants were then removed for assay of histamine and in
some cases, NCBP. Histamine was assayed by a standard
10 cells/tube. The stimulated PMN's and mast cells were
fluorometric method
188
Control tubes contained mast cells
cytochalasin
+
stimuli, but no PMN's
185
Results PMN's incubated with mast cells were not prevented
from responding to the degranulating stimuli, as assessed by
their release of NCBP (Table 15). This PMN activation did not
result, however, in any increase in histamine secretion above
that seen in unstimulated suspensions alone.
It is of interest that concentrations of both ZAS and
LMW fr capable of causing wheal and flare reactions in the
skin did not trigger release of any histamine from mast cells.
At the end of the experiment, the mast cells were still
viable, and secreted histamine normally in response to the
stimulus 48/80.
Experiment 5 The effects of the anti-inflammatory drugs,
aspirin, hydrocortisone and ibuprofen on the skin response
to ZAS and histamine.
Methods Eighteen normal subjects were injected with 5<^ul
-4
intradermal histamine (1.2 x 10 M) and ZAS (20% and 50%), and
wheal and flare responses measured as before. Six subjects in
each group then received the following
A. Hydrocortisone lOOmg by intravenous bolus injection
B. Aspirin 600mg q.i.d. for three days
C. Ibuprofen 400mg t.i.d. for three days.
Group A then received an identical set of skin injections,
beginning 30 minutes after the injection of hydrocortisone.
Groups B and C received the repeat skin injections on day 4,
two hours after the last tablet.
Results
A. Hydrocortisone
Hydrocortisone caused no change in haemoglobin or
186
Table l 5
Release of histamine from mast cells incubated with
PMN's and a PMN deqranulatinq stimulus, and














































Mast cells alone Mast cells + PMN1s release
0.68 2.21
1 . 36 1 .22
0.68 0 .54
1 .63 5.58
1 .09 1 . 36
0.95 1 .77 37.3
1 . 77 1 . 36 37.2




0 .00 0 . 00
0.00 1 .22







1 . 50 3.26
2.04 2.18 47.28
0.00 0.00 48.24
0 . 00 0.00 38. 72
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platelet concentrations, but produced the well documented
neutrophilia and lymphopenia, (Fig 64). An unexpected finding
was the highly significant monocytopenia, which has also been
189
previously described
Hydrocortisone intravenously did not however cause any
changes in the wheal and flare reactions to 50% or 20% ZAS
(Fig 65) or to histamine (Fig 66).
B. Aspirin
Aspirin produced no changes in wheal responses to 20% or
50% ZAS (Fig 67). The flare areas after both ZAS
concentrations were reduced by about 25%, but this was not
statistically significant. There was likewise no significant
reduction in the wheal and flare response to histamine by
aspirin (Fig 68).
C. Ibuprofen
Ibuprofen did not affect skin responses to either 50% or
20% ZAS (Fig 69) or to histamine (Fig 70).
Experiment 6 The skin response to intradermal injection of
medium from phagocytosing PMlNI's.
Principle
When PMN's phagocytose a bacterium or inert particle, a
proportion (50-90%) of the secondary granule contents appears
44
extra-cellularly . The stimulus (if particulate) and the
cells can then be removed, leaving a neutrophil conditioned
medium (PNCM) containing granule contents and other PMN
secretory products.
Method
A. By phagocytosis of Candida guilliermondii
n Before W\ After
* p<0.05, **p<0.01, ***p<0.001
HP Platelets WCC I'MN's Lymphocytes Monocytes
Fig 64. Changes in haematological parameters in normal
subjects (mean ± SEM, n = 6) before, and 30 mins after
hydrocortisone 1U0mg intravenously.
Hb - haemoglobin; WCC - White Cell Count; PMN's -
neutrophils
Fig 65. Wheal and flare responses in normal subjects to 20%
and 50% ZAS, before, and 30 mins after, intravenous
hydrocortisone 100mg. (mean + SEM, n = 6).
Fig 66. Wheal and flare response to histamine (1.2 x 10 4m)
in normal subiects before, and 30 mins after intravenous
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12mlns 30 mins Flare 12 mins 30 mins Flare
Fig 67. Wheal and flare responses produced by 20% and 50%
ZAS in normal subjects before and after aspirin 600mg qid
for 3 days.
(mean + SEM, n = 6).
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12 mins 30mins Flare
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Fig 68. Wheal and flare response to histamine 1.2 x 10 M
in normal subjects before ana after aspirin 600mq qid
for 3 days. (mean ± SEM, n = 6)
Fig 69. Wheal and flare responses to 20% and 50% ZAS in
normal subjects before ana after ibuprofen 400mg tid for




Fig 70. Wheal and flare response to histamine 1.2 x 10 M
in normal subjects before and after ibuprofen 400 mq tid
for 3 days (mean ± SEM, n = 6).
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PMN's from the subject to be tested were incubated at a
6 6
concentration of 12.5 x 10 /ml with 62 x 10 /ml Candida
guilliermondii for 60 minutes at 37°C on a rotator. These
conditions have already been shown to allow maximal
phagocytosis of Candida"*"^.
The cells and Candida were removed by centrifugation at
1700g at room temperature for 10 minutes followed by passage
through a 0.2p filter. The supernatant was stored under
liquid till injection.
B. By phagocytosis of latex beads
2mls of latex beads (10^/ml, mean diameter O.^u) were
opsonised by incubation with 2mls of the subject's serum at
37°C on a rotator for 60 minutes. The beads were washed twice
in PBS by spinning for 10 minutes in a microcentrifuge and
2+ 2+
then resuspended in PBS containing ImM Ca and 0.7mM Mg but
no albumin. Because of losses during washing, the beads were
recounted at this stage in a counting chamber and mixed with
the subject's PMN's at a bead: cell ratio of 50:1 (cell cone =
7 9
5 x 10 /ml; bead cone = 2.5 x 10 /ml). The cell/bead mixture
was incubated at 37°C for 60 minutes on a rotator and the
cells and beads removed by spinning in a microcentrifuge
followed by passage through a 0.2p filter as before.
Control supernatants were prepared from tubes containing
cells alone, and opsonised beads alone. To ensure that
phagocytosis had occurred, a cytospin preparation was stained
with Leishman stain. To assess PMN secretion during
phaocytosis, an aliquot of PMN's was sonicated and NCBP
release during phagocytosis was assessed by measurement of
NCBP in the PNCM and in the sonicate.
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Results Initial experiments used C. guilliermondii as the
phagocytic stimulus. The PNCM thus generated had a very small
degree of wheal-producing activity in the skin (Fig 71, Exp 1)
but several days later the skin sites became red, itchy and
scaley. This was presumed to be due to pre-existing
anti-Candida antibodies in the subject reacting with unremoved
Candidal antigens in the PNCM, which could possibly also have
accounted for the small immediate inflammatory response. For
this reason, subsequent preparations of PNCM were performed
with latex beads as the phagocytic stimulus. These latex
beads were actively taken up by the PMN's (Fig 72) associated
with release of about 40% of the total NCBP (Table 16).
Despite this, the PNCM so produced did not result in any
wheals and flares when injected into the skin of two different




NCBP levels from PMN sonicates and in the
Supernatants from PMN's undergoing phagocytosis
of opsoniseci beads
Experiment 1 Experiment 2
Sonicate 4896.3 2413.9 (ng/1)
Cells & Beads 1873.4 1073.5













Sal N 50% 20% 10%
PNCM
CANDIDA
Exp. 2 Exp. 3
Sal PNCM Sal Beads Cells PNCM
neat alone alone neat
BEADS BEADS
Fig 71. The effects of the supernatant from phagocytosing
PMN's (PNCM) injected intradermally■
Fig 72. Cytospin preparation of neutrophils showing
ingested latex beads in the cytoplasm of nearly every
cell. Some cells contain 15-20 beads. (Leishman stain).
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DISCUSSION
The studies in this chapter have attempted to delineate
the mechanism(s) by which PMN's might act to produce a wheal
and flare response in the skin, and although no definite
conclusions have been reached, some interesting points have
emerged.
The results with CGD subjects have proved difficult to
interpret. The fact that the subject with CGD, known to have
very low superoxide production, can generate a wheal and flare
of any size in response to ZAS, suggests at least that
oxidative metabolism of PMN's is not the sole mechanism
involved. While oxidants may be the main source of
127
permeability producing activity in some in vitro models '
177
, clearly other mechanisms also operate in vivo. For
190
example, CGD PMN's can synthesise thromboxanes and
191
leukotrienes normally in vitro, and while these may not
themselves be the mediators involved, it does suggest that
deficiency of the oxidase does not render the cell incapable
of inflammatory activity. Had more CGD subjects been tested,
clear differences between them and normals might have become
apparent but this remains speculative.
The CGD carriers showed normal histamine reactions and a
normal flare response to ZAS, but there is a suggestion that
wheal production by ZAS was impaired. By the Lyon hypothesis,
whereby one X chromosome in every cell in females is rendered
inactive, these subjects should have 50% normal and 50%
affected PMN's in the circulation. This means that the two
cell populations may not behave identically with respect to
adhesion to endothelium or migration to inflammatory sites.
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However, the normal cells seem to be able to compensate in
terms of bacterial defence, since these carriers gave no
history of increased tendency to infections, and could
therefore presumably compensate for the defective cells in the
overall response to complement. Studies on greater numbers of
subjects would be required to ascertain this.
Subjects with CGL showed a clearcut impairment of both
wheal and flare response to ZAS, with normal responses to
histamine, and normal complement levels. As with the
neutropenic subjects, the defect was particularly obvious when
LMW fr was the stimulus. These observations do not in fact
help in elucidating the PMN mechanism(s) involved in
generating a permeability change, for the defects described in
CGL cannot be localised to one area of cell metabolism. In
addition to the defects described above, impaired lipoxygenase
192
activity , and failure of release of inhibitors of myeloid
193
colony growth have been described. These new findings may,
like the others, reflect a defect in stimulus-response
coupling in CGL cells, which, even when the disease is
controlled by drugs, are still found in the marrow and
peripheral blood. Such a defect does not seem to lead to
impaired host defence, but might give clues to the mechanism
of the abnormal control of granulopoiesis seen in the
condition.
The studies using local antihistamines were done to see
whether mast cell activation could be implicated in the skin
response to ZAS. Local clemastine was effective in greatly
reducing histamine wheals and flares, as previously
187
reported . The drug also had some inhibitory effects on ZAS
198
induced wheals and flares, unlike its effects in the rabbit,
in which the response to C5 was not affected at all by
121
antagonists . The degree of inhibition seen in the human
subjects was similar for ZAS and histamine flares. However,
ZAS wheals were reduced much less than those caused by
histamine.
It could be argued, therefore, that flares are produced
by either stimulus through the same mechanism, one which can
be partly inhibited by clemastine and which therefore might
involve release of mast cell histamine. This argument would
not hold for wheals, since the inhibition produced by the drug
was so different for the two stimuli. The results suggest
rather that a histamine independent mechanism might be at
least partly responsible for the permeability response to ZAS.
This histamine-independent system might involve PMN's.
Interpretation of the results, however, is rendered even
more complicated by the observations on the inhibitory effects
of H-^ antagonists on PMN degranulation, as will be described
in Chapter 6. An alternative explanation of the in vivo data
is that the inhibitory effects of clemastine on skin responses
to ZAS are due to its actions on PMN's, not its anti-histamine
properties. In addition, the blocker brompheniramine
injected locally also appears to inhibit wheals produced by
194
the PAF analogue AcGEPC , so that antagonism of PAF secreted
from activated PMN's might be a yet further action of
antagonists in this system. The inhibition of PMN's by
antagonists in vitro however, requires high drug
concentrations, which although they can be injected locally
into the skin cannot be achieved in plasma by oral
199
administration of the drug. Histamine antagonism, however, is
seen with concentrations achievable orally. Thus the results
of studies using oral clemastine, where both histamine and ZAS
responses were partially reduced, does suggest that the
inhibition seen with local clemastine is not solely due to PMN
inactivation, but that histamine antagonism might also be
taking place.
A further piece of evidence to suggest that histamine
release is probably not the only permeability-producing effect
of ZAS is that the kinetics of the responses to the two
121
stimuli are different. Williams et al observed that Cn5a
wheals had a tj£ for resolution of 90-100 minutes, while that
for histamine wheals was only 4-6 minutes. Such estimations
were not possible using our method of measurement, for each
single thickness measurement using calipers can itself reduce
155
volume by up to 10% . However, by comparing wheal sizes for
the two stimuli at 12 and 30 minutes, it was possible to
confirm that ZAS wheals of comparable initial volume had
decreased in size by 30 minutes much less than histamine
wheals. This suggests that ZAS had induced a much more
sustained mechanism of permeability production, supporting the
idea that a histamine-independent mechanism is operating. The
kinetics of response of whole ZAS appear similar to those of
^ * 195
pure Cj. or C,. des Arg
A further hypothesis tested was that activated PMN's
themselves triggered mast cell secretion. This was considered
possible because at least two such mechanisms have been
described, one from the myeloperoxide-H^C^-halide system of
128
PMN's and the other requiring other oxidative metabolites,
200
but not PMN cationic proteins have also been
196
implicated in mast cell activation . This hypothesis was
particularly interesting, because it might have explained the
impaired responses in CGL, where H2C>2 production appears to be
186
deficient . Under the conditions tested, however, no PMN
activation of mast cells occurred, despite normal PMN
secretion of NCBP and mast cell responsiveness to the
degranulating stimulus 48/80. There are two possible
explanations for this. One is that the incubation period of
mast cells and PMN's together was too short and another is
that the ratio of PMN's to mast cells was too low. A study
which appeared after this experiment was performed suggested
that a 40-60 minute incubation period was necessary"*""^,
admittedly with non-cytochalasin treated PMN's, although
detectable amounts of histamine were present by 10 minutes.
The PMN : mast cell ratio of 0.5:1 (as used here) was probably
far too low, as ratios of 10:1 - 50:1 seem to be optimum^l
An alternative approach would be to prepare PNCM, concentrate
by lyophilisation if necessary, and test the concentrated
solution for mast cell degranulating activity.
An important incidental observation in the experiment
with mast cells was that neither ZAS nor LMW fr containing the
des Arg forms of and , caused any PMN-independent
release of mast cell histamine, in contrast to the potent mast
cell releasing properties of unchanged and C,-^. As the
mast cells were of rat origin, it cannot be absolutely certain
that these preparations would have no activity for human mast
cells, but the findings do support the hypothesis that mast
cell involvement in the skin response to ZAS is probably only
201
minor.
The complete lack of inhibition of skin ractions by any
of the three anti-inflammatory drugs tested is not totally
unexpected. The concentrations of these drugs achievable in
plasma by conventional doses are insufficient to produce the
91
inhibition of PMN secondary granule release and superoxide
197
production seen with high concentrations of ibuprofen and
indomethacin in vitro. There has been one report (published
after this study was completed), suggesting that PMN's from
subjects taking ibuprofen orally can show reduced FMLP-induced
lysozyme release"'"0"'", but the doses of drug used were twice
those taken by the subjects reported here. Interestingly,
even the higher dose of ibuprofen failed to inhibit
FMLP-induced superoxide production. Any inhibitory effects
produced by these drugs, therefore, would primarily reflect
inhibition of cycloxygenase, in the case of aspirin and
ibuprofen. The actions of hydrocortisone will be discussed
below. In the rabbit, the increase in blood flow and vascular
permeability and leucocyte infiltration caused by intradermal
198 199
E coli or zymosan activated plasma could be reversed by
systemic indomethacin or local acetylsalicylic acid. However,
administration of exogenous PGE2 into the skin reversed not
only the changes in blood flow and vascular permeability, but
restored the leucocyte infiltrate also. Since PGE^ is not of
itself chemotactic, the inference is that the numbers of
leucocytes present reflect solely the changes in flow and/or
permeability, and are not themselves influenced by the drugs.
As Williams has shown, lesions produced by intradermal C,. in
the rabbit depend on the simultaneous presence of vasodilator
202
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prostaglandins . As discussed in Chapter 4, this
requirement for prostaglandins appears to be much less
important in the response to C in man, and is clearly not a-Del
rate limiting step. Thus prostaglandins appear to play only a
minor role in the vascular response to activated complement in
this system. The significance of the finding of increased
PG]^ production from endothelial cells exposed to hydrogen
peroxide from activated PMN's is therefore unclear^0.
The actions of hydrocortisone are more complex. The
rapid production of neutrophilia is mainly due to movement of
marginated PMN's from the endothelial surface into the
circulating pool. There is also a small contribution from
young PMN's which emerge from the marrow, although these do
not appear to differ from peripheral blood PMN's in their
3
granule contents . Hydrocortisone also acts at a cellular
level to inhibit the membrane phospholipase which makes
arachidonic acid and other lipids available for synthesis of
prostaglandins, leukotrienes and platelet activating factor.
It is not clear whether these cellular effects would be in
operation only 30 minutes after a bolus injection of
hydrocortisone, but, as seen from the peripheral blood counts,
the effects on PMN distribution had occurred. It is generally
accepted that PMN activation and secretion takes place only
23
when the cells are on a suitable surface , such as
endothelium. Despite its effects on marginated PMN's
hydrocortisone does not seem to have prevented this, and of
course the stimulus of extravascular ZAS may well have
overridden any hydrocortisone-induced tendency of the cells
not to adhere to the endothelium. Similar results have been
203
obtained in the rabbit where much larger doses of
hydrocortisone failed to inhibit the increased blood flow and
vascular permeability or the leucocyte infiltration stimulated
by ZAS201.
Anti-inflammatory drugs seem therefore to have very
little role in inhibiting the actions of activated complement
in this system, consistent with their limited usefulness in
states of generalised complement activation such as ARDS.
The final experiments in this chapter attempted to find
permeability-producing activity in supernatants from
phagocytosing PMN's. Phagocytosis is associated with a
44
respiratory burst, and ingestion of either Candida or coated
202 .
latex beads is associated with the appearance of of the
secondary granule contents in the extracellular environment.
There is evidence from animal work that supernatants from
PMN's stimulated with archidonic acid or A00,0_, could increase^jlo /
the permeability of post-capillary venules in a hamster cheek
203
pouch model . Phagocytosis seemed a more appropriate
stimulus for human studies, since the stimulus could be
totally removed with the cells. The lack of
permeability-producing activity in supernatants from
phagocytosing PMN's suggests that the permeability factor(s)
are unstable, have short half lives, or need to be generated
in situ for an effect to be seen. Direct contact with
endothelium, for example, may be necessary for any effect of
superoxide or other oxygen radicals to become apparent.
Similarly, any mast cell stimulus would only be effective if
it were stable in a cell free environment. The latex beads
used as a phagocytic stimulus may themselves have adsorbed out
204
some active factors.
In summary, therefore, the work in this chapter has not
provided firm evidence of the mechanism of action of ZAS and
PMN's in this system. However, the data do not suggest a
major role for cyclooxygenase products in this model.
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CHAPTER 6
THE EFFECTS OF HISTAMINE AND HISTAMINE ANTAGONISTS ON
STIMULUS-MEDIATED COBALAMIN BINDING PROTEIN RELEASE FROM
NEUTROPHILS.
(in collaboration with Neil Jackson, B Med Sci Honours student)
INTRODUCTION
The possibility that histamine antagonists might have an
inhibitory effect on PMN activation arose from the observations
in the last chapter on their inhibitory action on the
inflammatory effects of intra-dermal complement. In normal
subjects, the wheal and flare response to activated complement
was significantly reduced by the prior injection of the
anti-histamine drug (H^) clemastine at high concentration.
While one obvious explanation for the inhibitory effect
of clemastine in the skin was that the inflammatory effects of
complement were being mediated at least in part via histamine
release, an alternative explanation is that both complement
fragments and clemastine were exerting their effects via PMN's.
This has prompted an examination of the in vitro effects of
histamine itself and of its antagonists on stimulus-mediated
NCBP release from PMN's. Such inhibition is produced, for
example, by high concentrations of anti-inflammatory agents, an
. . . 91
effect independent of cyclo-oxygenase inhibition
Histamine has long been known to act via cell surface
receptors, which in the last 15 years, have been considered to
204 205
be of 2 classes, H^ and H£ ' . The relative distribution
206
of and ^ receptors varies throughout the body, with H-^
predominating in the lung, for example, and H^ in the gastric
mucosa. Histamine activates both and H^ receptors equally,
but histamine antagonists, because of their ring substitutions
show preferential binding to either or H^ receptors
This specificity is not absolute in the case of antagonists
which also show some binding to receptors. H2 antagonists
show much greater specificity, with very little binding to
receptors.
Physiological concentrations of histamine also appear to
modulate PMN function, but reports are conflicting as to its
overall effect. Inhibition by histamine of (3 glucuronidase
207
release , FMLP-induced superoxide production and
degranulation^0^' f and chemotaxis across membranes^"*" have
all been described. On the other hand, stimulation of cell
211 212
movement and thromboxane production by histamine have
also been reported. The nature of PMN histamine receptors is
213 208
also uncertain, for both and H2 receptors have been
identified.
In an attempt to clarify the situation, this study has
examined the separate and combined effects of histamine and
and H2 antagonists on FMLP-induced NCBP secretion from
cytochalasin B treated PMN's in vitro. Secretion has also been




Experiment 1 Effect of anti-histamine drugs on NCBP assay.
Method Identical aliquots of PMN sonicate were mixed with an
-4
equal volume of each drug (final concentration 10 M) ,
histamine (10 M) or PBS as control, and the liberated NCBP
assayed as before.
Results NCBP values in the presence of the drugs were always
within 10% of values obtained without them. (Table 17).
Table 17 The Effect of H, and H0 Antagonists on the-L
Cobalamin Binding Protein Assay
Drug Present Value of S.E.M
Sonicate (%) (n=4)
No Drug 100.0 -
-4
Promethazine (10 M) 92.7 8.2
-4
Clemastine (10 M) 98.4 6.7
-4
Cimetidine (10 M) 95.0 7.4
... -4
Ranitidine (10 M) 98.4 6.9
-3
Histamine (10 M) 97.2 6.8
Experiment 2 Effect of clemastine on cell viability.
Method PMN's 2 x 10 /ml were suspended in clemastine 10^ M for
15 minutes and their viability tested with trypan blue as
described in Chapter 2.
Results Cell viability after 15 minutes incubation with
_3
clemastine 10 M (higher than concentrations used
experimentally) was always >94%.
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Experiment 3 Effect of and H^ antagonists on NCBP release
by FMLP or LMri fr.
Method Injectable preparations of the antagonists
clemastine and promethazine and the H„ antagonists cimetidine
and ranitidine were diluted in PBS to 10~" - 10" M. 2 x 10
PMN's in 0.7ml PBS-A were incubated with 0.1ml drug for 5
minutes at 37°C. Cytochalasin B (final concentration 5yug/ml)
was added and the incubation continued for a further 5 minutes.
The degranulating stimulus, either FMLP (final concentration
-.7
10 M) or low MW fr (66^1)was then added, and after 5 minutes,
degranulation was terminated by centrifugation at 4°C. The
supernatants were retained for NCBP assay.
Results The results of experiments involving and
antagonists will be expressed as % release, where
% release =% NCBP release with drug 100 %
% NCBP release without drug 1
The antagonists clemastine and promethazine both showed
dose-dependent inhibition of NCBP release when stimulated by
either FMLP or LMW fr (Fig 73). Promethazine was slightly more
-5
potent than clemastine at concentrations of 10 M and below,
-4
but both drugs caused complete inhibition of release at 10 M.
H2 antagonists, on the other hand, caused no significant
inhibition of LMW fr-induced release at any concentration,
although, when FMLP was the stimulus, there was some inhibition
of release at drug concentrations of 10~*^M and greater (Fig
74). In all cases, however, inhibition of release was




Fig 73. The effect of antagonists on NCBP release by
FMLP and low molecular weight fraction.
(mean ± SEM, n - 6)
» » Cimetidine
a ■ Ranitidine
Stimulus - FMLP 10"7M Stimulus - LMW fr 66|jl
Fig 74. The effect of antagonists on NCBP release by
FMLP and low molecular weight fraction.
(mean ± SEM, n = 6).
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Experiment 4 Effect of stimulus concentration on
antagonist-mediated inhibition of NCBP release.
6
Method Keeping a constant drug concentration (10~* M) , both
clemastine and promethazine were used with concentrations of
-5 -9
FMLP from 10 M - 10 M, as above.
Results If the inhibitory effect of a drug can be overcome by
increasing the stimulus concentration, then % release will
increase with stimulus concentration, provided that the drug
concentration is kept constant. When FMLP was the stimulus,
— 6
neither promethazine nor clemastine at 10 M caused any
significant change in % release between FMLP concentrations of
10"5 - 10 "^M (Fig 75). At 10 ^M FMLP, inhibition by
promethazine actually fell, allowing 76% release, while that by
clemastine greatly increased, allowing only 42% release. The
reason for this difference is not apparent. When LMW fr was
the stimulus, inhibition by both clemastine and promethazine
was constant (but very slight) when 50pl or more LMW fr was
added (Fig 75). With less LMW fr than this, % release by both
drugs fell. In the case of LMW fr, a lower drug concentration
would probably have demonstrated the effect more clearly.
These results suggest that inhibition of release by H-^
antagonists is influenced by stimulus concentration only at the
lower end of the dose response curve for the stimulus, but that
at higher stimulus concentrations, inhibition remains fairly
constant.
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Fig 75. The effect of stimulus concentration on H antagonist
mediated inhibition of NCBP release.
(mean t SEM, n - 6).
Fig 76. The effect of cell washing on H. antagonist
mediated inhibition of NCBP release.
(mean t SEM, n = 6). Stimulus = FMLP 10 M.
Experiment 5 Effect of cell washing on
antagonist-mediated inhibition of NCBP release.
g
Method PMN's 2 x 10 /ml were incubated with either clemastine
or promethazine 10~*^ - lo"^M for 5 minutes at 37°C. The cells
were then centrifuged at 4°C at 115g for 5 minutes and washed
once by resuspending in cold PBS devoid of calcium, magnesium
or albumin and centrifuging at 115g for 5 minutes. The cells
were then resuspended in PBS-A and exposed to cytochalasin B
and FMLP 10~^M as before. After centrifugation at 4°C 50yil
supernatant was removed for NCBP assay as before. To assess
cell and NCBP loss during washing, the cell pellet was
resuspended and sonicated. Control cells without drug were
washed and otherwise treated identically.
Results Washing the cells after incubation with either drug
completely removed the inhibitory effect (Fig 76) , restoring %
-4
release to 100% or greater, except for promethazine at 10 M,
when % release improved from 0% to 80%.
Experiment 6 The effect of histamine on basal and
FMLP-induced NCBP release.
-3
Method Cells were exposed to either histamine alone (10 -
—8 —6lo"" M) or histamine followed by cytochalasin B and FMLP 10 M
as above.
3 -9
Results Histamine alone (10 - 10 M) caused no release of
NCBP from cytochalasin B treated PMN's. When added before
FMLP, however, histamine caused dose-dependent inhibition of
NCBP release (Fig 77). This was not as pronounced as the
inhibition produced by antagonists (Fig 73) as, even at
-3
10 M, 38% of the release obtained by FMLP alone was seen.
100
Fig 77. The effect of histamine on NCBP release
from cytochaiasin B treated PMN' s by FiViLP 1Q~bM
(mean ± SEM, n : b).
Experiment 7 The effects of combining and antagonists
either with histamine or with each other on FMLP-induced NCBP
release.
Method Cells were incubated for 5 minutes at 37°C with drug A,
then, without washing, with drug B for 5 minutes. They were
-7
then exposed to cytochalasm B and FMLP 10 M as before.
The following combinations were used:-
Drug A Drug B
i. Clemastine 10"4 - 10"*3m Histamine 10"5m
i i. Promethazine 10"4 - 10"'5m Histamine io"5m
iii. Histamine 10"4 - 10"*3m Clemastine 10~6m
iv. Histamine 10~4 - 10~*3m Promethazine io"6m





Oi—1 3m Cimetidine io"6m
vii. Clemastine 10~4 - 10"*3m Cimetidine 10~6m




A. Histamine and antagonists [(i) - (iv) ]
When cells were incubated firstly with either
promethazine or clemastine, and then with histamine, the
inhibitory effect on FMLP-induced release was very similar to
that seen when the drugs were used alone [Fig 78 (i) and (ii)].
However when histamine preceded the drugs, the inhibition seen
with either drug alone or with histamine alone was abolished,
so that release was restored to more than 80% of the FMLP-only



































B. Histamine and antagonists [(v) and (vi) ]
When the cells were exposed to cimetidine before
histamine, there was less inhibition of NCBP release at high
concentrations of drug than when cimetidine was used alone [Fig
—6
79 (i)]. At drug concentrations of 10 M and below, there was
no significant change in inhibitory effects. Exposing the
cells to cimetidine after histamine reproduced the effect seen
in Fig 78 when antagonists followed histamine, namely that
the inhibitory effect of histamine alone was abolished [Fig 79
(ii) ] .
C. and antagonists [(vii) and (viii)]
When clemastine was present first, no greater inhibition
of release was produced by the subsequent addition of
cimetidine [Fig 80 (i)] . The inhibitory effect of cimetidine,
however, was somewhat abrogated by subsequent addition of
clemastine [Fig 80 (ii)], an effect most marked at high
concentrations of cimetidine.
Experiment 8 The effect of systemic clonastine on NCBP
release.
Method Six healthy volunteers of both sexes, aged 21-48 took
oral clemastine 1 mg b.d. (the standard therapeutic dose) for 3
days. NCBP release in response to LMW fr and FMLP was examined
in PMN's prepared from each of them before and after
administration of the drug. The intracellular level of NCBP in
10~* cells (obtained by sonication) was also examined in
unstimulated cells before and after administration of the drug.
Results There was no difference in intracellular levels of
c;
NCBP/10 cells before and after administration of the drug (Fig
21
Fig 79. The effect of combining Hn antagonists and
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Fig 80. The effect of combining H. and antagonists on
NCBP release by FMLP 10-/M (mean t. SEM, n = 6).
81). Similarly, NCBP release in response to 3 concentrations






























































The effects of and ^ antagonists on NCBP release
appear to be fundamentally different. Both the antagonists
tested produce dose-dependent inhibition of NCBP release in
response to either FMLP or LMW fr, with complete inhibition of
-4
release at a concentration of 10 M. This inhibition is
therefore seen at drug concentrations 10-100 fold lower than
91
those required for NSAI-mediated inhibition . Inhibition of
release by antagonists, on the other hand, is never more
than 20% when LMW fr is the stimulus, and, even at a drug
-4
concentration of 10 M reaches only 40% when FMLP is the
91
stimulus. Like NSAI'S , the inhibitory effect of
antagonists is reversed by cell washing, suggesting reversible
binding to the cell surface. Their inhibition can also be
overcome to an extent by increasing the stimulus concentration,
91
but this is much less marked than with NSAI's , and suggests
that antagonists do not work by simply competing with the
stimulus for surface receptors. Other workers have similarly
found no effect of these drugs on either binding or
OA O
internalisation of FMLP
The effects of antagonists may best be explained by
-»6
their actions on cell membranes at concentrations of 10~* M or
more, at which they have local anaesthetic type properties,
inhibiting transmembrane depolarisation and calcium flux (S
Hill, personal communication), events which precede NCBP
release in PMN's. These effects are also seen, but to a lesser
extent, with H^ antagonists, which might explain the partial
inhibition seen with these drugs at high concentrations.
In contrast to their effects in vitro, the inhibitory
effects of antagonists are not reproduced in PMN's from
subjects taking clemastine orally. Since their effect in vitro
is abolished by cell washing, and since PMN preparation from
whole blood involves several washing steps, this lack of effect
is not very surprising. It was theoretically possible that
the drugs could have become incorporated into the cells during
maturation and therefore remained inhibitory after cell
washing, but there was no evidence that this occurred.
Another factor influencing the failure of systemic
clemastine to block PMN activation is that the peak free blood
-9 214
level of the drug following conventional dosage is 10 M ,
well below the concentrations effective in vitro. Considerable
binding (>95%) to serum proteins is the major reason for the
low level achieved (Thompson EM, personal communication) .
The actions of histamine itself appear to be more
complex. Although having no effects on NCBP release in resting
PMN's, histamine inhibits FMLP-induced NCBP release, although
with a much flatter dose-response curve than antagonists
over the range tested. Such inhibition of stimulus-induced PMN
responses has also been shown by other workers, with effects on
degranulation^0"^' ^ , superoxide and hydrogen peroxide
208 210
production and chemotaxis . Histamine may produce these
effects via an action on adenylate cyclase, since cAMP in
unstimulated cells rises ten-fold in the presence of histamine
6 215
10 M . Cyclic AMP levels in zymosan-stimulated cells are
also increased by 80% by histamine lO^M^l associated with
impairment of ^-glucuronidase release. Such blockage of
degranulation is greatly potentiated by the phosphodiesterase
215
inhibitor 3-isobutyl-l-methylxantheine , again suggesting
222
that inhibition is mediated via high levels of cAMP. The cAMP
may act intracellularly to directly block protein kinase. The
failure of histamine to inhibit PMN activation by the protein
216
kinase activator phorbol myristate acetate is consistent
with this mode of action.
The experiments combining histamine with H^ and
antagonists attempted to determine which histamine receptors
are involved in its inhibitory effects. Previous studies had
reported reversal of inhibition of both cellular function and
207 208
cAMP elevations by specific H^ antagonists ' . We have
similarly found that cimetidine added before or after histamine
abrogates the inhibition of release seen with histamine alone.
The finding of reversal of inhibition when histamine is
combined with antagonists requires an additional
explanation. This may be because histamine itself, when
prevented from occupying receptors by or poorly specific
antagonists, begins to exert non-receptor mediated effects
on the cell membrane (Hill S, personal communication). These
effects tend to promote NCBP release, thus overcoming the
inhibitory effects of antagonists provided the histamine is
present first. Histamine added after H^ antagonists does not
alter the dose-response curves for the drugs alone. Thus
histamine may have either inhibitory effects on PMN
degranulation, as when no antagonists are present, or
stimulatory effects, as in the presence of H^ or
antagonists.
The relevance of the above in vitro findings to PMN .
activation and inhibition remains speculative. At first glance
it would appear that the concentrations of H^ antagonists
223
required to inhibit PMN activation would preclude any such use
clinically, being more than 1000 fold greater than the peak
plasma level achievable wih conventional doses. However, the
same is true for NSAI's and steroids, where 'normal' plasma
levels are in the micromolar range, while levels effective in
vitro are in the millimolar range. Despite this, gram doses
of corticosteroids may be given in ARDS and other states of
7 8
shock , during which millimolar concentrations may be reached
in plasma. Local administration, for example, into the lung
may also provide a means of achieving PMN inhibitory
concentrations in vivo. Thus, as drugs with potential for
reducing PMN activation, antagonists may yet find a clinical
use.
The levels of histamine effective at inhibiting PMN's, on
the other hand, fall well within the range present
physiologically. Tissues undergoing repair have high levels of
217
endogenous histamine . This may have a role in switching off
the PMN activation triggered by activated complement so that
PMN products do not impede the reparative processes. At the
same time, PMN activation, at least by opsonised particles,
2X8
releases a histaminase enzyme , so that a balance between PMN
activation and inhibition may be struck. One situation where
high histamine levels do seem to impair PMN function is in
hyperimmunoglobulinaemia E where reduced chemotaxis with
staphylococcal infection is seen. Interestingly the




INHIBITION OF NEUTROPHIL COBALAMIN BINDING PROTEIN RELEASE
AND PHAGOCYTOSIS BY EXTRACTS OF TANACETUM PARTHENIUM
(FEVERFEW) (In collaboration with Dr S Heptinstall)
INTRODUCTION
Following the observations that granule release from
91
PMN's could be inhibited by both NSAI1s and H^ antagonists,
it was observed that degranulation of platelets could be
effectively inhibited by extracts of the herb feverfew
(Tanacetum parthenium) (Heptinstall S, personal
communication). This prompted examination of the effects of
this herb on human PMN's.
Feverfew has been used medicinally for centuries to
treat not only fever, but also such diverse disorders as
migraine, arthritis, psoriasis and disordered labour and
220 221
menstruation ' . Evidence of its efficacy has till
recently been largely anecdotal, but a recent controlled trial
of feverfew tablets in migraine sufferers did suggest positive
222
benefit from their use . At the present time, it seems
likely that feverfew, in one form or another, is taken by
223
thousands of sufferers from the above conditions
Recently, there has been renewed interest in establishing the
chemical nature of the active principle of feverfew and its
biochemical and cellular effects.
It has long been known that an active preparation can be
extracted from the plant by either water or alcohol, and
indeed a tea brewed from the leaves has been a traditional
form of consumption. The literature contains little, however,
on the precise mode of action of such extracts. One study has
demonstrated an inhibitory effect of feverfew extract (FFE) on
prostaglandin synthesis in seminal vesicles, thought not to be
224
due to cyclooxygenase inhibition . The possibility that FFE
might influence PMN reactivity arose from studies on blood
platelets. In 1981, Makheja and Bailey reported activity of a
water-soluble FFE, which inhibited platelet aggregation in
response to collagen, ADP, and thrombin, but not to
225
arachidonic acid . Thromboxane synthesis stimulated by
thrombin was also inhibited, but not if a external source of
arachidonic acid was provided. This study raised the
possibility that FFE might be acting as an inhibitor of
membrane phospholipases. Recent studies by Dr S Heptinstall
and colleagues have confirmed the inhibitory actions of FFE on
226
platelet aggregation induced by various stimuli
Aggregation in response to adrenaline, collagen and the
thromboxane A^ (TXA£) mimetic U46619 was abolished, and the
irreversible aggregation induced by ADP and by sodium
arachidonate (NaAA) was converted to a reversible response.
/ 14
Release of <X granules, assessed by secretion of C-serotonm,
was also inhibited by FFE, in response to ADP, adrenaline,
NaAA, collagen and U46619. In contrast, secretion induced by
the calcium ionophore A was increased rather thanZJIO /
decreased in the presence of FFE, and the platelet aggregation
induced by A„_10_ was not inhibited. The effects of FFE on2 Jlo /
TXA^ synthesis in platelets depended on the nature of the
stimulus. FFE had little effect on TXA^ synthesis induced by
NaAA, ADP or thrombin, but that induced by adrenaline was
greatly reduced.
To see whether the effects of FFE on platelets could be
reproduced in PMN'S, its actions on NCBP release induced by
various stimuli were studied. To see whether other PMN
functions could also be influenced, the effects of FFE on PMN
phagocytosis of opsonised yeast have been assessed.
EXPERIMENTAL WORK
Experiment 1 Preparation of Extracts of Feverfew.
Methods
A. Chloroform-methanol extraction
Initial extracts were pepared from plants kindly
supplied by Dr E W Jones, Department of Medicine, University
Hospital, Nottingham. Leaves of the plant were air-dried for
several weeks at room temperature, then ground to a powder in
a mortar and pestle. Extraction was performed in a 1:2
mixture of chloroform and methanol (lOOmg powder to 5ml
mixture) in a tissue homogeniser. Unextracted material was
removed by centrifugation and passage through filter paper.
The chloroform/methanol was blown off under N^ and the extract
resuspended in PBS. After filtration and adjustment of the pH
to 7.4, the extract was stored at -20°C.
B, PBS extraction
A large batch of PBS-extracted material was prepared
from plants kindly supplied by Mrs Ruth Brown.
Air-dried leaves were powdered as before, then 16 grams
of powder were suspended in 200 mis PBS and extracted by
homogenisation in a domestic food processor for 20 minutes.
Unextracted material was removed by centrifugation and
filtration as before, the pH adjusted, and the extract stored
at -20°C in 5ml aliquots. On thawing this extract for the
first time a brown precipitate appeared, which could be
removed by filtration without loss of the extract's activity.
The extract was stable at -20°C for at least 3 months and
could be thawed and refrozen repeatedly with only slight loss
of activity.
Result Extracts prepared in either chloroform/methanol or in
PBS behaved similarly in all experiments.
Experiment 2 Effect of FFE on PMN viability.
Method Viability was tested after 15 minutes incubation with
FFE using trypan blue as before.
Result Neither extract had any significant effect on cell
viability which was >95% after 15 minutes.
Experiment 3 Use of Feverfew extracts as inhibitors of NCBP
release.
Method The general method described in Chapter 6 was
followed. The PMN's were exposed to the feverfew extracts
(FFE) for 5 minutes, followed by 5 minutes with cytochalasin B
(if used) and 5 minutes with the stimulus.
The stimuli used were:-
(i) EACA ZAS
(ii) FMLP
(iii) Sodium Arachidonate (NaAA), previously




(v) Phorbol myristate acetate (PMA)
NCBP release obtained in the presence of FFE was
expressed as a percentage of that obtained in the presence of
stimulus plus buffer alone.
Results
(i) and (ii) EACA-ZAS and FMLP
In preliminary experiments, fixed volumes of
PBS-extracted FFE greatly inhibited NCBP release from
cytochalasin B treated PMN's in response to three different
concentrations of EACA-ZAS or FMLP (Fig 82). The
dose-response curve for FFE was almost identical for the 2
stimuli, showing significant inhibitory activity by only 20yUl
FFE with complete inhibition by 200 yjl (Fig 83) .
J
(iii) Sodium arachidonate (NaAA)
Preliminary experiments established significant release
of NCBP by 0.25 mM AA within 5 minutes whether cytochalasin B
was present or not (Fig 84a). Release by O.lmM AA was little
enhanced by the addition of CB, and the increase produced by
it with 0.25 mM AA was much less than that seen with either
FMLP or EACA-ZAS (Chapters 2 and 3). Release by 0.25 mM AA,
either with or without CB, was inhibited in a dose-dependent
manner by either PBS-extracted or
chloroform/methanol-extracted FFE (Fig 84b). The shape of the
dose-response curve differed to that seen when either FMLP or
EACA-ZAS was the stimulus (Fig 83), with much less inhibition
of release by low concentrations of FFE.
_Uv) A23187
Significant NCBP release (45-50%) was demonstrated in
Chapter 3 by 2yjM A23187* Release by this stimulus in the
presence of chloroform-methanol-extracted FFE demonstrated,
with small amounts of FFE, a steady rise in NCBP release (Fig
85), reaching 140% of control values with 50-70FFE. This
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Fig 82. NCBP release from cytochalasin B treated PMN's by
EACA-ZAS and FMLP without and with constant volumes of FFE
( n = 2 ) .
ul Feverfew extract added
Fig 83. The effect of PBS extracted FFE on NCBP release
from cvtochalasin B treated PMN's by 5% EACA-ZAS and 10~5M
FMLP. (mean ± SEM, n = 4).
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Fig 84. NCBP release by arachiaonic acid and % release by
PBS- and chloroform-methanol extracted FFE with 0.25mMAA
with and without cytochalasin B (mean ± SEM, n = 4),
pi FFE added
Fig 85. The effect of chloroform-methanol extracted FFE
on NCBP release from non-cytochalasin B treated PMN's by
2gM (mean ± SEM, n = 4).
;Z j I o /
concentrations, but with up to 100yul FFE, no inhibition of
release was produced. This effect is therefore fundamentally
different to that seen with other stimuli.
(v) Phorbol myristate acetate (PMA)
Fig 86 shows the dose response curve for NCBP release by
PMA in the presence and absence of FFE (100yUl PBS-extracted).
At all concentrations of PMA, the addition of FFE
significantly inhibited NCBP release. At a constant PMA
concentration of 500 ng/ml, addition of 30 jal or more of FFE
caused significant inhibition of release (Fig 87).
Experiment 4 The effect of timing of addition and cell
washing on the inhibitory effects of FFE.
Method To ensure that FFE was not merely inhibiting the
actions of cytochalasin B, comparison was made of inhibition
when the order of addition was:-
a) FFE > CB > stimulus (either FMLP or LMW fr)
b) CB > FFE r» stimulus
c) CB ^ FFE/Stimulus together
To see whether the effect of FFE could be removed by
washing, cells were incubated in FFE for 5 minutes as before,
then spun at 115g for 5 minutes. They were then washed once
by resuspension in cold PBS and centrifugation at 115g for 5
minutes, then exposed to cytochalasin B and stimulus as
before.
Results Fig 88 shows that the effect of FFE was identical
whether it was added before the CB (bar 2) or after the CB
(bar 4). To achieve maximal inhibition, it appeared necessary
to add the FFE before the stimulus (bar 2), for when it was
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PMA concentration
Fig 86. NCBP release from cytochalasin B treated PMN's in
the presence and absence of 100[a 1 PBS-extractea feverfew
by phorbol myristate acetate (PMA). (mean ± SEM, n = 4).
Fig 87. NCBP release from cytochalasin B treated PMN's by
phorbol myristate acetate (500ng/ml) in the presence of
different volumes of PBS-extracted FFE (mean ± SEM, n = 4).
added at the same time as the stimulus (bar 5), NCBP release
approached, although did not reach, the level produced by
stimulus alone (bar 1). The effect of washing the cells after
incubation with FFE seemed to depend to an extent on the
stimulus. For LMW fr, washing removed very little of the
inhibitory effect (bar 3), but when FMLP was the stimulus,
washing removed about a third of the inhibition seen (bar 3).
Experiment 5 Separation of FFE into low molecular weight
(<30,000 Daltons) and high molecular weight (>30,0CO
Daltons) fractions.
Methods 1ml aliquots of PBS-extracted FFE were applied to the
30,000 MW partition membrane as described in Chapter 2 and
centrifuged at 2000g at room temperature for 30 minutes. The
resulting fractions were tested for inhibitory activity as
above.
Results The inhibitory fraction of FFE, appeared to be, as
expected, of low molecular weight, for while the high MW
fraction produced no inhibition of FMLP-induced NCBP release,
the dose-response curve for the low MW fraction closely
resembled that for whole FFE (Fig 89).
Experiment 6 The effect of FFE on PMN phagocytosis of
Candida guilliermondii.
Method C. guilliermondii cultured in glucose broth were
sonicated for 30 seconds to break up clumps, and opsonised by
incubation with fresh human serum for 60 minutes at 37°C on a
rotator. After centrifugation, the Candida were resuspended
at a concentration of 4xl0^/ml in tissue culture medium TC
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Fig 88. Effect of washing and time of addition on the
effect of 50[jl PBS-extracted FFE on NCBP release from
cytochalasin B-treated PMN's by IQOul LMW fr. or FMLP 10 3M
(mean ± SEM, n = 4).
1 CB + stimulus only
2 FFE —> CB —> stimulus
3 FFE —» wash —>CB —* stimulus
4 CB —> FFE —> stimulus
5 CB —> FFE/stimulus together
Fig 89. NCBP release from cytochalasin B treated PMN's by
FMLP IQ'^M in the presence of the high and low MW fractions
of FFE (n = 2).
199. The Candida were incubated with PMN's at a ratio of 4.5
Candida : 1 cell for 45 minutes at 37°C to allow phagocytosis.
This ratio and incubation period have previously been shown to
186
be optimal for phagocytosis to occur . The reaction was
stopped by the addition of cold 6nuM EDTA and centrifugation at
4°C. Cytospin preparations were made and stained with
Leishman stain. Three replicate coded slides were studied
microscopically for each experimental condition. Two hundred
PMN1s on each slide were examined, and the number of Candida
in each cell counted. The data were then analysed in 2 ways:
1. the percentage of PMN's containing one or more
Candida was calculated and termed 'percentage
186
phagocytosis'
2. the number of Candida in each cell was counted and a





This allowed for an effect of FFE on the number of Candida
which each cell could take up, rather than simply making a
crude assessment of whether the cell could phagocytose any
yeasts at all.
Results Incubation of phagocytosing PMN's with FFE
significantly increased the number of cells which fail to
ingest any Candida at all (Fig 90). In addition, cells which
were actively phagocytosing ingested significantly fewer
Candida than normal in the same time period when FFE was
present, shifting the distribution curve for number of Candida
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Fig 90. Effect of PBS-extracted FFE on phagocytosis of
Candida guilliermondii, showing the number of cells which
have phagocytosed > 1 Candida. Mean ± SEM, n = 3, with
each having 3 replicates.
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Fig 91. The effect of FFE on the number of Candida
ingested by PMN's (mean t SEM, n = 3, each with 3 replicates).
DISCUSSION
Both water-soluble and lipid-soluble extracts of FFE
inhibited NCBP release from activated PMN's, while
water-soluble preparations could also inhibit phagocytosis.
Inhibition of degranulation was most marked with stimuli
operating through cell surface receptors, such as FMLP and
EACA-ZAS, but release in response to arachidonic acid was also
blocked. This argues against the suggestion that feverfew
225
operates as a phospholipase inhibitor , as the exogenous
arachidonic acid provided would be able to bypass the blockage
of release of cellular arachidonic acid from membrane
phospholipids. Observations in platelets also suggest that
inhibition of degranulation or aggregation by FFE can occur
either without inhibition of thromboxane synthesis, or under
conditions where thromboxane synthesis is prevented by
226
aspirin . Thus another mechanism of action must be
postulated.
The effects of FFE, unlike those of non-steroidal
anti-inflammatory drugs, cannot be reversed by washing the
cells, suggesting a mode of action other than blockade of
stimulus-receptor binding. Occupation of cell surface
receptors by a stimulus triggers activation of two separate
stimulus-response coupling mechanisms within the cell. These
25
are firstly calcium mobilisation and secondly activation of
protein kinase C by the formation of diacyl glycerol from
27
membrane lipids (see Chapter 1, Section A).
Two pieces of evidence suggest that FFE has little
effect on calcium mobilisation. Firstly, PMN and platelet
degranulation stimulated by the calcium ionophore A23187
226
not inhibited by FFE , and is in fact somewhat enhanced.
Secondly, FFE is able to block platelet thromboxane synthesis
in response to adrenaline, a stimulus which differs from other
platelet activators in causing no increase in the
228concentration of free calcium within the platelets . Thus
an alternative site of action for FFE must be found, which may
prove to be at sites on the activation pathway for protein
kinase C, the pathway probably involved in adrenaline-mediated
activation of platelets. A further observation which suggests
that the pathway to protein kinase C activation is at least
partially blocked by FFE is that PMN degranulation by PMA,
which activates protein kinase C directly, is rather less
inhibited by FFE that is degranulation in response to stimuli
which act via surface receptors. However, FFE does inhibit
PMA-induced secretion to a significant extent, suggesting that
blockade of protein kinase C activation is not the only site
of action of FFE. The microfilament/microtubule system
important in both phagocytosis and secretion may be one
possible site.
Phagocytic processes in PMN's are susceptible to
inhibition by a number of compounds of plant origin. The
fungal metabolite cytochalasin B, despite its enhancement of
49
degranulation" , is inhibitory by virtue of its ability to
229
block the polymerisation of cytoskeletal actin
Colchicine, from the plant Colchium autumnale, also blocks
phagocytosis, this time by inhibiting the cytoplasmic
microtubule system important in cytoskeletal orientation and
230
stability . Unlike cytochalasin B, colchicine also inhibits
stimulus-mediated granule release, but appears to be much less
potent than feverfew. Release of p glucuronidase by opsonised
zymosan particles was reduced only by 40% by colchicine at a
-5 231
concentration of 10 M
The exact chemical nature of the active principle(s) in
FFE has not yet been identified. The plant contains a group
of sesquiterpene lactones which are lipophilic. The main
lactone in FFE is parthenolide (MW = 248 daltons), from which
the plant takes its name. Parthenolide has similar effects to
whole FFE on platelets, (Dr S Heptinstall, personal
communication) and other fractions active in platelet
inhibition have also been identified. Like parthenolide, they
all contain a chemical grouping which can undergo interaction







known as the Michael addition.
The principal source of SH-groups in platelets is
glutathione. Measurable levels of glutathione SH groups in
resting platelets fall with time after addition of FFE, an
effect which can be prevented by cysteine (containing -SH) but
not serine or glycine (Dr S Heptinstall, personal
communication) . Cysteine can also reverse some of the
inhibition of platelet aggregation and degranulation produced
by FFE. It is not yet known whether similar involvement of SH
groups is seen in the effects of FFE on PMN's, but it may be
relevant that the assembly of microtubules required for both
granule secretion and phagocytosis requires conversion of
reduced glutathione (glutathione - SH) to the oxidised form
232
g-s-s-g .
It remains to be seen whether PMN1s from subjects taking
oral feverfew show the same inhibition of degranulation and
phagocytosis as is seen in vitro. While blockade of granule
release in platelets and PMN's might be beneficial to an
extent in migraine and rheumatoid arthritis, the effects on
phagocytosis may prove to be an undesirable side effect. If
223
as is suggested further clinical trials of feverfew will be
undertaken, then studies of PMN function should be an integral
part of such trials.
CHAPTER 8
CONCLUSIONS, AND IMPLICATIONS OF NEUTROPHIL SECRETION IN THE
INFLAMMATORY RESPONSE
The studies described here have demonstrated the
importance of C as a source of degranulating activity for
PMN's, have examined the inhibition of such degranulation by
H^ antagonists and feverfew extracts, and have attempted to
investigate the ways in which C^ fragment-induced PMN
activation might produce microvascular changes in vivo.
What are the implications of these findings in the
understanding of inflammatory and immune processes?
C^ fragments appear to be the main fluid phase
complement-derived chemotactic stimulus for PMN's but it is
difficult to assess their importance in the anti-bacterial
role of the cells. Complement activation leads to coating of
bacteria by for which PMN's have receptors, but C^
fragments may also be important in bringing PMN's and bacteri
together. Human C may be deficient in either quantity or
function. One family in whom C,. was less than 0.05% of norma
in 4 of 5 siblings, experienced recurrent infections with the
intracellular pathogens Neisseria meningitidis and N.
233
gonorrhoeae . As expected, chemotactic activity could not
be generated by zymosan from their sera, although no defects
of phagocytosis or killing were present. The CH^ assay
showed no detectable haemolytic activity in the C^ deficient
individuals, while the alternative complement pathway
haemolytic assay showed a delayed endpoint corrected by the
2 4 *
addition of C,_. No inhibitor was present. Neisserial
infections are well recognized in individuals with defects of
233
any of the membrane attack complex components . How
protection from other bacteria is achieved is not certain, for
the maximum concentration of C^. which could be generated from
serum containing less than 0.05% of normal is 5 ng/ml, only
one tenth of the minimum concentration detectable by
chemotaxis. The direct chemotactic action of bacterial
21
peptides such as FMLP may largely compensate.
Functional defects of immunologically normal C,_ have
been described in a family where the defect was present in 15
147
relatives . The index case was a child who had repeated
local and systemic infections with various Gram-negative
bacteria and coagulase positive staphylococci. The patient's
serum showed inability to enhance chemotaxis towards, or
phagocytosis of E coli, Staph aureus or yeasts, a defect
correctable by the addition of normal serum or C^, but not by
C^. Phagocytosis of pneumococci, which is independent of C,-,
was normal. C<- in the serum was normal by both IEP and
immunodiffusion.
It is of interest that quantitative deficiency and
functional impairment of Cj- should render individuals
susceptible to different groups of micro-organisms. It may be
that the abnormal actually blocks the binding of any normal
Cj_, or of other complement components, thus compounding the
defect and increasing the range of bacteria which cannot be
ingested. Further detailed study of the C<_a molecule in such
families could reveal much about the nature of C^-neutrophi 1
binding and activation.
An inhibitor of C,. -induced chemotactic activity has
also been described in patients with SLE, and has been
implicated in the increased susceptibility to pyogenic
234
infections seen in that condition . The inhibitor described
did not inhibit chemotaxis in response to other stimuli, and,
oddly, did not impair C -mediated aggregation orjd
degranulation. It appears to be quite different to the
chemotactic factor inhibitor described by Berenberg and
6 8
Ward . It thus appears that fragment-mediated PMN
activation is physiologically important in anti-bacterial
defence.
The in vivo studies performed here also suggest a key
role for activated PMN's in the production of
complement-induced permeability"changes in small vessels.
However, not every situation in which PMN's are stimulated
leads to such permeability changes and tissue injury. For
93
example, the well-described dialysis leucopenia , thought to
be due to complement activation and pulmonary PMN
sequestration, has never been reported to cause clinical
features of ARDS. Studies in sheep infused with zymosan
activated plasma also report marked PMN accummulation in
alveoli, but although there is early endothelial injury, this
has recovered by 4 hours, even though PMN's remain in the
235
pulmonary micro-circulation . The pulmonary damage
following infusion of cobra venom factor into rats has also
236
been shown to be transient . Experiments using cultured
endothelial cells from bovine pulmonary arteries in Boyden
chambers have demonstrated that PMN1s can migrate across
endothelial layers in response to activated complement without
damage to the endothelium, as demonstrated by light and
electron microscopy. The PMN's appear to remain in close
proximity to the endothelium at all times such that no leak of
237
radiolabelled water or sucrose is seen . In contrast, the
addition of histamine to the preparation causes focal
dilatations in junctions between endothelial cells, with
238
leakage of radiolabelled solutes . Thus additional factors
must dictate whether permeability changes result from contact
between activated PMN'S and endothelium. In health there is a
large pool of marginated PMN's, particularly in the lungs, yet
no damage to lung tissue results. Traditional concepts of
complement-induced lung injury have assumed that the important
event is the activation of PMN's, with the endothelium being
damaged almost as an 'innocent bystander'. However, it now
appears that the endothelium plays a more active role in
influencing the outcome of such PMN activation than previously
thought. It has been suggested that direct damage to or other
alterations in endothelial cells themselves must take place
239
before activated PMN's can further impair their integrity
For example PMN adherence to endothelium can be increased by
239 240
exposure of the endothelial layer to endotoxin , viruses
241
or hyperbaric oxygen . Such damage may also expose
242
endothelial receptors for Fc and , thus providing a
mechanism for cell to cell adhesion with PMN's coated with
immune complexes and complement. Normal intact endothelium
may actually limit PMN contact with itself, by promoting PMN
emigration through the vessels into the tissues. PMN's in
Boyden chambers, for example, move much more rapidly through
into pulmonary artery implants when the endothelial layer is
247
intact239.
It may be therefore, that to produce permeability
changes and tissue damage a stimulus has to not only activate
PMN's but also damage endothelium directly, and that stimuli
which affect only PMN's will cause only mild and transient
243
endothelial damage. Circulating factors such as fibrinogen
244
and fibronectm also alter PMN adherence to endothelium,
52
as do PMN factors themselves, particularly lactoferrin
Relatively little is known about endothelial activation and
behaviour, but further study of PMN-endothelial interaction
may fill in many of the gaps in knowledge of the inflammatory
processes.
Where these processes are damaging to tissues it may be
of advantage to block PMN responsiveness, at least partially.
High concentrations of anti-inflammatory drugs can do so in
vitro, and now antagonists and feverfew extracts can be
added to the list of drugs active in this way. The difficulty
in translating in vitro activity into clinical effect is well
demonstrated by the observation that conventional doses of
hydrocortisone and anti-inflammatory agents completely failed
to block skin responses to activated complement, perhaps
because plasma levels of the drugs were too low to inhibit PMN
activation. Similarly, degranulation of PMN's from subjects
taking clemastine orally was normal, again because of failure
to achieve high enough concentrations of the drug in plasma.
The problem of achieving suitably high drug concentrations in
vivo could perhaps be overcome by local administration to
affected sites, for example via a nebuliser to the lungs or
directly into inflammed joints.
As well as modifying endothelial function, secretory
products from activated PMN's can influence the behaviour of
other cell types, notably monocytes and macrophages, and
thereby the activity of T and B lymphocytes and granulocyte
precursors. Impaired lymphocyte reactivity and absent skin
responses to various T and B cell mitogens have been reported
g
m patients with peripheral blood PMN counts of >15 x 10 /I
from whatever cause (excluding chronic granulocytic
245
leukaemia) . Other possible causes of this anergy were
excluded as far as possible, and normal responses returned
when the PMN count fell. Of course the underlying causes of
the neutrophilia could have produced anergy by independent
means, but it remains an interesting speculation that factors
from PMN's themselves could have been responsible.
The monocyte/macrophage factor interleukin-1 (IL-1)
appears to link many of the diverse effects of infection and
inflammation, causing neutrophilia, fever, breakdown of muscle
protein, synthesis of collagen from fibroblasts, and release
of acute phase proteins from the liver as well as activation
246
of T and B lymphocytes . The neutrophilia is primarily due
to release of young PMN's from the bone marrow. Factors from
PMN's undergoing phagocytosis or activation by soluble stimuli
may be able to modulate IL-1 synthesis and thus influence many
aspects of inflammatory and immune responses. This could
certainly produce anergy and may be relevant in the T cell
unresponsiveness of Hodgkin's disease, in which PMN's appear
to be hyperactive, with high neutrophil alkaline phosphatase
247 248, 249
scores , and increased superoxide production . In
addition, pulmonary fibrotic disease may be partly due to
24 9
activated PMN's causing increased IL-1 synthesis by pulmonary
macrophages, with subsequent stimulation of collagen
250
production . A further monocyte product inhibited by PMN
secretions is the colony stimulating factor required for the
55
growth of myeloid colonies in culture . This feedback
control of granulocyte numbers appears to involve
57
lactoferrin , and may be defective in chronic granulocytic
193
leukaemia
It can thus be seen that the PMN has important secretory
functions. Release of granule contents, oxidation products
and lipid mediators all play a part in the generation of the
features of inflammation. The studies described here have
demonstrated in vitro and in vivo models suitable for the





Blood cell counter and Isoton II: - Coulter DN, Coulter,
Harpenden.
Centrifuges: - Damon IEC Centra 7
- 4° centrifuge - Beckman TJ6
- Microcentrifuge - MSE.
Cell sonicator: - Rapidis 'S' model - Ultrasonics Ltd,
Shipley.
^ counter: - Intertechnique CG4200.
Spectrophotometer: - Pye Unicam SP1800.
Cytospin: - Shandon-Elliott.
Filter systems: - 0.8yu - Millipore
0.2.u - Millipore.
)
Micropartition membrane and holders: - Amicon Corporation.
LP^ polypropylene tubes: - Luckham's.
Universal containers: - Sterilin.
lml syriges: - Gillette (Sabre).
27 gauge needles: - Monoject.
Skin calipers: - Mitutoyo, Japan.
Serum harvester: - Glasrock Products Inc.
2. Chemicals
Agarose: - Miles Serevac.
Monopoly resolving medium: - Flow Laboratories, Irvine
Lymphocyte separation medium: - Flow Laboratories, Irvine
Phosphate buffered saline tablets:- Flow Laboratories, Irvine
Earl's balanced salt solution: - Flow Laboratories, Irvine
"^CoB^2 (high specific activity): - Radiochemicals.
Centre, Amersham.
Dextran - (Lomodex 70): - Fisons Ltd, Loughborough.
Candida guilliermondii: - Public Health Laboratory,
Nottingham.
Diffquik: - Merz and Dade.
Epsilon amino caproic acid: - BDH.
Ethylene diamine tetraacetic acid (EDTA): - BDH.
Ethylene-bis-(oxy-ethylene-nitrile)
tetraacetic acid (EGTA): - BDH.
Calcium chloride: - BDH.
Magnesium chloride: - BDH.
Bovine haemoglobin: - BDH.
Sodium azide: - BDH.
Glycine: - BDH.
Ammonium chloride: - BDH.
Phorbol myristate acetate: - Sigma.
Latex beads: - Sigma.
Dimethyl sulphoxide: - Sigma.
Formyl-methionyl-leucyl-phenylalanine: - Sigma.




Cyanogen bromide activated sepharose 4B: - Sigma.
Bovine serum albumin: - Sigma.
Zymosan: - Sigma.
Coomassie blue: - Sigma.
Activated charcoal: - Sigma.
>»
Ethanolamine: - Sigma.
Trypan blue: - Sigma.
Cytochalasin B: - Sigma.
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Arachidonic Acid: - Sigma.
3. Drugs
Clemastine: - Sandos.
Histamine: - McCarthy's Ltd.
Cimetidine: - Smith, Klein & French.
BW 755C: - Boots Ltd.
Prostaglandin - Upjohn Ltd.
Hydrocortisone:
- Hydrocortisone sodium succinate BP - Boots Ltd.
Ibuprofen: - Boots Ltd.
Aspirin: - Aspirin tablets BP.
4. Antisera
Anti-H IgG - Goat anti-human IgG (gamma chain):
- Kent Laboratories. Lot No 1010 AM3.
Anti-H C3 (1) - Rabbit anti-human C3 (C3, C3c, C3d):
- Blood Transfusion Service, Bristol.
Anti-H C3 (2) - Rabbit anti-human C3 (C3d):
Dako Laboratories. Lot No A063 - 010D.
Anti-H C3 (3 - Goat anti-human C3 (C3, C3c):
Kent Laboratories. Lot No 103053.
Anti-H C3 (4) - Sheep anti-human C3 (C3, C3a, C3c):
Seward Laboratories. Lot No BA10 - 18186.
Anti-H C5 (1) - Goat anti-human C5:
Kent Laboratories. Lot No 1100 Nl.Anti-H C5 (2) - Sheep
Anti-human C5:
Seward Laboratories. Lot No BA12 - 1653A.
APPENDIX 2
BUFFERS
1. Phosphate buffered saline (PBS). pH = 7.40
8000mg NaCl
200mg KC1 or 10 PBS tablets
200mg KH2P04 (Flow Laboratories)
1442mg Na2HP04"2H20
The volume was made up to 1 litre with distilled water,
This was used for all PMN washing and counting
procedures to prevent spurious degranulation.
2. Phosphate buffered saline with added calciunv magnesium




The volume was made up to approximately 900mls with
distilled water. To prevent formation of precipitates of
calcium or magnesium phosphate, 1ml of 1.0M CaCl2 and 0.7ml
1.0M MgCl2 were each diluted in 10mls distilled water and
added dropwise to the PBS in a mixer. The solution was
autoclaved at this stage. One gram of cobalamin-binding
protein-free bovine serum albumin was then added, and when
dissolved, the solution was made up to 1 litre with distilled
water and stored at 4°C.
autoclaved and stored at 4°C.
200mg KC1 or 10 PBS tablets
Final concentrations of: calcium = 1 millimolar
magnesium = 0.7 millimolar
BSA = 0.1%
This solution was used for all degranulation studies.
3. Coupling buffer. (for anti-C^ column preparation)
8.401g NaHCO^ (final cone = O.lM)
29.22g NaCl (final cone = 0.5M)
made up to 1 litre with distilled water. The pH was adjusted
to 8.3.
4. Acetate buffer.
4.7mls glacial acetic acid
2.45g sodium acetate
58.44g sodium chloride (final cone = 1-OM)




58.44g sodium chloride (final cone = 1.0M)
made up to 1 litre with distilled water. The pH was adjusted
to 8.0 with strong sodium hydroxide.
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